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SUMMARY 	
	 V	
Summary 
 
Autophagy comprises a group of cellular pathways that enables eukaryotic cells 
to deliver cytoplasmic constituents for lysosomal degradation, to recycle 
nutrients and to survive during starvation. In addition to these primordial 
functions, autophagy has emerged as a pivotal mechanism in orchestrating 
innate and adaptive immune responses. Autophagosomes intersect with MHC 
class II-containing compartments (MIICs) and autophagy-related proteins are 
known to support antigen loading for increased CD4+ T cell immunity. 
Reactivation and expansion of autoreactive CD4+ T cells within the 
central nervous system (CNS) are considered to play a key role in the 
pathogenesis of multiple sclerosis (MS) and its animal model, experimental 
autoimmune encephalomyelitis (EAE). How encephalitogenic lymphocytes 
recognize the CNS as their target organ to induce inflammatory demyelination is 
incompletely understood. Our study shows that CNS dendritic cells (DCs) require 
expression of the autophagy protein ATG5 for myelin-specific CD4+ T cell 
reactivation. Mice with conditional deletion of ATG5 in CD11c+ DCs are 
completely resistant to develop adoptively tranferred EAE and depict 
substantially reduced CD4+ T cell expansion within the CNS. Endogenous myelin 
peptide presentation to CD4+ T cells following phagocytosis of injured, 
phosphatidylserine-exposing oligodendroglial cells is abrogated in the absence of 
ATG5. 
CD1d molecules survey endocytic compartments to bind lipid antigens in 
MIICs before recycling to the plasma membrane. We show that mice with DC-
specific deletion of the essential autophagy gene Atg5 exhibited better CD1d-
restricted glycolipid presentation in vivo. These effects led to enhanced invariant 
Natural Killer T (iNKT) cell cytokine production upon antigen recognition and 
lower bacterial loads during Sphingomonas paucimobilis infection. Enhanced 
iNKT cell activation was independent of receptor-mediated glycolipid uptake and 
costimulatory signals. Instead, loss of Atg5 in DCs impaired clathrin-dependent 
internalization of CD1d molecules via the adaptor protein complex 2 (AP2) and 
consequently increased surface expression of stimulatory CD1d-glycolipid 
complexes. Thus, ATG5 facilitates the recruitment of AP2 to CD1d molecules 
resulting in attenuated iNKT cell activation, which is in contrast to the 
supporting role of macroautophagy in CD4+ T cell stimulation. 
 
These results illustrate that the use and function of ATG5 is context-dependent 
therefore a clear and comprehensive concept of how the autophagy machinery 
couples to antigen-presentation and lymphocyte activation appears to be required 
to predict the outcome of therapeutic interventions in this pathway to boost 
adaptive immunity. 
 
 
 
 
 
 
 
ZUSAMMENFASSUNG 	
	 VI	
Zusammenfassung 
 
Autophagie umfasst eine Reihe zellulärer Signalwege, welche es eukaryotischen 
Zellen ermöglichen, zytoplasmatische Bestandteile dem lysosomalen Abbau 
zuzuführen, Nährstoffkomponenten wiederzuverwerten und trophische 
Mangelzustände zu überleben. Zusätzlich zu diesen ursprünglichen Funktionen 
hat sich die Autophagie als zentraler Mechanismus in der Orchestrierung 
angeborener und adaptiver Immunantworten herauskristallisiert. 
Autophagosomen fusionieren mit MHC-Klasse-II-haltigen Kompartimenten 
(engl. MHC class II-containing compartments, MIICs) und Autophagie-verwandte 
Proteine (engl. autophagy related genes, ATGs) unterstützen bekanntermaßen 
Antigenbeladung zur Verstärkung der CD4+ T-Zell-Antwort. 
Der Reaktivierung und Expansion autoreaktiver CD4+ T-Zellen innerhalb 
des zentralen Nervensystems (ZNS) kommt eine Schlüsselrolle in der  
Pathogenese der Multiplen Sklerose (MS) und ihres Tiermodells Experimentelle 
autoimmune Enzephalomyelitis (EAE) zu. Wie enzephalitogene Lymphozyten 
das ZNS als ihr Zielorgan zur Induktion entzündlicher Demyelinisierung 
erkennen, ist unvollständig verstanden. Unsere Studie zeigt, dass ZNS 
dendritische Zellen (engl. dendritic cells, DCs) die Expression des Autophagie-
Proteins ATG5 für die Reaktivierung Myelin-spezifischer CD4+ T-Zellen 
benötigen. Mäuse mit konditionaler Deletion von ATG5 in CD11c+ DCs sind 
vollständig resistent gegenüber der Entwicklung adoptiv transferierter EAE und 
zeigen substanziell reduzierte CD4+ T-Zell-Expansion innerhalb des ZNS. Die 
Präsentation endogener Myelin-Peptide gegenüber CD4+ T-Zellen nach 
Phagozytose beschädigter Phosphatidylserin-exponierender oligodendroglialer 
Zellen ist in Abwesenheit von ATG5 aufgehoben. 
CD1d-Moleküle durchlaufen endozytische Kompartimente um Lipid-
Antigene in MIICs zu binden bevor sie zur Plasmamembran rezyklieren. Wir 
zeigen, dass Mäuse mit DC-spezifischer Deletion des essentiellen Autophagie-
Gens Atg5, eine bessere CD1d-restringierte Glycolipid-Präsentation in vivo 
vorweisen. Dies führte nach Antigen-Erkennung zu erhöhter Produktion von 
Zytokinen durch invariante natürliche Killer T-(iNKT-) Zellen und einer 
geringeren bakteriellen Last während Sphingomonas paucimobilis Infektion. Die 
erhöhte iNKT-Zell-Aktivierung war unabhängig von Rezeptor-mediierter 
Glycolipid-Aufnahme und costimulierenden Signalen. Vielmehr behinderte der 
Verlust von Atg5 in DCs die Clathrin-abhängige Internalisierung von CD1d via 
Adapterprotein-Komplex 2 (AP2) und erhöhte infolgedessen die 
Oberflächenexpression stimulierender CD1d-Glycolipid-Komplexe. Somit 
begünstigt ATG5 die Rekrutierung von AP2 zu CD1d Molekülen was, im 
Gegensatz zu der unterstützenden Rolle der Makroautophagie bei der CD4+ T-
Zell-Stimulation, zu einer verminderten iNKT-Zell-Aktivierung führt. 
 
Diese Resultate illustrieren, dass die Verwendung und Funktion von ATG5 
kontextabhängig ist und daher ein klares und vollumfängliches Konzept wie die 
Autophagie-Maschinerie Antigenpräsentation und Lymphozyten-Aktivierung 
reguliert, notwendig erscheint um den Ausgang therapeutischer Interventionen 
in diesem Signalweg zur Verstärkung der adaptiven Immunantwort, 
vorherzusagen.  
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1. Introduction 
 
1.1 Autophagy Pathways and Autophagy-Related Protein Functions 
Organisms with subcellular compartmentalization and membrane-bound 
organelles face constant challenges in order to maintain metabolic integrity and 
homeostasis. Autophagy comprises a set of evolutionary conserved catabolic 
pathways that converge in the guided direction of assigned cargo to the 
endolysosomal system (Deter and De Duve, 1967; Deter et al., 1967; Mizushima 
and Komatsu, 2011). Initially, autophagy was recognized for its contribution in 
keeping energy homeostasis, and degradation of aberrant protein aggregates 
(Hara et al., 2006; Komatsu et al., 2006) and as mediator of development-
associated forms of cell death (Denton et al., 2012). In recent years, however, 
autophagy’s function has exceeded the originally allotted role as a mere protein 
degradation system alongside the proteasomal machinery. In addition to 
regulating cellular proteostasis and cell death, autophagy pathways are 
increasingly recognized for actively participating in physiological and 
pathological immune responses. In doing so, autophagy pathways limit 
intracellular proliferation of pathogens (Thurston et al., 2012), restrict secretion 
of proinflammatory mediators (Saitoh et al., 2008), and tweak T cell responses by 
orchestrating both loading and preservation of antigens on and surface-
expression of antigen-presenting molecules (Loi et al., 2016; Paludan et al., 2005; 
Romao et al., 2013; Schmid et al., 2007). 
 
Canonical autophagy implicates at least three distinct pathways: 
macroautophagy, microautophagy and chaperone-mediated autophagy (Codogno 
et al., 2011). Although all of the above mentioned pathways coalesce in the 
lysosome, they considerably differ (albeit showing some overlap), in their means 
of cargo transportation, triggering events and regulatory factors.  
 
1.2 Macroautophagy 
Macroautophagy (MA), the canonical autophagy pathway sensu strictu, is 
evolutionary conserved from yeast to mammalian cells and characterized by 
highly regulated membrane reorganization processes with the subsequent de 
novo formation of a 0.5–1.5 µm wide double-membraned vesicle termed 
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autophagosome (Mizushima et al., 2002). Upon sequestering neighboring parts of 
the cytoplasm, the autophagosome subsequently fuses with lysosomes resulting 
in enzymatic cargo break down (Deretic, 2016; Feng et al., 2014). The process is 
partitioned in five sequential steps (1. induction/nucleation, 2. elongation, 3. 
closing/maturation, 4. fusion, 5. degradation) that are orchestrated by hierarchies 
of autophagy-related genes/proteins (Atgs/ATGs) and other essential components, 
in a tightly regulated enzymatic cascade (Codogno et al., 2011; Mizushima et al., 
2011; Tsukada and Ohsumi, 1993) (Figure 1.1). Albeit originally identified in 
yeast, mammalian counterparts for many Atgs have been characterized and some 
ATGs are so far exclusively reported in mammalian cells and lack yeast orthologs 
(Mizushima et al., 2011). Among all autophagy pathways, MA is to date the most 
extensively investigated one and, depending on the target constituent 
encompasses subentities such as macromitophagy, -pexophagy, -xenophagy, and -
lipophagy (Klionsky et al., 2007; Levine et al., 2011; Mizushima et al., 2011; 
Randow and Youle, 2014; Singh et al., 2009). 
Figure 1.1 Autophagy pathways converge in the lysosomal compartment.  
Macroautophagy. The phagophore emanates most likely from ER-derived membrane 
sources at a PI3P-rich (not depicted) structure called the omegasome. Upon recruitment of 
LC3 on the outer and inner leaflet of the forming autophagosome, cytoplasmic cargo is 
engulfed and LC3 removed from the outer membrane as the autophagosome is closed. The 
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completed vesicles may now be further matured via step-wise fusion with the endocytic 
compartment resulting in the generation of amphisomes or immediately fuse with 
hydrolytic enzymes-containing lysosomes. Chaperone-mediated autophagy. Target 
proteins that contain an exposed KFERQ sequence motif are guided in an hsc70-
dependent manner towards LAMP-2A, which resides in the lysosomal membrane. Upon 
unfolding of the target protein, LAMP-2A multimers together with lysosomal hsc70 
facilitate the transport into the lysosomal lumen. LC3-associated phagocytosis. Ligation of 
an appropriate receptor (e.g. TLR2, Dectin-1, TIM4, etc.) leads to receptor-mediated 
phagocytosis recruitment and binding of LC3 to the outer membrane of the LAPosome. By 
analogy with the MA pathway, completed LAPosomes may either fuse with other 
endocytic vesicles or directly merge with lysosomes. Microautophagy. Cytosplasmic cargo 
can be directly targeted to endosomal compartments/multivesicular bodies (MVB) in a 
hsc70-, phosphatidylserine (Ptd-L-Ser)- and ESCRT-dependent manner. Exosomes 
containing cytoplasmic material may emanate from the MVB and be secreted into the 
extracellular space. The molecular events and regulatory processes orchestrating the 
direct invagination of cytoplasmic constituents into lysosomes remains largely 
unbeknownst.  
 
1.2.1 ATGs and Autophagosome Formation 
De novo synthesis and maturation of the autophagosome as well as the 
trafficking of such vesicles to and fusion with lysosomes are distinctive features 
of MA in opposition to other autophagy pathways. Formation of this typifying 
vesicle requires approximately 5-10 min and is under the control of an ever-
growing number of ATGs (Feng et al., 2014; Mizushima et al., 2001; 2011; Suzuki 
et al., 2016). The finalized autophagosome is usually swiftly turned over but may 
reach a half-life of 10-25 min (Pfeifer, 1978; Schworer et al., 1981). The key 
proteins that initiate and govern the formation of the autophagosome can be 
assembled in functionally designated groups: unc-51-like kinase (ULK)-complex 
(1), the class III phosphatidylinositide 3-kinase (PI3K) complex (2), the 
ATG2/WD repeat domain phosphoinositide-interacting protein (WIPI)-complex 
and the ATG9 cycling system (3), the ATG12-conjugation system (4) and the 
microtubule-associated protein 1 light chain 3 (LC3)-conjugation system (5) 
(Feng et al., 2014; Mizushima et al., 2011; Shibutani and Yoshimori, 2014).  
The autophagosome emanates from the double-membraned phagophore (also 
called isolation membrane), which sequesters and closes around designated parts 
of the cytoplasm to form the completed autophagosome. The emergence of said 
phagophore constitutes the induction/nucleation phase. However, the exact 
assembly platform and membrane source for the generation of these initial 
structures are still debated. Similar to the pre-autophagosomal structure (PAS) 
that is observed adjacent to the vacuole in yeast, an autophagosome formation 
site, represented by dot-like accumulations of ATGs, has been identified in 
mammalian cells (Itakura and Mizushima, 2010). Primary suspect organelles to 
provide membranes include specialized PI3P-enriched endoplasmic reticulum 
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(ER) domains coined omegasomes (Axe et al., 2008). 3D electron tomography 
studies corroborated these results by showing that the double-membraned 
phagophore originates in between two protruding ER flaps. The phagophore then 
entwines one of the two extensions and finally buds off the ER containing the 
previously enfolded ER flap. This model is further supported by the fact that 
>70% of autophagosomes contain ER-derived cargo (Hayashi-Nishino et al., 2009; 
Ylä-Anttila et al., 2009). Nevertheless, other membrane sources for 
autophagosome generation have been suggested. Amongst them is the outer 
mitochondrial membrane (Hailey et al., 2010). These two opposing results might 
be brought together by a recent study that identified ER-mitochondria contact 
sites as the originating platform for the autophagosome initiation (Hamasaki et 
al., 2013). The VAMP3-dependent heterotypic fusion between early endosome-
derived ATG9+ vesicles and recycling endosome-derived ATG16L1+ vesicles has 
also been suggested to contribute to autophagosome precursor generation (Puri et 
al., 2013). Additionally, ER exit sites (Guo et al., 2012; Zoppino et al., 2010), the 
ER-Golgi intermediate compartment together with coat protein complex II 
(COPII) (Ge et al., 2013; 2014), the plasma membrane (Ravikumar et al., 2010) 
and a novel compartment comprised of ATG9+ vesicles and tubules (Mari et al., 
2010) were implicated in providing membrane material. It is conceivable that 
different subentities of MA preferentially harness distinct membrane sources. 
Possibly, there is a hierarchy of membrane reservoirs that sequentially may 
serve as alternative when other sources have been exploited. Furthermore, 
various tissues with specific composition of subcellular compartments may differ 
in their means to utilize membranes for autophagosome generation.  
 
1.2.2 The ATG Core Machinery 
 
1.2.2.1 The ULK-Complex 
The ULK-complex is an upstream ATG-unit and, by differential phosphorylation 
of ULK1 (the main mammalian orthologue to yeast ATG1), a direct target of MA 
regulation via target of rapamycin complex 1 (TORC1) and AMP-activated 
protein kinase (AMPK) respectively (Egan et al., 2011; J. Kim et al., 2011). 
ULK1/2 builds a stable complex with FIP200, ATG13 and ATG101 (Ganley et al., 
2009; Hara and Mizushima, 2009; Hosokawa, Hara, et al., 2009). Not composition 
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of the complex itself but rather differential phosphorylation of its members 
procures promotion or inhibition of MA. In a state of MA inactivation TORC1 
restrains the process via coordinate phosphorylation of ULK1/2 and ATG13. 
During activation, MA-promoting phosphorylation of ULK1/2 via AMPK, ULK1/2 
autophosphorylation and ULK1/2-mediated phosphorylation of ATG13 and 
FIP200 occurs followed by translocation of the entire complex to autophagosomal 
initiation sites possibly on tubulovesicular areas comprised of ER and ATG9+ 
vesicles (Chan et al., 2007; Y.-Y. Chang and Neufeld, 2009; Ganley et al., 2009; 
Hara et al., 2008; Karanasios et al., 2016). ATG101 may facilitate 
phosphorylation of ATG13 and minimize its proteasomal degradation (Hosokawa, 
Sasaki, et al., 2009; Mercer et al., 2009).  
 
1.2.2.2 The Class III PI3K-Complex 
The tetrameric core of this complex consists of vacuolar protein sorting protein 
(Vps)34 (a phosphoinositide 3 kinase), Vps15 (a regulatory subunit of Vps34 also 
called p150), Beclin 1 (orthologue of ATG6) and ATG14L (aka ATG14 and 
Barkor) (Itakura et al., 2008; Q. Sun et al., 2008; Suzuki et al., 2016). NRBF2 
(orthologue of ATG38) is a recently identified additional subunit of the complex 
that augments the enzymatic activity of the lipid kinase Vps34 (Araki et al., 
2013; Ohashi et al., 2016; Young et al., 2016). The lipid kinase complex is 
recruited to autophagosomal initiation sites in an ULK1-complex/ATG9-
dependent manner (Itakura and Mizushima, 2010; Matsunaga et al., 2010).  
The key function of the complex is to produce PI3P via Vps34-mediated 
phosphorylation of phosphatidylinositol. Presence and accumulation of PI3P is 
essential for MA as PI3P-enriched membrane areas then function as platforms to 
which downstream PI3P-binding partners can be recruited. Regulation of MA 
occurs also on the level of the PI3P-complex in that death-associated protein 
kinase (DAPK) promotes autophagosome formation by unleashing Beclin 1 from 
the Bcl-2/Bcl-XL complex (Zalckvar et al., 2009).   
 
1.2.2.3 The ATG12-Conjugation System 
This first of two ubiquitin-like conjugation systems that orchestrate 
autophagosome formation consists of the MA-essential molecules ATG12, ATG7, 
ATG10 ATG5 and ATG16L1 (Mizushima et al., 2011). Constitutively and 
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independent of cellular nutrient status, ATG12 is activated via E1-like enzyme 
ATG7, followed by transfer to E2-like enzyme ATG10 which catalyzes the 
covalent conjugation of ATG12 to ATG5. Via binding to ATG5, the conjugate then 
forms a complex with ATG16L1 (Geng and Klionsky, 2008). WIPI2 now attracts 
the ATG5-ATG12-ATG16L1-complex by means of a recently identified binding 
site in ATG16L1 to the site of autophagosome generation (Dooley et al., 2014). 
Additionally, it has been suggested that ATG16L1 is also recruited to the 
phagophore via binding to ULK-complex member FIP200 (Gammoh et al., 2013; 
Nishimura et al., 2013). On site, the complex then functions as an E3-like 
enzyme for the second conjugation system. The complex is regularly found on the 
outer membrane of the phagophore but dissociates from there upon completion of 
the autophagosome (Mizushima et al., 2001).  
 
1.2.2.4 The LC3-Conjugation System 
The second and final conjugation system is comprised of the ubiquitin-like LC3, 
the hydrolase ATG4, ATG7 and ATG3, which function as E1- and E2-like 
enzymes, respectively. The pro-form of LC3 is cleaved by ATG4 leading to 
exposure of a C-terminal glycine residue (Hemelaar et al., 2003; Kabeya et al., 
2004). The resulting protein termed LC3-I is then lipidated with 
phosphatidylethanolamine (PE) at said glycine residue by means of ATG3 and 
ATG7 (Ichimura et al., 2000; Kabeya et al., 2000; Tanida et al., 2004). This PE-
lipidation of LC3 is assisted by the ATG5-ATG12-conjugates via E3-like activity 
(Fujita, Itoh, et al., 2008; Geng and Klionsky, 2008). Additionally, the ATG5-
ATG12-ATG16L1-complex guides and determines LC3 to its subcellular 
destination (Fujita, Itoh, et al., 2008). This lipidated form of LC3, also called 
LC3-II is initially found symmetrically distributed on the inner and outer 
membrane of the phagophore (Kabeya et al., 2000; 2004; Kimura et al., 2007). 
There it appears to aid in elongation of the phagophore as well as coordinate 
tethering and hemifusion of its membranes, finally leading to closure of the 
phagophore to what is now called autophagosome (Fujita, Hayashi-Nishino, et 
al., 2008; Nakatogawa et al., 2007; Sou et al., 2008; Weidberg et al., 2010). Upon 
vesicle closure, LC3 on the outer membrane is being cleaved from PE via ATG4 
while intraluminal LC3 stays associated with the organelle which makes LC3-II 
a valuable marker for the detection of autophagosomes (Kimura et al., 2007; 
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‘Guidelines for the use and interpretation of assays for monitoring autophagy 
(3rd edition).’, 2016). In addition to its contribution during membrane 
reorganization, LC3 mediates MA-cargo selectivity by functioning as an adaptor 
molecule (Johansen and Lamark, 2011).  
 
1.2.3 Regulation of Macroautophagy 
Most mammalian cells carry out MA on a constitutive level at varying degrees. 
However, depending on the cell type, macroautophagic activity can be induced 
and modulated in numerous ways. Primarily nutrient deprivation is a potent 
stimulus of autophagy and starvation-induced autophagy is a common means to 
investigate MA under experimental conditions (Efeyan et al., 2015; Mizushima 
and Klionsky, 2007). The process receives regulatory input on both a systemic 
and a cellular level (Efeyan et al., 2015). Amongst the most upstream regulatory 
units of the MA machinery is the antagonistic interplay of coordinate 
phosphorylation by the two serine/threonine protein kinases AMPK and TORC1 
(Egan et al., 2011; J. Kim et al., 2011) (Figure 1.2). 
 
Figure 1.2 Regulatory network of macroautophagy (MA). 
This figure illustrates the most important regulatory interplay of molecules that govern 
MA activity. Growth factors can signal via PI3K to Akt, which in turn inhibits the Beclin 
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1-containing class III PI3K-complex. Akt may also repress transcription of autophagy-
promoting genes via direct inhibition of transcription factor FOXO3. Additionally Akt 
reduces macroautophagic activity by inhibiting TSC1/TSC2. Akt interaction with PRAS40 
promotes mammalian TORC1 (mTORC1) activity thereby further damping MA. The 
calcium/calmodulin (Ca2+/CaM) serine/threonine kinase DAPK fosters MA via 
phosphorylation of Beclin 1 at T119 which leads to dissociation of Beclin 1 from Bcl-2. The 
TSC1/TSC2-complex can promote MA by inhibiting the mTORC1 activator and GTPase 
Rheb. AMPK and mTORC1 are the two cardinal regulatory units that control MA. 
mTORC1 may repress the process via phosphorylation of ULK1/2 and/or ATG13. 
mTORC1 activity is increased by amino acid sensing Rag GTPases via interaction with 
Raptor. The Rag GTPases also facilitate translocation of mTORC1 to the lysosomal 
membrane, which serves as a prerequisite for the aforementioned mTORC1-promoting 
activity of Rheb. AMPK promotes MA by several means: phosphorylation of ULK1/2 
and/or ATG13 at different residues than mTORC1, direct interaction with FOXO3 and by 
directly disinhibiting the inhibitory units mTORC1 and Raptor. AMPK itself can be 
triggered by increasing levels of AMP relative to ATP, free Ca2+ and activity of LKB1, 
TAK1 and CAMKK2. 
1.2.4 Autophagosome Maturation and Fusion with the Endolysosomal 
System 
A hallmark of all autophagic pathways is their convergence into the lysosomal 
system. During MA, this event requires the coordinated membrane fusion of the 
autophagosome and endolysosomal vesicles (Figure 1.1). Prior to terminal fusion 
with lysosomes, autophagosomes may (or may not) fuse with vesicles of the 
endocytic compartments like early or late endosomes. The resulting amphisomes 
subsequently fuse with lysosomes to form autolysosomes. These partly 
sequential, partly parallel fusion events underscore the dynamic nature of MA. 
Hence, observed accumulation of autophagosomes needs to be carefully 
interpreted, for it can mean both bona fide induction of the process and blocked 
lysosomal fusion.  
 
Autophagosomes are widely distributed throughout the cytoplasm. For these 
vesicles to fuse with lysosomes and late endosomes (which are predominantly 
located juxtanuclear) autophagosomes need to be efficiently guided towards this 
area. Members of the cytoskeleton have been shown to orchestrate the regulated 
trafficking of autophagosomes from the periphery to sites at which membrane 
fusion occurs. In fact, microtubules might even aid in autophagosome formation 
and subsequent fusion with endosomal compartments (Fass et al., 2006; Köchl et 
al., 2006). In an antagonistic interplay, the members of the motor protein family 
dynein/dynactin-complex and kinesin were shown to be involved in guiding 
autophagosomes alongside microtubules towards lysosome-rich areas, a process 
during which the trafficked vesicles become increasingly acidified as they 
approach the juxtanuclear area (Kimura et al., 2008; Maday et al., 2012). 
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Consequently, disruption of the dynein machinery exacerbates aberrant protein 
aggregation in experimental models of neurodegeneration due to dysfunctional 
MA (Ravikumar et al., 2005). Interestingly, dynamic distribution of lysosomes 
within the cytoplasm may actually constitute a mechanism via which autophagic 
flux is regulated (Korolchuk et al., 2011).  
In accordance with general membrane reorganizsation, also the fusion of 
autophagosomes with endolysosomal vesicles is in large parts orchestrated by 
members of small GTPases called Rabs, membrane-tethering complexes and 
SNAREs. Studies in yeast suggest that ATG4-mediated cleavage of the LC3 
orthologue ATG8 from the outer membrane constitutes one prerequisite that 
renders the autophagosome ready for fusion (Nair et al., 2012; Z.-Q. Yu et al., 
2012). Possibly, absence of molecules, that are involved in the early phase of 
autophagosome biogenesis functions as yet another signal (Ganley, 2013).  
 
Our understanding of the precise molecular events during autophagosome 
biogenesis and fusion has significantly improved during the last decade and 
enticing models have been proposed as on how the phagophore is initiated. 
However, one needs to be cautious as of how the aforementioned molecular 
interplay of ATGs can be generalized since most results were obtained studying 
starvation-induced MA. There is evidence that autophagosomal biogenesis, 
subsequent fusion partners, -sites and -mechanisms are highly dependent on 
induction stimulus and cargo (Ganley, 2013). Furthermore, the degree as to 
which these processes are actually carried out in sequence remains enigmatic. It 
is likely that numerous steps occur in parallel and distinct ATGs might not only 
carry out a single function but take on several tasks within the cascade. The 
molecular interactions between ATGs and the kinetics of the process may also 
significantly differ between mammalian species and even on a tissue level there 
might be specifics to MA that need to be taken into account.  
Finally, at least for some ATGs that are essential for MA, an even more 
promiscuous role has begun to unfold in that these proteins also facilitate MA-
independent functions in cellular reprogramming, dynamic membrane re-
distribution, pathogen clearance and antigen presentation (Kimmey et al., 2015; 
Kroemer and Levine, 2008; Loi et al., 2016; Radoshevich et al., 2010; Subramani 
and Malhotra, 2013; Zhao et al., 2008). 
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1.3 Non-Canonical Autophagy Pathways 
Non-canonical autophagy comprises a set of recently characterized pathways that 
either result in autophagosome formation but omit the usage of distinct parts of 
the classical MA-machinery or constitute autophagosome-independent pathways 
that utilize key components of the MA-network (Codogno et al., 2011; Münz, 
2015). One can at least differentiate 5 distinct entities: LC3-associated 
phagocytosis, Beclin 1-independent autophagy, autophagosome-formation from 
multiple phagophores and pathogen-specific autophagy modification, autophagy-
associated unconventional protein secretion, and defective ribosomal products-
containing autophagosome-rich blebs. Due to its implication in antigen 
presenting pathways (Cadwell, 2016; Codogno et al., 2011; Münz, 2015) I will 
focus here on LC3-associated phagocytosis. 
 
1.3.1 LC3-Associated Phagocytosis 
During phagocytosis, a specialized way of endocytosis, cells internalize solid 
extracellular constituents in a receptor-mediated fashion. The resulting 
phagosome is step-wise matured and subsequently fuses with the lysosomal 
compartment in order to break down the incorporated material (Gray and 
Botelho, 2017). Recently, a novel organelle, the single-membraned LC3+ 
phagosome or LAPosome, has been identified and the process of its generation 
and fate was coined LC3-associated phagocytosis (LAP) (Figure 1.3) (Romao and 
Münz, 2014; Sanjuan et al., 2007). LAP, that links both phagocytosis of 
extracellular cargo and members of the autophagy molecular core machinery, is 
initiated by ligation of a variety of extracellular receptors (Henault et al., 2012; 
Ma et al., 2012; Martinez et al., 2011; Romao et al., 2013; Sanjuan et al., 2007). 
Although some components of the MA-machinery are essential for LAP (e.g. 
ATG5, ATG7, LC3, Beclin 1), the process is independent of others (e.g. the ULK-
complex including ULK1/2, FIP200, ATG13, ATG101, WIPI1).  
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Figure 1.3 LC3-associated phagocytosis.  
The ligation of LAP-triggering receptors such as phosphatidylserine (Ptd-L-Ser)-
recognizing TIM4, TLR2, Dectin-1 or Fcγ receptors will ensue receptor-mediated 
phagocytosis and subsequent PI3K-dependent association of the NADPH oxidase NOX2 
with the phagosome. The NOX2-derived reactive oxygen species (ROS) and laposomal 
PI3P (not depicted) mediate the recruitment and binding of LC3 to the outer membrane of 
the LAPosome. Instead of terminal fusion with the lysosomal compartment, the completed 
LAPosome may also fuse with endosomal vesicles including MHC class II loading 
compartments in which after enzymatic digestion, LAPosomal content can be loaded upon 
MHC class II molecules followed by the presentation of the resulting peptides to CD4+ TH 
cells.  
 
LAP-triggering receptors include Toll-like receptors (TLRs), Fc-receptors, C-type 
lectins and phosphatidylserine (Ptd-L-Ser)-binding receptors (Henault et al., 
2012; Ma et al., 2012; Martinez et al., 2011; Romao et al., 2013; Sanjuan et al., 
2007). Upon activation of a LAP-triggering surface receptor, a PI3PK complex 
that differs in its composition from the one involved in MA, is recruited to the 
cytosolic membrane of the phagosome followed by the recruitment of the NADPH 
oxidase NOX2. These events are not preceded by involvement of the canonical 
ULK complex. The LAP-associated PI3PK complex is made up by Beclin 1, 
Vps34, Vps15 (analogous to MA) but is devoid of ATG14 (Martinez et al., 2015). 
Instead it includes UVRAG and Rubicon (not members of the canonical PI3PK 
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complex). Similar to MA, the PI3PK complex is set out to generate PI3P on the 
LAPosome. The association of the modified PI3PK complex on the LAPosome is 
potentially liaised via Rubicon which, together with PI3P also appears to be key 
in recruiting, stabilizing and activating the NADPH oxidase NOX2 to the 
organelle (Martinez et al., 2015). Rubicon has been suggested to mediate NOX2 
stabilization by interaction of its serine-rich domain (AA 567-625) with the NOX2 
subunit p22phox whereas PI3P stabilizes the NOX2 subunit p40phox (Martinez et 
al., 2015; Ueyama et al., 2011). LAPosomal PI3P in concert with NOX2-
dependent ROS production then initiates the two canonical MA conjugation 
systems (see above), which results in efficient deposition of lipidated LC3 on the 
outer LAPosomal membrane (Martinez et al., 2015). Consequently, LAP is highly 
dependent on the MA proteins ATG5, ATG12, ATG16L1, ATG7, ATG3 ATG4 and 
lipidated LC3. Molecules that have been described by one group to be dispensable 
for canonical MA but are thought to be essential for LAP include NOX2 and 
Rubicon (Martinez et al., 2015).  
 
Taken together and in contrast to the canonical MA pathway, during which LC3 
conjugation to the phagophore allows for recruitment of cytoplasmic substrates 
into forming autophagosomes via LC3-binding anchor proteins such as 
p62/sequestosome 1, LAP handles formerly extracellular particles that access the 
cell through phagocytosis and occurs without the formation of a double-
membraned vesicle and in the absence of p62/sequestosome 1 on LC3+ single-
membraned phagosomes (Martinez et al., 2015; Münz, 2015; Romao and Münz, 
2014). So far LAP has been implicated in efficient clearance of Saccharomyces 
cerevisiae and Aspergillus fumigatus (Martinez et al., 2015; Sanjuan et al., 2007). 
However, in the case of Listeria monocytogenes infection, LAPosomes have been 
described as Listeria-containing compartments that promote persistent infection 
(Lam et al., 2013). In plasmacytoid DCs, LAP, induced upon binding of immune 
complexes via FcγR, is required to assemble the interferon regulatory factor 7 
(IRF7)-signaling compartment which is essential for IRF7 activation and 
subsequent IFNα secretion downstream of TLR9 ligation (Henault et al., 2012). 
LysM-Cre+ conditional knockout mice for LAP-essential proteins mainly target 
CD11b+/F4/80+ macrophages and CD11b+Ly-6G+ neutrophils. Aged mice that are 
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deficient of LAP activity in these myeloid subsets spontaneously acquire a lupus-
like phenotype (Martinez et al., 2016).  
 
1.4 Antigen Presentation : Selected Pathways and Mechanisms 
Conventional CD4+ and CD8+ T cells constitute a powerful and effective arm of 
the adaptive immune system. As opposed to a more general immune response of 
the innate immune system, that is predominantly based on pattern recognition 
indicating danger and presence of pathogens, adaptive immune responses via 
CD4+ and CD8+ T cells are highly selective with regard to what they react to. 
This functional selectivity is morphologically based upon the high variability of 
existing T cell receptor clones. V(D)J recombination in thymic T lymphocytes, 
which involves somatic rearrangement of gene segments relevant for distinct T 
cell receptor expression, is at the basis of this high variability (Janeway, 1996). 
Unlike B lymphocytes, which are able to recognize native antigen of numerous 
biochemical make-up via their B cell receptor, CD4+ and CD8+ T cells are 
imperceptive to native antigen and may only recognize their cognate antigens, 
which are exclusively peptides, in the context of MHC class I (CD8+ T cells) and 
MHC class II (CD4+ T cells) presentation of said antigens. This phenomenon in 
conjuncture with the fact that a given T cell recognizes its cognate antigen only 
in association with a specific MHC-encoded allelic product is commonly referred 
to as MHC-restriction (Janeway, 1996; Kazansky, 2008).  
 
The two antigen presenting pathways, the MHC class I and II pathways, not just 
only activate distinct T lymphocyte subsets but are essentially complementary in 
their means to survey the organism for relevant cues and protect it from harm. 
Whereas MHC class I molecules, which are expressed on almost all nucleated 
cells, predominantly present antigenic peptides that originate from endogenously 
synthesized cytosolic proteins, MHC class II molecules are constitutively only 
expressed on professional antigen presenting cells (APCs) such as dendritic cells, 
macrophages an B cells, and mainly present peptides that emanate from the 
endocytic compartment. This dichotomy is on the foundation of cell-mediated 
immunity and allows for an efficient segregation of the T cell effector functions 
following either the cognate interaction with virus-infected/cancerous host cells 
or an APC. The former leading to efficient elimination of the antigen-presenting 
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cell thereby limiting the spread of a pathogen or malignant cell growth, the latter 
driving CD4+ T helper (TH) cell responses including B cell help which culminates 
in the efficient production of plasma cell derived antibodies that can target 
extracellular pathogens (Janeway, 1996).  
 
Aside from conventional MHC class I and -II-restricted, peptide recognizing T 
cells also their unconventional counterparts, which recognize small-molecule 
metabolites, glycolipids or modified peptides, help to shape immune responses in 
various immunological contexts such as anti-tumor, anti-microbial or 
autoimmune repsones. CD1d-restricted natural killer T (NKT) cells together with 
γδ T cells and MR1-restricted mucosal-associated invariant T (MAIT) cells belong 
to the group of innate-like T lymphocytes (Godfrey et al., 2015; Vermijlen and I. 
Prinz, 2014). As compared to conventional T cells, much less is known about the 
modes of interaction between such innate-like T cells with APCs in the context of 
antigen-presentation. A comprehensive understanding of the underlying 
mechanisms and detailed molecular pathways that govern and are involved in 
the effective generation and maintenance of antigen/antigen-presenting 
molecules in APCs is much needed in order to gain further insight into T cell 
function, conventional and unconventional alike, in normal and pathological 
states. 
 
1.4.1 MHC Class II Antigen Presenting Pathway 
While upregulated on facultative APCs such as endothelial cells and myoblasts 
following specific inflammatory signals (e.g. IFNγ) (Hohlfeld and Engel, 1990) 
(Hohlfeld and Engel, 1991; Shiao et al., 2007; Wiendl et al., 2000), in steady state 
MHC class II molecules are almost exclusively expressed on professional APCs 
such as DCs (Kambayashi and Laufer, 2014). Antigenic peptides that are 
presented to CD4+ T cells via MHC class II, result from proteolysis of self- and 
non-self proteins in the endosomal/lysosomal compartment (Trombetta and 
Mellman, 2005). Polymorphic MHC class II molecules are being synthesized in 
the ER, where αβ dimers of MHC class II associate with the non-polymorphic 
pseudopeptide invariant chain (Ii). Ii aids MHC class II molecules in passing the 
ER quality control system and, by means of a specific targeting sequence motif, 
promotes efficient egress of MHC class II molecules on their way from the ER to 
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the Golgi apparatus (Figure 1.4). Upon traversing the trans Golgi network on 
their way to the plasma membrane, another targeting motif facilitates the αβ-Ii 
complex to undergo clathrin-mediated endocytosis and therefore grants the 
complex access to the endocytic pathway, where eventually MHC class II can 
encounter antigenic peptides (Dugast et al., 2005; McCormick et al., 2005). In its 
capacity as a pseudopeptide, Ii prevents antigenic peptides to bind until 
proteolytically processed (Roche and Cresswell, 1990). The αβ-Ii complex passes 
from early endosomal to late endosomal/lysosomal compartments, where both 
abundance of proteolytic enzymes and sufficiently low pH, fulfill the 
requirements for efficient antigen processing and loading on MHC class II 
molecules (Blum et al., 2013). Sequential proteolysis of Ii by enzymes such as 
cathepsins L and S, during passage along the endocytic pathway, leaves a small 
remnant peptide called class II-associated invariant chain peptide (CLIP) within 
the MHC class II peptide binding groove (Ghosh et al., 1995). Presence of the 
place holder peptide CLIP precludes binding of antigenic peptides to MHC class 
II (Trombetta and Mellman, 2005). The molecular chaperones and MHC class II-
like proteins  H2-DM and HLA-DM in mice and humans respectively, facilitate 
antigenic peptide loading via catalyzing the dissociation of CLIP from its complex 
with MHC class II (Denzin and Cresswell, 1995). HLA-DM/H2-DM, both display 
a much more limited polymorphism as compared to MHC class II and are under 
the control of another set of non-peptide binding MHC class II-like chaperones, 
namely HLA-DO (humans) and H2-O (mice) respectively (Denzin et al., 1997; 
Liljedahl et al., 1996; van Ham et al., 1997). These two chaperones most likely 
assure that CLIP is only removed in an adequaetely acidic environment, where 
efficient antigen processing can occur. Once CLIP is dissociated from MHC class 
II, antigenic peptides may bind to the molecule and antigenic peptide:MHC class 
II complexes are being transported by endosomal/lysosomal tubules to and 
inserted in the plasma membrane. Absence of the targeting sequence in Ii now 
warrants a certain stability of the complex in the plasma membrane and 
therefore ensures efficient cognate CD4+ T cell interaction, however, MHC class 
II molecules may still be internalized and recycle back through the endocytic 
compartment (Hiltbold and Roche, 2002). 
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Figure 1.4. MHC class II antigen presentation.  
MHC class II molecules are synthesized in the ER where they associate with the invariant 
chain (Ii) followed by transport via the secretory pathway through the trans-Golgi network 
to the plasma membrane. From there, MHC class II/Ii-complexes are internalized by 
clathrin-mediated endocytosis and guided towards endosomal compartments. Ii is 
proteolytically cleaved, and class-II-associated invariant chain peptide (CLIP) remains in 
the antigen binding groove. Antigenic material may reach the endosomal compartment 
through phagocytosis or macroautophagy. Within the endosomal system proteolytic 
processing generates antigenic peptides that can subsequently be loaded onto MHC class II. 
CLIP is eventually exchanged with antigenic peptides via the non-polymorphic H2-DM, 
which is negatively regulated by H2-O. MHC class II molecules loaded with antigenic 
peptides are transported via endosomal tubules and/or vesicles to the plasma membrane 
where they can interact with CD4+ TH cells. 
 
1.4.1.1 Autophagy-Related Protein Function in Antigen Processing and 
Presentation With a Focus on the MHC Class II Pathway 
Professional APCs such as DCs employ several means of acquiring antigen. Aside 
from macropinocytosis, clathrin-mediated endocytosis and phagocytosis (which 
comprises clathrin-mediated and -independent uptake of material), autophagy 
constitutes an important set of pathways that contribute as source for antigens 
in APCs (Roche and Furuta, 2015). The first compelling evidence for the 
existence of an endogenous MHC class II pathway came from a study on 
describing how the endogenous measles virus matrix and nucleocapsid protein-
derived antigens could be presented to CD4+ T cells via MHC class II (Jacobson et 
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al., 1989). Only one year later, Nuchtern et al. confirmed these findings for yet 
another viral antigen by reporting the efficient loading of influenza A matrix 
protein-derived peptides onto MHC class II (Nuchtern et al., 1990). Further proof 
for the existence of endogenous MHC class II loading pathways was obtained 
through the direct analysis of peptides bound to MHC class II molecules. In fact, 
around 20-30% of natural ligands eluted from MHC class II molecules from B 
cells and DCs were found to be derived from endogenous protein sources 
(Adamopoulou et al., 2013; Rammensee et al., 1999). In a next step, MA was 
newly identified as a pathway that delivers endogenous antigenic constituents 
into endosomal MHC class II-containing compartments (MIICs) for subsequent 
recognition by CD4+ T cells (Nimmerjahn et al., 2003; Paludan et al., 2005; 
Schmid et al., 2007). The ability to deliver endogenous antigens to MHC class II 
seems to be differentially relevant depending on the APC (Brazil et al., 1997).  
 
MA is constitutively active in a variety of MHC class II positive APCs like DCs 
and B cells (Dengjel et al., 2005; Nimmerjahn et al., 2003; Paludan et al., 2005) 
and can be induced following immune stimulation of these cells through 
germline-encoded pattern-recognition receptors such as Toll-like receptors 
(TLRs) or inflammatory cytokines (Delgado et al., 2008; H. K. Lee et al., 2007; Xu 
et al., 2007). Colocalization studies indicate that in professional APCs, 
autophagosomes frequently fuse with MIICs, and that experimental delivery of 
antigens to autophagosomes by targeting the autophagosomal membrane 
through fusion with LC3 results in robust recognition by antigen-specific CD4+ T 
cells (Dengjel et al., 2005; Schmid et al., 2007). Additionally, not only 
haematopoietic APCs but also thymic epithelial cells expend MA to generate 
endogenously derived MHC class II-bound peptides for positive and negative 
selection of CD4+ T cells (Aichinger et al., 2013; Nedjic et al., 2008). Furthermore, 
macroautophagy has been implicated in generation and MHC class II-
presentation of peptidylarginine deiminase-citrullinanted peptides (a group of 
peptides against which antibody responses are frequently found in autoimmune 
disorders such as rheumatoid arthritis) in DCs and macrophages (Ireland and 
Unanue, 2011). 
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Aside from macroautophagy also the non-canonical autophagy pathway LAP has 
been implicated in antigen presentation via MHC class II. Although the 
functional benefit of coupling lipidated LC3 to a phagosome is still not completely 
understood some have argued that the coating of the phagosome with LC3-II 
allows the vesicle to travel faster along microtubules which results in faster 
fusion with the lysosomal compartment (Ma et al., 2014; Martinez et al., 2011; 
Sanjuan et al., 2007). However, studies that report more rapid cargo degradation 
were predominantly obtained using murine macrophages. Human studies on the 
other hand show that in prototypical APCs such as dendritic cells, LAP seems to 
retain antigenic cargo for sustained MHC class II antigen presentation rather 
than promoting its degradation (Romao et al., 2013). Antigenic containment and 
stabilization in combination with low levels of lysosomal proteases has been 
speculated to be a crucial mechanism by which DCs maintain efficient and 
prolonged antigen presentation (Delamarre et al., 2005; Romao and Münz, 2014; 
Romao et al., 2013). Lee and colleagues reported that in murine DCs, TLR-
dependent phagocytosed HSV-2 can be found in LC3+ single-membraned vesicles 
reminiscent of LAPosomes. In absence of LAP-essential protein ATG5 
subsequent HSV-2-specific CD4+ T cell responses were markedly reduced, 
arguing for inefficient MHC class II-dependent presentation of LAP-deficient DC 
towards cognate T cells (H. K. Lee et al., 2010). Interestingly, pharmacological 
induction of canonical MA via TORC1 inhibitor rapamycin did not lead to 
enhanced MHC class II presentation of phagocytosed antigens arguing for a non-
MA pathway linking phagocytosis and MHC class II presentation (H. K. Lee et 
al., 2010). 
A recent study extended the role of non-canonical autophagy pathways during 
antigen presentation to the MHC class I pathway. It was shown, that absence of 
ATG5 in CD11c+ DCs entailed impaired internalization of MHC class I molecules 
from the plasma membrane. The defect was mainly based on reduced 
recruitment of adaptor-associated kinase 1 (AAK1) to cell surface bound MHC 
class I. Furthermore, this stabilization of MHC class I molecules on the surface of 
APCs lead to enhanced CD8+ T cell responses upon influenza and LCMV 
infections in vivo (Loi et al., 2016).   
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1.4.1.2 Experimental Autoimmune Encephalomyelitis: In Vivo Model for 
CD4+ T Cell-Mediated Autoimmunity  
The emergence, activation and expansion of autoreactive T cells are considered 
crucial events in the development and progression of MS and encephalitogenic  
CD4+ T cells are the main driving forces in the rodent animal model of multiple 
sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) (Nylander 
and Hafler, 2012; A. P. Robinson et al., 2014; Sospedra and Martin, 2005; Terry 
et al., 2014). MS is a chronic immune-mediated disease of the CNS that develops 
in young adults with a complex predisposing genetic trait (Dendrou et al., 2015). 
Similar to other autoimmune diseases, HLA-DR and -DQ alleles within the HLA 
class II region on chromosome 6p21 are by far the strongest risk-conferring genes 
and are thought to account for 10-60% of the genetic risk of MS (International 
Multiple Sclerosis Genetics Consortium (IMSGC) et al., 2013; International 
Multiple Sclerosis Genetics Consortium et al., 2011). Although it is generally 
accepted that MHC class II molecules influence autoimmune disease risk by 
cognate interactions with autoreactive CD4+ T lymphocytes, our knowledge of 
how MHC class II-mediated antigen presentation confers risk for autoimmune 
diseases and regulates CD4+ T cell autoreactivity at the molecular level is still 
very sketchy.  
 
EAE, in which disease is induced by immunization of susceptible mice with 
myelin antigen together with adjuvant or by peripheral introduction of pre-
activated myelin-specific CD4+ T cells to naïve mice, represents a well 
established and suitable model to study CD4+ T cell-mediated autoimmunity 
(Krishnamoorthy and Wekerle, 2009). Advances in technologies of genetic 
ablation and transgenesis in mice of C57BL/6 background and the development 
of myelin-oligodendrocyte glycoprotein (MOG)-induced EAE in C57BL/6 mice 
contributed substantially to our understanding of cellular and molecular 
pathways in MS pathogenesis as well as to the development of therapeutic 
agents (Friese et al., 2006; Krishnamoorthy and Wekerle, 2009; A. P. Robinson et 
al., 2014; Terry et al., 2014). 
 
Before infiltrating the CNS, autoreactive CD4+ T cells are primed in the 
peripheral immune system. Priming can be targeted to skin draining lymph 
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nodes after subcutaneous immunization with myelin antigen and complete 
Freund's adjuvant (CFA) during active EAE induction. In MS, the site where 
autoreactive T cells are primed is not known, but the human disease is usually 
not elicited by vaccinations and persists in the absence of any systemic 
inflammatory challenges. Local reactivation and sustained expansion of 
autoreactive T cells within the CNS are considered instrumental in both MS and 
EAE. This effector phase can be modeled by adoptive transfer of primed myelin-
specific CD4+ T cells into naïve mice (adoptive transfer EAE, AT-EAE) and 
depends on the presence of CD11c+ antigen-presenting cells (APCs) (Greter et al., 
2005; Paterka et al., 2016). How autoreactive CD4+ T cells become activated and 
cause autoimmune tissue damage during the course of MS and EAE are, 
however, incompletely understood, partly because the detailed antigen 
processing route of how myelin self-antigens are processed and presented 
towards CD4+ T cells has not been fully elucidated.  
 
1.4.2 CD1d Antigen Presenting Pathway 
 
1.4.2.1 CD1d Assembly and Trafficking 
The CD1 family is comprised of five isoforms that can be partitioned in two 
groups. Group 1 consists of CD1a, CD1b, CD1c and CD1e and group 2 only 
includes CD1d. While all isoforms can be found in humans, only CD1d is 
expressed in mice (Van Kaer et al., 2016). DCs constitutively express CD1d and 
may activate invariant natural killer T (iNKT) cells by presenting antigenic 
glycolipids. CD1d is a highly conserved non-polymorphic MHC class I like 
transmembrane molecule and is regulated by cytokines or through engagement 
of innate receptors (Sköld et al., 2005). Similar to MHC class I molecules CD1d is 
a heterodimer that is non-covalently coupled to β2-microglobulin. Many 
hematopoietic and non-hematopoietic cell types express CD1d constitutively on 
their surface or upregulate it upon activation (Balk et al., 1994; Blumberg et al., 
1991; Busshoff et al., 2001; Canchis et al., 1993; de Lalla et al., 2004). However, 
in mice, constitutively CD1d-expressing dendritic cells (DCs) appear to be the 
most potent presenter of exogenous antigenic glycolipids (Arora et al., 2014; Fujii 
et al., 2002; 2004). Similar to MHC class I molecules, CD1d molecules are 
synthesized, folded and equipped with β2-microglobulin in the ER (H. S. Kim et 
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al., 1999). Analogous to the placeholder function of the pseudopeptide CLIP in 
MHC class II, CD1d most likely leaves the ER with a spacer lipid in its antigen-
binding groove in order to maintain stability. The biochemical nature of these 
lipids and the exact mechanisms underlying these transfer processes are not 
fully elucidated yet. However, the ER chaperone protein microsomal triglyceride 
transfer protein (MTP) has been suggested to load phospholipids onto nascent 
CD1d (Dougan et al., 2005). The pharmacological inhibition of MTP lead to 
significantly reduced CD1d-presentation of the prototypical experimental 
glycolipid antigen α-galactosylceramide (αGalCer) while leaving MHC class II 
presentation of ovalbumin (OVA) unperturbed (Dougan et al., 2005). CD1d, after 
having passed several protein quality control checkpoints, follows the secretory 
pathway and is being guided to the Golgi apparatus and subsequently reaches 
the cell surface (Kang and Cresswell, 2002b; H. S. Kim et al., 1999). From there, 
CD1d is being internalized by its cytoplasmic tyrosine-based sorting motif in an 
adaptor protein complex 2 (AP2)-dependent manner and delivered to several 
endosomal compartments. Importantly, a fraction of CD1d molecules also 
associates with MHC class II molecules in these endosomal compartments 
(Jayawardena-Wolf et al., 2001; Kang and Cresswell, 2002a). Interaction of CD1d 
with AP3 mediates sorting into lysosomes (Cernadas et al., 2003; Elewaut et al., 
2003; Vartabedian et al., 2016). Lipid antigens destined for CD1d-presentation 
can be derived from most subcellular compartments but usually encounter 
loading onto CD1d only in the endosomal/lysosomal system, where exogenous 
antigens face enzymatic processing and where endogenous antigens are recycled 
to (Figure 1.5). CD1d molecules survey and sample different endosomal 
compartments via a targeting motif in its cytoplasmic tail (Chiu et al., 2002; 
Jayawardena-Wolf et al., 2001). Deletion of the cytoplasmic tail does not 
influence CD1d surface expression, but abrogates the presentation of endogenous 
and exogenous lipids (Chiu et al., 2002). CD1d also associates with the MHC 
class II chaperone Ii (Jayawardena-Wolf et al., 2001). In an independent 
pathway, that appears to be especially important for the presentation of 
Mycobacterium tuberculosis-derived lipid-antigens, Ii diverts CD1d directly 
towards the lysosome (Sillé et al., 2011). 
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1.4.2.2. Lipid Loading on CD1d 
CD1d itself is unable to extract and acquire lipids from membranes and therefore 
is in need of lipid transfer proteins (LTPs) which, in analogy to the MHC class 
II/H2-DM interaction, facilitate loading of antigens within the 
endosomal/lysosomal compartment. Low molecular weight proteins called 
saposins (A, B, C, and D), GM2 ganglioside activator (GM2A) and the Niemann-
Pick type C1 and C2 proteins (NPC1 and NPC2, respectively) have so far been 
identified to mediate the loading of lipids on CD1d molecules (Kang and 
Cresswell, 2004; Sagiv et al., 2006; Schrantz et al., 2007; Zhou et al., 2004). 
Additionally, in the cases of saposins and GM2A, it was reported that these 
molecules also aid in the unloading of lipids from the CD1d antigen binding 
groove (Vartabedian et al., 2016). However, the detailed mechanisms that govern 
these loading/unloading processes and determine how loaded CD1d is sent to the 
plasma membrane, whereas unloaded CD1d dwells in the endosomal/lysosomal 
compartment, as well as the relevance of the autophagy machinery in lipid 
antigen loading within endosomal compartments, remains to be addressed. 
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Figure 1.5. CD1d antigen presentation.  
CD1d molecules are synthesized in the ER where they associate with β2-microglobulin.  
Microsomal triglyceride transfer protein (MTP) facilitates loading of ER-derived 
endogenous spacer lipids onto CD1d in order to stabilize the molecule for further  
transport. In an independent pathway, some CD1d molecules associate in the ER with 
invariant chain (Ii). The Ii/CD1d complexes, after travelling through the trans-Golgi 
network, are directly guided to the lysosome. The non-Ii associated CD1d molecules also 
pass the trans-Golgi network on their way to the plasma membrane. From there, CD1d is 
internalized by clathrin-mediated endocytosis and guided towards endosomal 
compartments where saposins, GM2 ganglioside activator (GM2A) and Niemann-Pick 
type C1 and C2 proteins (NPC1, NPC2) help exchanging spacer lipids with exogenous or 
other endogenous lipids. Loaded CD1d may either be transported to the lysosome in an 
adaptor protein 3 (AP3) dependent manner, or directly transported to the plasma 
membrane in order to interact with invariant natural killer T cells (iNKT). 
 
1.4.2.3.  Invariant Natural Killer T Cells  
NKT cells belong to the group of innate-like T lymphocytes, and represent an 
important link between innate and adaptive immune responses. They recognize 
CD1-presented lipid antigens, can be activated in both antigen-dependent and 
independent manners, secrete large amounts of cytokines upon activation and 
exhibit remarkable functional plasticity with both proinflammatory and 
immunoregulatory characteristics (Godfrey et al., 2015; Salio, Silk, et al., 2014). 
Depending on their T cell receptor (TCR) variability, CD1d-restricted NKT cells 
can be subdivided into type I or invariant NKT (iNKT) cells and type II or diverse 
NKT (dNKT) cells. Type I NKT cells are characterized by the expression of a 
semi-invariant T cell receptor (iTCR) (Vα14Jα18/Vβ8.1/Vβ8.2/Vβ8.3/Vβ7/Vβ2 in 
mice and Vα24Jα18/Vβ11 in humans) (Brennan et al., 2013; Macho-Fernandez 
and Brigl, 2015). The Vα14 TCR is exclusively used by iNKT cells but not by 
conventional T cells (Taniguchi et al., 2015). Furthermore, iNKT cell subsets bear 
molecules on their surface that were believed to be characteristic for natural 
killer (NK) cells like NKG2D (Kuylenstierna et al., 2011), KLRG (Shimizu et al., 
2014), IL-12 receptor (Brigl et al., 2011) or NK1.1 (CD161) (Benlagha et al., 2000; 
Godfrey et al., 2004; Kawano et al., 1997; Matsuda et al., 2000), hence their 
name. However, although this feature may characterize some NKT subsets, other 
subsets do not show expression of NK cell markers at all and the more stable 
prerequisite for belonging to the iNKT cell compartment therefore appears to be 
CD1d-restriction (Godfrey et al., 2015). Unlike conventional CD4+ or CD8+ T 
cells, iNKT cells recognize antigenic glycolipids which are presented via the 
monomorphic MHC class I-like molecule CD1d (Bendelac et al., 1995; 2007). 
Invariant NKT cell responses have proven to be highly conserved between 
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humans and mice. They enhance activation of innate immune cells such as 
dendritic cells (DCs) or NK cells and shape immune responses in concert with 
other lymphocytes such as B cells, thereby acting not only as an amplification 
relay but also as a shunter at the interface of innate and adaptive immunity 
(Brossay et al., 1998; Carnaud et al., 1999; P.-P. Chang et al., 2012; Hammond 
and Kronenberg, 2003) 
Invariant NKT cells can be activated via interaction of the iTCR:CD1d:glycolipid 
tri-molecular complex or in an iTCR-independent manner (e.g. via cytokines) 
(Brigl et al., 2011; Kawano et al., 1997). Upon activation, iNKT cells readily 
expand and undergo significant remodeling of their surface expression patterns 
with regards to several markers such as NK1.1 and the iTCR (Wilson et al., 
2003). Although iNKT cells have adaptive characteristics, they exist in a 
preactivated memory T cell-like effector state ready to release copious amounts of 
immunomodulatory cytokines (such as IFNγ, IL-4, IL-13, IL-17, GM-CSF and 
TNF-α) not only upon engagement of their iTCR but also in response to innate 
signals (Brigl et al., 2011). One of their key features is cytokine-mediated 
transactivation of other innate and innate-like immune subsets thereby 
amplifying initial responses (Carnaud et al., 1999; Paget et al., 2009; Schneiders 
et al., 2012; Smyth et al., 2002; 2005). However, iNKT cells may also provide both 
antigen-specific cognate and non-cognate help for B cells (P.-P. Chang et al., 
2012; King et al., 2012; Leadbetter et al., 2008) and in turn can be activated by B 
cells (Bialecki et al., 2009; Zietara et al., 2011). Interestingly, unlike non-cognate 
B cell help, antigen-specific B cell help induces a discontinuous germinal center B 
cell expansion, rapid initial IL-10-producing B cell expansion but fails to induce 
humoral memory, all in line with a more innate-biased response (Vomhof-Dekrey 
et al., 2015).  
A key difference between iNKT cells and conventional T cells is the onset of the 
response to a certain stimulus, which occurs in case of iNKT cells already a few 
hours after engagement, as opposed to several days in the case of conventional T 
cells (Crowe et al., 2003; Godfrey et al., 2015). 
 
1.4.2.4 Invariant Natural Killer T Cell Activation by Dendritic Cells 
The interaction between iNKT cells and DCs is not unidirectional but 
characterized by reciprocal feedback loops depending on the biochemical 
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structure of the CD1d ligand as well as the nature of the APC (Arora et al., 2014; 
Brennan et al., 2013). Until recently, it remained a conundrum as of how iNKT 
cells can be activated in a pathological setting in absence of an appropriate lipid 
agonist. It is now evident that DCs are able to transduce innate signals towards 
iNKT cell responses. Activation of iNKT cells can often be a combination of 
recognition of cognate lipid antigen and iTCR-independent signals. DCs will 
CD1d-present endogenous glycolipids in response to pathogen- and danger-
associated molecular patterns (PAMPS/DAMPS) (Paget et al., 2007). iNKT cells 
constitutively express IL-12 receptor and primitive pattern recognition receptor 
(PPRR)-mediated secretion of IL-12 by DCs leads to phosphorylation of STAT4 
and consecutive IFNγ release by iNKT cells (Brigl et al., 2011; Kitamura et al., 
1999). Furthermore, direct cellular contact between DCs and iNKT cells in a 
CD40:CD40L-dependent manner leads to a feed-forward signal, resulting in 
additional IL-12 production by DCs and consecutive further upreguation of IL-12 
receptor on iNKT cells. CD40/CD40L as well as CD28:CD80/CD86 interactions 
are required for subsequent iNKT cell mediated-IFNγ secretion whereas IL-4-
secretion was described to be solely dependent on CD28:CD80/CD86 interaction 
(Hayakawa et al., 2001; Kitamura et al., 1999). Coadministration of the iNKT cell 
agonist αGalCer and OVA in CD40−/− and CD40L−/− mice leads to abrogation of 
CD4+ and CD8+ T cell responses, while DCs were not affected in their ability to 
present antigen on MHC class I or II, and are capable of upregulating CD80/86 
(Fujii et al., 2004). Recent reports show that acellular artificial APCs loaded with 
iNKT cell agonists can activate and expand human iNKT cells in vitro as 
potently as autologous immature DCs. Engineering artificial APCs with 
differential association to costimulatory factors therefore may help to obtain 
valuable insights into the crosstalk between iNKT cells and DCs and will foster 
our understanding of how to harness their therapeutic potential (East et al., 
2012; Shiratsuchi et al., 2009; W. Sun et al., 2012) 
 
1.4.2.5 Invariant Natural Killer T cell-Mediated Maturation and 
Licensing of Dendritic Cells 
As a feed-back loop, αGalCer activated iNKT cells contribute rapidly to 
maturation of DCs in vivo resulting in upregulation of surface MHC class II, 
costimulatory molecules CD40, CD80, CD86 and endocytic receptor Dec-205, as 
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well as increased IFNγ secretion. Invariant NKT cell matured DCs elicit specific 
CD4+ and CD8+ T cell responses against a coadministered peptide. The observed 
DC maturation is highly dependent on iNKT cells since administration of 
αGalCer into iNKT-lacking Jα281 mice fails to induce DC maturation (Fujii et al., 
2003). Challenge with OVA-expressing tumors leads to significant tumor 
resistance in animals that had been challenged with OVA in combination with 
iNKT cells agonist αGalCer (Hermans et al., 2003).  
 
1.4.2.6 Modifications of Invariant Natural Killer T Cell Responses: 
Implications for Human Health and Disease 
Their ability to mature DCs and to transactivate both cytotoxic T lymphocytes 
and NK cells for tumor cell eradication (Fujii et al., 2013; Pardoll, 2012) reflect 
the potential of iNKT cells in improving cancer immunotherapy. However, in 
contrast to promising studies performed in experimental models (Harada et al., 
2005), clinical trials using direct administration of soluble αGalCer in cancer 
patients so far failed to show promising results (Giaccone et al., 2002). Aside from 
high interindividual variability in iNKT cell frequencies and inefficient targeting 
of particular subsets of lipid antigen presenting cells, direct administration of 
antigenic glycolipids was shown to induce PD1:PDL1-dependent long term 
anergy (Parekh et al., 2005; 2009; Sullivan and Kronenberg, 2005) or induction of 
regulatory IL-10 producing iNKT cells (Lynch et al., 2015; Sag et al., 2014) which 
negatively affect anti-tumor responses (Sag et al., 2014). As an alternative to 
αGalCer administration, DCs can be glycolipid-pulsed ex vivo followed by re-
infusion. This strategy has proven to induce prolonged activation of iNKT cells 
rather than a regulatory/anergic phenotype, inhibits metastasis in an 
experimental melanoma model and can expand human iNKT cells in vivo (Fujii 
et al., 2002; Toura et al., 1999; van der Vliet et al., 2003). Additionally, adoptive 
transfer of αGalCer-pulsed matured DCs expands iNKT cells in advanced stage 
cancer patients (D. H. Chang et al., 2005). A clinical phase I study in a limited 
number of individuals with metastatic malignancies reported that transfer of 
immature monocyte-derived DCs loaded with αGalCer is associated with a 
stronger recall-response (Nieda et al., 2004). The use of in vitro matured DCs as 
compared to immature DCs significantly increases the observed beneficial effects 
(D. H. Chang et al., 2005; Nieda et al., 2004). Another phase I trial, during which 
INTRODUCTION 	
	 27	
patients with head and neck squamous cell carcinoma (HNSCC) were treated via 
singular coadministration of autologous in vitro expanded iNKT cells 
(intraarterial) and submucosal application of αGalCer-loaded APCs, showed 
partial clinical response (Kunii et al., 2009). In a small phase II clinical study in 
HNSCC patients using the same treatment regiment, 50% of the patients 
depicted tumor regression while 50% showed stable disease (Yamasaki et al., 
2011). Promising results were reported from a phase I-II study in non-small cell 
lung cancer patients: sequential intravenous administration of αGalCer-pulsed 
PBMCs increased the frequencies of IFNγ-producing cells in a majority of 
patients. This iNKT cell-mediated TH1 skewing in responders was associated 
with significantly prolonged median survival time (Motohashi et al., 2009). In a 
follow-up study, two candidate genes, LTB4DH and DPYSL3, were proposed to 
predict responsiveness to above mentioned treatment regimen (Okita et al., 
2010). Late stage cancer patients often are immune suppressed and retrieving 
enough APCs from these individuals for autologous transfer might prove 
difficult. Therefore, novel artificial APC constructs might help to circumvent lack 
of appropriate autologous APC numbers (East et al., 2012; Shiratsuchi et al., 
2009; W. Sun et al., 2012). Moreover, novel glycolipid-antigen delivery systems 
that systematically target relevant APC populations are currently being 
investigated. Some of these nanovector systems already show promising results. 
αGalCer-containing silica microspheres, poly(lactic-co-glycolic acid) (PLGA) 
polymers and modified liposomes have already been reported to efficiently elicit 
iNKT cell responses (Barral et al., 2010; Macho-Fernandez et al., 2012; 
Nakamura et al., 2013). In order to initiate in situ responses of DCs, artificial 
adjuvant vector cell systems have been recently introduced. Herein, allogeneic 
CD1d-expressing NIH3T3 fibroblasts loaded with αGalCer were transfected with 
target-antigen mRNA. Injection of NIH3T3 fibroblasts leads to activation of 
iNKT cells, consecutive maturation of DCs and activation of NK cells and 
antigen-specific CTLs. Animals immunized with adjuvant vector cells showed 
potent immunity against antigen-bearing tumors. Memory cytotoxic T 
lymphocyte (CTL) responses could still be detected 12 months after initial single 
injection (Fujii et al., 2009; 2013). 
Humans, as compared to inbred mice, show high interindividual variability in 
iNKT cell frequencies. Patients with low steady state numbers of iNKT cells 
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might not profit from autologous transfer of lipid-pulsed APCs. Mouse embryonic 
fibroblast-derived induced pluripotent stem cells (iPSCs) can readily differentiate 
into functional iNKT cells. These iPSC-derived NKT cells are able to produce 
IFNγ and mediate anti-neoplastic effects in vivo (Watarai et al., 2010). Therefore, 
patients with low iNKT cell frequencies may be reconstituted with iPSC-derived 
iNKT cells as an efficient means to fully harness their immunomodulatory 
potential (Fujii et al., 2013). 
First attempts in using engineered iNKT cells with chimeric antigen receptors 
(CARs) show promising results. CAR-bearing iNKT cells home to designated 
tumor sites, eradicate tumor cells and effectively execute cytotoxicity against 
tumor associated macrophages (TAMs) without inducing graft-versus-host 
disease (GvHD) (Heczey et al., 2014). Additionally, CD62L+ CD19-specific CAR-
bearing iNKT cells show potent immunotherapeutic efficacy in a B cell 
lymphoma model (G. Tian et al., 2016).  
In conclusion, murine studies and clinical trials performed to date demonstrate 
that therapeutic strategies that harness the biology of iNKT cells are generally 
well tolerated and, in some cases, effective in inducing tumor regression and 
prolonged survival. All of the tested and currently investigated strategies 
harness both the powerful cytolytic and adjuvant activity of iNKT cells in order 
to enhance protective anti-tumor immune responses. In order to fully harness 
their therapeutic potential it will not only be key to elucidate the differential 
effector functions and modes of activation of the distinct iNKT cell subsets but 
also the immunological contexts and transcriptional programs that direct iNKT 
cell progenitors into development towards a specific subpopulation as well as 
determinants that gear specific iNKT cell subsets to distinct anatomical sites 
(Benlagha et al., 2005; Gapin, 2016; Y. J. Lee et al., 2015).  Profound mechanistic 
insight into understanding how DCs activate and instruct iNKT cells and which 
factors regulate iNKT cell response is a prerequisite for improving the efficacy of 
iNKT cell-targeting therapies. In addition, clinical trials will be instrumental in 
identifying the optimal ligand and APC population to induce anti-tumor iNKT 
cell activation and in determining the routes and intervals of administration to 
achieve sustained immune responses.  
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1.5 Hypothesis 
Autophagy pathways converge in the endosomal/lysosomal compartment, where 
antigen loading onto MHC class II and the non-classical MHC class I CD1d 
molecule takes place. We therefore hypothesized that absence of the essential 
autophagy protein ATG5 impairs antigen loading and restrains CD4+ T cell and 
iNKT cell responses. To this end, we investigated mice with conditional deletion 
of ATG5 in CD11c+ APCs in in vivo models for i) CD4+ T cell-driven 
autoimmunity, i.e. EAE, and ii) for iNKT-cell-mediated protection from infectious 
pathogens, i.e. Sphingomonas paucimobilis infection. 
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2. Results 
 
2.1 ATG5 in DCs Drives CD4+ T Cell-Mediated CNS Autoimmunity 
 
2.1.1 Phenotypic Analysis of DC-Atg5+/+ and DC-Atg5−/− Mice 
In order to assess the role of autophagy during DC-mediated antigen 
presentation we made use of a Cre/loxP-based conditional knockout targeting 
the autophagy protein ATG5 in professional antigen presenting cells. To this 
end, conditional knockout mice (C57BL/6) for disruption of Atg5, an essential 
component of both the canonical pathway of macroautophagy and LC3-
associated phagocytosis (LAP), in CD11c+ antigen presenting cells (Atg5flox/flox 
× CD11c-Cre-GFP, designated DC-Atg5−/−) were generated. Targeted deletion 
of Atg5 was confined to the CD11c+ immune compartment represented by 
distinct increase in the GFP-signal in CD11c+/MHC class II+ splenic DCs in 
DC-Atg5−/− mice as compared to Atg5flox/flox control littermates (designated DC-
Atg5+/+) (Figure 2.1.1 A, B). By contrast, Ly-6C+/CD11b+/CD11cneg splenic 
monocytes, splenic CD19+/MHC class II+ B cells and splenic CD4+ T cells did 
not express GFP indicating cell type specific deletion of Atg5 within the 
CD11c+ DC subset (Figure 2.1.1 A). Furthermore, knockout of Atg5 was also 
confirmed on protein level, using CD11c+ BMDCs (Figure 2.1.1 C). DC-
Atg5−/−-derived CD11c+ BMDCs were devoid of ATG5-ATG12-complex, showed 
a marked accumulation of LC3-I but levels of the lipidated form of LC3 (LC3-
II) could not be detected in these cells (Figure 2.1.1 C). Having confirmed 
that ablation of ATG5 was indeed confined to the CD11c+ compartment, we 
next investigated if tissue-specific knockout of an essential autophagy gene 
would lead to alterations with regard to the frequency of our target cells. 
When comparing DC-Atg5−/− vs. DC-Atg5+/+ mice, no difference in frequencies 
of splenic CD11+/MHC class II+ cDCs were detected (Figure 2.1.1 D). 
Moreover, surface levels of MHC class II and costimulatory molecules CD40 
and CD86 remained unchanged in DC-Atg5−/− mice (Figure 2.1.1 E).  
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Figure 2.1.1 Characterization of DC-Atg5−/− vs. DC-Atg5+/+ mice 
(A) Representative histograms depicting GFP-Cre-expression of either CD11c+/MHC class II 
(MHCII)+ splenic conventional DCs (cDCs), Ly-6C+/CD11b+/CD11c− monocytes, B cells CD4+ 
T cells in DC-Atg5+/+ (black triangles) or DC-Atg5−/− (red circles) mice in steady state. (B) 
Quantification of GFP-Cre median fluorescence intensity (n: DC-Atg5+/+ = 7; DC-Atg5−/− = 9). 
(C) Western blot analysis for protein expression of ATG5-ATG12-complex, LC3-I and LC3-II 
in CD11c+ BMDCs derived from DC-Atg5+/+ or DC-Atg5−/− mice. Actin served as a loading 
control. One representative of 2 experiments is shown. (D) Quantified frequencies of splenic 
CD11c+/MHC class II+ DCs in naïve DC-Atg5+/+ and DC-Atg5−/− mice. (E) Representative 
histograms and (F) quantification of median fluorescence intensity (MFI) for MHC class II 
(upper panel), CD40 (middle panel) and CD86 (lower panel) on CD11c+/MHC class II+ 
splenic DCs. Pooled data of 3 independent experiments is shown. Each dot represents one 
individual animal. Statistical analysis: unpaired two-tailed student t test, mean ± s.e.m., ns 
= not significant, *P< 0.05, **P< 0.01 and ***P< 0.001. 
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2.1.2 Absence of ATG5 in CD11c+ Cells Protects Mice from Adoptive 
Transfer EAE 
Next, we wanted to address whether autophagic activity in CD11+ antigen 
presenting cells regulates the onset and/or severity of autoimmune-mediated 
neuroinflammation. For this purpose, we made use of EAE, a commonly used 
animal model of MS. Since we were particularly interested in the role of DC-
inherent autophagy during CNS reactivation of encephalitogenic CD4+ T cells, 
we chose to apply the adoptive transfer model of EAE (AT-EAE), during which 
preactivated myelin-specific CD4+ T cells are injected into naïve recipients. 
We found that absence of Atg5 in CD11c+ cells leads to complete protection 
from developing AT-EAE upon transfer of T cell receptor-transgenic (TCR-tg) 
MOG35-55-specific CD4+ T cells derived from 2D2/TCRMOG animals (Figure 
2.1.2 A, left and middle panel). Furthermore, as opposed to DC-Atg5+/+ 
control littermates, DC-Atg5−/− mice did not show any signs of weight loss after 
transfer of preactivated effector cells (Figure 2.1.2 A, right panel). These 
results were confirmed using non-TCR-tg polyclonal encephalitogenic CD4+ 
T cells obtained from MOG35-55 immunized C57BL/6 wild type mice (Figure 
2.1.2 B). To ensure that the observed protective effect was not due to Cre-
recombinase, which is present in DC-Atg5−/− mice but absent in DC-Atg5+/+ 
control littermates, CD11c-Cre mice were used as recipients for AT-EAE. In 
contrast to DC-Atg5−/− mice, CD11c-Cre mice were fully susceptible to 
developing AT-EAE and showed a similar disease onset, severity and weight 
loss pattern as C57BL/6 wild type mice (Figure 2.1.2 C). 
 
 
RESULTS 
	 33	
Figure 2.1.2 Preactivated, encephalitogenic CD4+ T cells require ATG5 
expression by CD11c+ cells to induce AT-EAE.  
(A) EAE was induced via adoptively transferring 2D2/TCRMOG-derived 
encephalitogenic CD4+ T cells into DC-Atg5+/+ (black triangles) or DC-Atg5−/− mice 
(red circles). Development of clinical EAE scores is depicted. Each data point 
represents the mean of animals from 4 independent experiments (n: DC-Atg5+/+ = 
32; DC-Atg5−/− = 35) (left panel). Quantification of disease incidence is shown (middle 
panel). Development of body weight is depicted. Each data point represents the 
mean of animals from 4 independent experiments (n: DC-Atg5+/+ = 32; DC-Atg5−/− = 
35) (right panel). Pooled data of 4 independent experiments is shown. (B) EAE was 
induced via adoptively transferring C57BL/6 wild type-derived encephalitogenic 
CD4+ T cells into DC-Atg5+/+ (black triangles) or DC-Atg5−/− mice (red circles). 
Development of clinical EAE scores is depicted. Each data point represents the 
mean of 7 animals (left panel). Quantification of disease incidence is shown (middle 
panel). Development of body weight is depicted. Each data point represents the 
mean of 7 animals (right panel). One representative of two independent experiments 
is shown. (C) EAE was induced via adoptively transferring 2D2/TCRMOG-derived 
encephalitogenic CD4+ T cells into C57BL/6 wild type mice (grey hexagons) or 
CD11c-Cre-GFP mice (brown diamonds). Development of clinical EAE scores is 
depicted. Each data point represents the mean of 6 animals. (left panel). 
Quantification of disease incidence is shown (middle panel). Development of body 
weight is depicted. Each data point represents the mean of 6 animals (right panel). 
One representative of two independent experiments is shown. 
 
When sacrificing animals at peak of disease (day 19), DC-Atg5+/+ animals 
depicted significantly smaller spleens (reflected by total weight and 
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spleen:body weight ratio) as compared to DC-Atg5−/− mice (Figure 2.1.3 A-C) 
which is in line with a previous study that showed atrophy of primary and 
secondary lymphoid organs during models of progressive EAE (Tsunoda et al., 
2005) 
 
Figure 2.1.3 DC-Atg5−/− do not show splenic atrophy at peak of disease.  
(A) Total spleen weight in mg and (B) spleen/bodyweight ratio on day of sacrifice 
upon AT-EAE. Each dot represents one individual animal. Pooled data of 3 
independent experiments is shown. Scale bar: 0.5 cm Statistics: unpaired two-tailed 
student t test. * P< 0.05, ** P< 0.01, *** P< 0.001. 
 
2.1.3 Characterization of CD11c-Expressing DCs in the CNS of DC-
Atg5−/− and DC-Atg5+/+ Mice at Steady State 
Based on the finding that absence of ATG5 in the CD11c+ compartment alone 
sufficed to prevent onset of AT-EAE, we next investigated whether a CD11c+ 
cell population was present in the CNS at steady state, if this subset 
expressed markers in keeping with a classical DC expression profile and if it 
is subject to Cre-mediated deletion of ATG5. Indeed, a small subpopulation of 
CD11b+ myeloid cells in the CNS coexpressed CD11c and MHC class II 
(Figure 2.1.4 A). The frequency of this subpopulation (defined as % of 
CD45hi/CD11b+ or % of CD11b+) was unchanged in DC-Atg5−/− as compared to 
DC-Atg5+/+ mice (Figure 2.1.4 B). This CD11c+ subset was efficiently targeted 
by Cre-recombination as indicated by strong GFP-expression, which was 
confined to the CD11c+ compartment and not detectable in DC-Atg5+/+ mice 
(Figure 2.1.4 C). Additionally, this CNS resident CD11c+ population 
(henceforth CNS DCs) expressed the surface molecules indicative of 
professional antigen presenting properties such as MHC class II, CD86 and 
CD40. When comparing the two genotypes, ATG5-deficient CNS DCs did not 
differ in their expression profile from DC-Atg5+/+-derived CNS DCs (Figure 
2.1.4 D). 
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Figure 2.1.4 Phenotypic characterisation of CD11c+ CNS DCs at steady state.  
(A) Gating strategy for flow cytometry analysis in the CNS of naïve DC-Atg5+/+ and 
DC-Atg5−/− mice. First, single leukocytes were defined by applying the respective 
gates (leukocytes: SSC-A vs. FSC-A; single cells: FSC-H vs. FSC-A). Next, it was 
gated on CD45+ cells while excluding Ly-6G+ neutrophils and dead cells. After 
gating on CD11b+ myeloid cells, microglia were defined as CD45lo/CD11b+. Inside 
the CD45hi/CD11b+ cell gate, it was further gated on CD11c+/MHC class II (MHCII)+ 
cells (CNS DCs). Within the remainder of the cells it was subgated on Ly-
6C+/CD11b+/CD11c− monocytes (not shown). (B) Quantified frequencies (of parent, 
left panel and of total CD11b+, right panel) of CNS resident CD11c+/MHCII+ DCs in 
naïve DC-Atg5+/+ and DC-Atg5−/− mice. (C) Representative histograms (upper panels) 
depicting GFP-Cre-expression of either CNS resident CD11c+/MHCII+ DCs (left 
panel) or Ly-6C+/CD11b+/CD11c− monocytes (middle panel) in naïve mice. 
Representative histogram depicting GFP-Cre-expression in CNS-infiltrating CD4+ T 
cells on peak of disease (right panel). Quantification of GFP-Cre median 
fluorescence intensity is depicted in the respective lower panels. (D) Representative 
histograms (upper panels) depicting either MHCII (left panel), CD86 (middle panel) 
or CD40 (right panel) median fluorescence intensity (MFI) of CNS resident 
CD11c+/MHCII+ DCs. Quantification of the respective surface molecules is shown in 
the lower panels. Pooled data of 2 independent experiments is shown (n: DC-Atg5+/+ 
= 5; DC-Atg5−/− = 5 for naïve myeloid compartments and n: DC-Atg5+/+ = 10; DC-
Atg5−/− = 12 for peak of disease CD4+ T cell analysis). Statistical analysis: unpaired 
two-tailed student t test, mean ± s.e.m., ns = not significant, *P< 0.05, **P< 0.01 and 
***P< 0.001. 
 
2.1.4 Characterization of Microglia in DC-Atg5−/− and DC-Atg5+/+ Mice 
at Steady State 
The major population of CD45+ CD11b+ cells in the CNS of a naïve mouse is 
comprised of microglial cells (Greter et al., 2015). Albeit not expressing CD11c 
or MHC class II constitutively, these CD45lo microglia have been described to 
upregulate surface levels of these molecules upon activation (Greter et al., 
RESULTS 
	 36	
2015; Ponomarev et al., 2005; Reichmann et al., 2002; Remington et al., 2007). 
We analyzed the CD45lo/CD11b+ microglial compartment in DC-Atg5−/− and 
DC-Atg5+/+ mice at steady state, and found their frequencies to be similar 
(Figure 2.1.5 A). Moreover, neither DC-Atg5−/−- nor DC-Atg5+/+-derived 
microglia expressed CD11c to the extent of CNS DCs (Figure 2.1.5 B, left 
panel) and DC-Atg5−/−-derived microglia did not express GFP indicating that 
despite low-level CD11c expression, the promotor activity does not support 
CD11c driven GFP-Cre-recombinase expression. This suggests that microglial 
cells do not delete Atg5 in DC-Atg5−/− mice (Figure 2.1.5 B, right panel). The 
surface levels of costimulatory molecules CD40 and CD86 on microglia were 
unchanged in DC-Atg5−/− mice and the overall expression of MHC class II was 
low (Figure 2.1.5 C).  
 
Figure 2.1.5 Characterization of microglial compartment in DC-Atg5−/− and 
DC-Atg5+/+ mice at steady state.  
(A) Frequencies of CD45lo/intCD11b+ microglial cells are unchanged in DC-Atg5−/− 
mice. (B) CD45lo/intCD11b+ microglial cells do not express CD11c to a substantial 
level at steady state compared to CD11c+/MHC class II (MHCII)+ CNS DCs (left 
panel). There is no increased GFP-Cre signal in microglia derived from DC-Atg5−/− 
mice as compared to DC-Atg5+/+ mice (right panel) (C) Surface expression levels of 
CD40, CD86 and MHCII are similar on microglia when comparing DC-Atg5+/+ and 
DC-Atg5−/− mice. Pooled data of 2 independent experiments is shown (n: DC-Atg5+/+ = 
5; DC-Atg5−/− = 5) Statistical analysis: unpaired two-tailed student t test, mean ± 
s.e.m., ns = not significant, *P< 0.05, **P< 0.01 and ***P< 0.001. 
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Taken together, we identified a subpopulation of CD11c+/MHC class II+ DCs 
within the non-diseased CNS that is specifically and exclusively targeted by 
Cre-mediated Atg5 deletion in DC-Atg5−/− mice. Loss of ATG5 in the CD11c+ 
compartment does not disturb frequency or expression levels of MHC class II 
and costimulatory molecules in this subset but completely protects conditional 
knockout animals from developing AT-EAE.  
 
2.1.5 Lack of ATG5 in CD11c+ DCs Limits Expansion of 
Encephalitogenic CD4+ T Cells Within the CNS 
Next, we analyzed frequencies and effector functions of CNS-infiltrating T 
cells in DC-Atg5−/− and DC-Atg5+/+ mice upon induction of AT-EAE. For this 
purpose, animals were sacrificed when DC-Atg5+/+ animals reached their peak 
of disease. In accordance with the complete absence of a clinical phenotype in 
these animals, DC-Atg5−/− mice depicted significantly smaller proportions of 
CNS infiltrating CD45+ cells as compared to DC-Atg5+/+ mice (Figure 2.1.6 A). 
Moreover, a significantly higher frequency of CD4+ T cells was present in the 
CNS of Atg5+/+ mice whereas the frequencies of CD8+ T cells was similar 
(Figure 2.1.6 B). The frequencies of total CD45+ and CD4+ but not CD8+ T 
cells positively correlated with the severity of EAE in DC-Atg5+/+ animals 
which is in accordance with the crucial role of CD4+ T cells in the 
pathogenesis of EAE (Ben-Nun, Wekerle and Cohen, 1981a; Krishnamoorthy 
and Wekerle, 2009) (Figure 2.1.6 C). Also, the frequencies of activated CNS 
CD44hi T cells were markedly reduced in DC-Atg5−/− mice (Figure 2.1.6 D) 
and the few CD4+ T cells present in the CNS of DC-Atg5−/− mice showed a 
mostly naïve phenotype reflected by a higher frequency of CD62L+/CD44neg 
cells (Figure 2.1.6 E).  
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Figure 2.1.6 Characterization of CNS-infiltrating T cells upon induction of 
adoptive transfer EAE in DC-Atg5−/− and DC-Atg5+/+ mice. 
(A) On day of sacrifice after adoptive transfer EAE induction, DC-Atg5−/− mice 
exhibit significantly fewer CD45+ infiltrates in the CNS. (B) Furthermore, 
quantification of immune cell subsets shows significantly lower proportions of CD4+ 
T cells in DC-Atg5−/− as compared to DC-Atg5+/+ mice on peak of disease in the CNS, 
whereas no difference is observed in the CD8+ T cell compartment. (C) Correlation 
analyses of total CD45+ cells (left panel), CD4+ T cells (middle panel) or CD8+ T cells 
(right panel) within live single cells with EAE disease severity. (D) On peak of 
disease, DC-Atg5−/− mice exhibit significantly lower frequencies of activated 
CD44+/CD4+ and CD8+ T cells in the CNS. (E) The CD4+ but not the CD8+ T cell 
compartment in DC-Atg5−/−-derived CNS contains more CD62L+/CD44neg cells as 
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compared to DC-Atg5+/+-derived CNS. Each dot represents one individual animal 
Pooled data of 2 independent experiments is shown. Statistical analysis: unpaired 
two-tailed student t test and two-tailed Pearson correlation test. ns = not significant, 
* P< 0.05, ** P< 0.01, *** P< 0.001. 
 
2.1.6 Analysis of CNS Regulatory T Cells at AT-EAE Peak of Disease  
Although the overall frequencies of CD45+ cells, and amongst those, the 
proportion of conventional CD4+ T cells, were lower in the CNS of DC-Atg5−/− 
animals, the frequencies of CD4+/CD25+/FOXP3+ T regulatory cells (TREGs) 
were increased in the CNS of DC-Atg5−/− animals (Figure 2.1.7 A). Both, DC-
Atg5−/−- and DC-Atg5+/+-derived CNS TREGs expressed similar amounts of 
CD103, a marker for effector/memory-like phenotype of murine TREGs 
(Huehn et al., 2004) (Figure 2.1.7 B). 
Figure 2.1.7 Analysis of CD4+/CD25+/FOXP3+ TREGs in the CNS of DC-
Atg5−/− and DC-Atg5+/+ mice upon induction of AT-EAE.  
(A) Quantified frequencies of CD4+/CD25+/FOXP3+ TREGs on day of sacrifice and 
(B) quantification of median fluorescence intensity (MFI) of CD103 on 
CD4+/CD25+/FOXP3+ TREGs. Each dot represents one individual animal. Pooled 
data of 2 independent experiments is shown. Statistical analysis: unpaired two-
tailed student t test, mean ± s.e.m., ns = not significant, * P< 0.05, ** P< 0.01, *** 
P< 0.001. 
 
These data indicate that protection from AT-EAE development in DC-Atg5−/− 
mice is associated with reduced activation and accumulation of 
encephalitogenic CD4+ T cells within the CNS. 
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2.1.7 CNS-Infiltrating CD4+ T Cells in DC-Atg5−/− Mice Maintain their 
Capacity to Produce Effector Cytokines 
In a next step, we investigated whether frequencies and/or effector functions 
of CNS-infiltrating T cells differ between DC-Atg5+/+ and DC-Atg5−/− mice 
during AT-EAE. We found that the overall frequencies of CNS-infiltrating 
leukocytes producing the proinflammatory cytokines IFNγ, IL-17A and GM-
CSF, upon ex vivo restimulation with MOG35-55 peptide was significantly 
diminished in DC-Atg5−/− compared to DC-Atg5+/+ mice at peak of disease 
(Figure 2.1.8 A). Restimulation with MOG35-55 lead to a significantly higher 
production of proinflammatory cytokines than restimulation with an 
irrelevant peptide derived from ovalbumin (OVA323-339) (Figure 2.1.8 B, C). 
Cytokine production was generally preserved in DC-Atg5−/− mice as, despite 
being largely reduced in numbers, the few CNS infiltrating T cells found in 
these mice showed similar production of IFNγ, IL-17A and GM-CSF upon 
MOG35-55 restimulation (Figure 2.1.8 B, C). 
 
 
 
Figure 2.1.8 Ex vivo restimulation of CNS-derived infiltrating immune cells 
and quantification of their effector cytokines.  
(A) DC-Atg5+/+-mice contain significantly more (% of live single cells) cytokine-
producing MOG35-55-specific CD4+ T cells in the CNS than DC-Atg5−/− mice upon AT-
EAE induction. (B) Both, DC-Atg5−/− and DC-Atg5+/+-derived CD4+ T cells are 
capable of secreting cytokines (IFNγ, IL-17A and GM-CSF) upon restimulation with 
MOG35-55 (but not with OVA323-339) to similar degrees. (C) Representative contour 
plot for GM-CSF+ CD4+ T cells in CNS of DC-Atg5−/− or DC-Atg5+/+ mice on peak of 
disease. Each dot represents one individual animal. Pooled data of 2 independent 
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experiments. Statistics: unpaired two-tailed student t test. ns = not significant, * P< 
0.05, ** P< 0.01, *** P< 0.001. 
 
Conversely, neither restimulation with MOG35-55 nor OVA323-339 led to the 
production of IFNγ, IL-17A or GM-CSF by spleen-derived CD4+ cells, 
indicating that at the time point of analysis the majority of encephalitogenic 
effector T cells had already homed to their target organ (Figure 2.1.9 A, B). 
 
Figure 2.1.9 Ex vivo restimulation of spleen-derived CD4+ T cells and 
quantification of their effector cytokines. 
(A) Splenic CD4+ T cells on day of sacrifice upon AT-EAE do not produce significant 
amounts of proinflammatory cytokines IFNγ, IL-17A and GM-CSF after ex vivo 
restimulation with MOG35-55 as compared to restimulation with OVA323-339. (B) 
Representative density plot for GM-CSF+ CD4+ cells spleens of DC-Atg5−/− or DC-
Atg5+/+ mice on peak of disease. Each dot represents one individual animal. Pooled 
data of 2 independent experiments. Statistics: unpaired two-tailed student t test. ns 
= not significant, * P< 0.05, ** P< 0.01, *** P< 0.001. 
 
These findings suggest that loss of ATG5 in CD11c+ APCs does not modify the 
encephalitogenic capacity of CNS-infiltrating CD4+ T cells to produce and 
release effector cytokines per se, but rather restrains their in situ reactivation 
and expansion. 
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2.1.8 Analysis of CNS Myeloid Cells at AT-EAE Peak of Disease  
We additionally profiled the CNS-infiltrating myeloid compartment following 
induction of AT-EAE. Frequencies of Ly-6G+ neutrophils and Ly-
6C+/CD11b+/MHC class IIneg monocytes and CD11b+/MHC class II+ 
inflammatory DCs (iDCs) were significantly lower in the CNS of DC-Atg5−/− 
animals (Figure 2.1.10 A-C). Within the iDC compartment the proportion of 
CD11c+/Ly-6C+ APCs was significantly higher in Atg5+/+ animals (Figure 
2.1.10 D).  
 
 
Figure 2.1.10 Characterization of CNS-infiltrating myeloid subsets upon 
induction of adoptive transfer EAE in DC-Atg5−/− and DC-Atg5+/+ mice. 
Quantified CNS frequencies of (A) Ly-6G+ neutrophils (depicted as % of live single 
CD45+ cells), (B) Ly-6C+/MHC class II (MHCII)+/CD11b+ monocytes, (C)  
MHCII+/CD11b+  inflammatory DCs (iDCs) and (D) CD11c+/Ly-6C+ iDCs on day of 
sacrifice (B-D depicted as % of live single CD11b+/CD45hi cells) . Each dot represents 
one individual animal. Pooled data of 2 independent experiments is shown. 
Statistical analysis: unpaired two-tailed student t test. ns = not significant, * P< 
0.05, ** P< 0.01, *** P< 0.001. 
 
2.1.9 Analysis of Microglia at AT-EAE Peak of Disease  
Furthermore, frequency and MHC class II expression levels of microglia were 
determined. Similar to steady state analysis, the overall frequency of this 
CNS resident subset was similar at peak of disease in both genotypes (Figure 
2.1.11 A). However, following induction of AT-EAE, MHC class II surface 
expression, which was generally low and similar between DC-Atg5−/−- and DC-
Atg5+/+-derived microglia at steady state (Figure 2.1.5 C), was markedly 
upregulated only on microglia of DC-Atg5+/+ mice (Figure 2.1.11 B, C). 
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Figure 2.1.11 Characterization of microglial compartment in DC-Atg5−/− and 
DC-Atg5+/+ mice upon induction of AT-EAE. 
(A) Quantified frequencies of CD45lo/int/CD11b+ microglial cells in DC-Atg5−/− and 
DC-Atg5+/+ mice on day of sacrifice upon AT-EAE induction. (B) Surface expression 
levels (median fluorescence intesity [MFI]) of MHC class II (MHCII) on microglia. 
(C) Representative histograms of MHCII surface expression on microglia. Each dot 
represents one individual animal. Pooled data of 2 independent experiments is 
shown. Statistical analysis: unpaired two-tailed student t test, mean ± s.e.m. ns = 
not significant, *P< 0.05, **P< 0.01 and ***P< 0.001. 
 
2.1.10 Endogenous Myelin Presentation by CD11c+ DCs is Abrogated 
in Absence of ATG5 
It has previously been reported that canonical macroautophagy can deliver 
intracellular antigens for MHC class II presentation thereby modifying 
subsequent CD4+ T cell responses (Schmid et al., 2007). EAE development is 
driven by an antigen that is not known to be intrinsically expressed by 
professional CD11c+ APCs and hence requires endocytosis, followed by myelin 
antigen processing and presentation. ATG proteins contribute to extracellular 
antigen processing through phagosome maturation, regulated through 
cytosolic recruitment and binding of LC3 during an autophagy pathway 
termed LC3-associated phagocytosis (LAP) (Martinez et al., 2015).  
We previously showed that both, DC-Atg5−/−- and DC-Atg5+/+-derived CD11c+ 
BMDCs phagocytosed similar numbers of either naked polystyrene beads or 
beads that had been decorated with MOG1-124 full length protein, suggesting 
that the general capacity of ATG5-deficient DCs to phagocytose extracellular 
material is not compromised (data Christina Sina).   
ATG-dependent phagocytosis of extracellular material via LAP requires 
pathway-specific triggering through receptor-mediated antigen uptake such 
as Ptd-L-Ser recognizing receptors, PAMP receptors (Toll-like receptor 
[TLR]1/2, TLR2/6, TLR4, TLR9 and Dectin), or Fc receptors recognizing DNA 
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immune complexes (Henault et al., 2012; Ma et al., 2012; Martinez et al., 
2011; 2016; Sanjuan et al., 2007). The phospholipid Ptd-L-Ser can be exposed 
on membrane debris derived from compromised cells or specifically 
translocated to the cell surface during apoptosis (Nagata et al., 2016). 
Oligodendrocyte injury and concomitant focal demyelination constitute unique 
pathological hallmarks of MS lesions and during EAE development (Frohman 
et al., 2006; Lucchinetti et al., 1999) and can even precede the formation of 
inflammatory infiltrates (Barnett and Prineas, 2004; Prineas and Parratt, 
2012; Traka et al., 2016). We therefore hypothesized that uptake of damaged 
Ptd-L-Ser-exposing oligodendroglial cells by CD11c+ DCs may trigger myelin-
specific T cell activation in an ATG5-dependent manner. In order to test this 
hypothesis, we established a sequential coculture system using UVB-
irradiated Ptd-L-Serhi compared to non-irradiated Ptd-L-Serlo MOG-
expressing oligodendroglial cells (ODCs) (Figure 2.1.12 A-C), which were 
coincubated with CD11c+ splenic DCs. Subsequently these ODC-pulsed 
CD11c+ APCs were cocultured with 2D2/TCRMOG-derived CD4+ T cells. 
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Figure 2.1.12 UVB-irradiation and subsequent Ptd-L-Ser-exposure of MOG-
expressing oligodendroglial MO3.13 cells. 
(A) Representative histogram comparing MOG-transduced oligodendroglial cell line 
MO3.13 (ODCMOG+) with wild type MO3.13 cells (wt ODC) for surface MOG-
expression. ODCMOG+ were either UVB irradiated (870 mJ/cm2) or left untreated, 
which resulted in Ptd-L-Serhi- and Ptd-L-Serlo-expressing ODCMOG+ (A), quantified 
via annexin V staining (B). (C) Representative light microscopy pictures of UVB 
irradiated or untreated ODCMOG+ cells. Pooled data of 3 independent experiments 
are shown. Statistics: unpaired two-tailed student t test. ns = not significant, * P< 
0.05, ** P< 0.01, *** P< 0.001. 
 
The sequential coculture system was first set up in C57BL/6 wild type mice. 
Endogenous myelin peptide presentation and subsequent cognate T cell 
activation was assessed by IFNγ production via cocultured MOG35-55-specific 
CD4+ T cells. Only coculture of CD11c+ DCs with Ptd-L-Serhi ODCs lead to 
noticable activation of and concomitant IFNγ secretion by MOG-specific CD4+ 
T cells (Figure 2.1.13 A). In a next step, DC-Atg5−/−- and DC-Atg5+/+-derived 
CD11c+ splenic DCs were used as APCs (Figure 2.1.13 B). Here, T cell IFNγ 
production upon presentation of endogenous myelin antigen derived from Ptd-
L-Serhi oligodendroglial cells was abrogated in ATG5-deficient DCs (Figure 
2.1.13 B).  
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Figure 2.1.13 Coculture analyses for the assessment of ATG5-dependent 
processing of antigenic material and subsequent presentation to CD4+ T 
cells. 
(A) Coculture of MOG-specific 2D2/TCRMOG-derived CD4+ T cells with C57BL/6 wild 
type-derived splenic CD11c+ dendritic cells (DCs) that had previously been pulsed 
with either Ptd-L-Serhi- or Ptd-L-Serlo-exposing ODCMOG+. CD4+ T cell response 
(IFNγ secretion) is augmented upon coculture with Ptd-L-Serhi- ODCMOG+-pulsed 
DCs. (B) Absence of ATG5 in DCs abrogates CD4+ T cell response upon coculture 
with Ptd-L-Serhi-exposing ODCMOG+-pulsed DCs. One representative of >3 
independent experiments are shown. Statistics: unpaired two-tailed student t test. 
ns = not significant, * P< 0.05, ** P< 0.01, *** P< 0.001. 
 
Taken together, these data indicate that LAP is an endocytic autophagy 
pathway that facilitates transport of antigenic material for MHC class II 
presentation to CD4+ T cells. Recognition and engulfment of injured 
oligodendroglial cells by CD11c+ DCs induces myelin peptide presentation on 
MHC class II molecules and subsequent activation of primed myelin-specific 
CD4+ T cells through this ATG5-regulated phagocytosis pathway. 
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2.2 The Role of DC-Inherent ATG5 During Presentation of Exogenous 
Lipid Antigens to Natural Killer T Cells 
 
2.2.1 Colocalization Analysis Between CD1d and LC3 in RAW 264.7 
Cells and Splenic CD11c+ DCs 
Previous studies have shown that the MHC class I-like antigen presenting 
molecule CD1d associates with MHC class II molecules in DCs and in B cells 
(Kang and Cresswell, 2002a). CD1d binds to MHC class II-Ii complexes in the 
ER, and the CD1d–MHC class II association is maintained in late 
endosomal/lysosomal MIICs (Kang and Cresswell, 2002a). Macroautophagy 
delivers antigens to late endosomes/lysosomes for loading on MHC class II 
molecules and CD4+ T cell recognition (Nedjic et al., 2008; Paludan et al., 
2005; Schmid et al., 2007). To determine whether autophagosomes colocalize 
with CD1d+ loading compartments, we initially performed laser confocal 
microscopy-based analyzes in RAW 264.7 cells (mouse leukaemic 
monocyte/macrophage cell line) investigating colocalization of CD1d protein 
with LC3 which is present on both autophagosomes and LC3-associated 
phagosomes (Martinez et al., 2015; Romao et al., 2013). We found that both 
molecules colocalized in RAW 264.7 cells upon inhibition of lysosomal 
acidification via chloroquine and TLR receptor ligation by TLR agonists LPS, 
imiquimod, poly(I:C) and Pam3CSK4 as determined by Pearson correlation 
coefficient analysis (Figure 2.2.1 A-D). Of all the TLR ligands applied, only 
Pam3CSK4 did not show a significant increase in colocalization compared to 
the untreated control. However, upon inhibition of lysosomal acidification, 
also the TLR1/2 ligand Pam3CSK4 significantly increased colocalization of 
CD1d and LC3 (Figure 2.2.1 D).  
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Figure 2.2.1 Colocalization analysis of LC3 and CD1d in RAW 264.7 cells. 
RAW 264.7 cells were incubated with either (A) LPS (500 ng/ml), (B) Imiquimod (10 
µg/ml), (C) poly(I:C) (25 µg/ml), (D) Pam3CSK4 (1 µg/ml) for 4 h, or left untreated. 
Chloroquine (CQ, 50 µM) was added during the last hour of incubation. Scatter dot 
plot representation and quantification of colocalization between CD1d and LC3 
(Pearson coefficient analysis) is depicted in the respective left panels. Each symbol 
represents one cell. Pooled data of 2 independent experiments are shown. 
Representative pictures are depicted in the right panel. Statistics: two-tailed Mann-
Whitney U Test, *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05.   
 
We proceeded with analyzing colocalization of LC3 and CD1d in sorted 
CD11c+ splenic DCs derived from C57BL/6 wild type mice. Since high 
susceptibility to induction of cell death precluded treatment of with 
chloroquine, cells were only treated with TLR agonists. As observed in RAW 
264.7 cells, LC3 and CD1d colocalized in steady state reflected by a Pearson 
coefficient >0.5. Treatment with TLR agonist CpG ODN and poly(I:C) further 
increased colocalization (Figure 2.2.2 A, B). 
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Figure 2.2.2 Colocalization analysis of LC3 and CD1d in splenic CD11c+ 
DCs. 
C57BL/6 wild type-derived splenic DCs were either incubated with CpG (2 µg/ml), 
poly(I:C) (25 µg/ml) for 4 h, or left untreated. (A) Scatter dot plot representation and 
quantification of colocalization between CD1d and LC3 (Pearson coefficient 
analysis). Each symbol represents one cell. Pooled data of 3 independent 
experiments are shown. (B) representative pictures are depicted. Original 
magnification with 63×, 1.4 NA oil immersion lens. Statistics: two-tailed Mann-
Whitney U Test, *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05.   
 
2.2.2 Absence of ATG5 Increases the NKT Cell Stimulatory Capacity 
of APCs In Vitro 
In order to investigate whether absence of the essential macroautophagy gene 
Atg5 in CD11c+ DCs inhibits CD1d antigen presentation similar to MHC class 
II presentation (H. K. Lee et al., 2010; Ma et al., 2012; Romao et al., 2013), we 
again made use of mice harboring a conditional knockout of Atg5 in CD11c+ 
DCs (Figure 2.1.1 A-E). In order to assess if autophagy is implicated in DC 
mediated glycolipid antigen presentation via CD1d to iNKT cells, FAC-sorted 
splenic CD11c+ DCs, isolated from DC-Atg5−/− and DC-Atg5+/+ mice, were 
pulsed with increasing amounts (0-10 µg/ml) of the prototypic iNKT agonist 
αGalCer and the response of iNKT cell hybridomas A.407 and FF13 was 
assessed. Contrary to what was expected, DC-Atg5−/−-derived DCs were 
significantly more potent in eliciting IL-2 production from both iNKT cell lines 
(Figure 2.2.3 A, B). Induction of the autophagy machinery in wild type DCs 
by noncytotoxic concentrations of the mTOR inhibitor rapamycin reduced IL-2 
production by iNKT cells (Figure 2.2.3 C, D). To further confirm these 
findings, we made use of an immortalized macrophage-like cell line generated 
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from DC-Atg5+/+-derived bone marrow cells. Induction of recombination by 
treatment with TAT-cre lead to substantial decrease in ATG5-ATG12-complex 
as well as LC3-II protein levels (Figure 2.2.3 E). In line with our previous 
results, immortalized macrophage-like cells with reduced ATG5 levels (MΘ-
Atg5−/−) were compared to the ATG5 competent control cell line (MΘ-Atg5+/+), 
superior in activating the iNKT cell hybridomas A.407 and FF13 (Figure 
2.2.3 F, G).	
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Figure 2.2.3 Coculture of glycolipid-pulsed ATG5-deficient APCs with iNKT 
cell hybridoma cell lines. 
(A) FAC-sorted CD11c+/MHC class II+ splenic DCs derived from DC-Atg5−/− and DC-
Atg5+/+ animals were pulsed with increasing concentrations of αGalCer or left 
untreated and subsequently cocultured with the iNKT hybridoma cell line A.407 or 
(B) FF13 for 24 h (αGalCer: 1 µg/ml). IL-2 concentration in cell culture supernatants 
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was measured via ELISA. Mean ± s.e.m. of pooled data from >3 independent 
experiments are shown. Each experiment contained at least 3 animals per group. (C) 
C57BL/6 wild type-derived purified splenic DCs were treated with rapamycin (RAP; 
12.5 µM; 4 h), subsequently pulsed with αGalCer (1 µg/ml; 4 h) and cocultured with 
iNKT hybridoma cell line A.407 (24 h). IL-2 concentration in cell culture 
supernatants was measured via ELISA. Mean ± s.e.m. of pooled data from 3 
independent experiments are shown. Each experiment contained at least 3 animals 
per group. (D) Quantification of cell death upon rapamycin treatment. C57BL/6 wild 
type-derived purified splenic DCs were treated with or without RAP (12.5, 25 µM; 4 
h) and subsequently analyzed for cell death via flow cytometry. Pooled data of 2 
independent experiments are shown. (E) Western blot analysis for protein 
expression of ATG5-ATG12-complex, LC3-I and LC3-II in MΘ-Atg5−/− and MΘ-Atg5+/+ 
cells. Actin served as a loading control. One representative of >3 experiments is 
shown. (F) MΘ-Atg5−/− and MΘ-Atg5+/+ cells were pulsed with αGalCer or left 
untreated and subsequently cocultured with the iNKT hybridoma cell line A.407 or 
(G) FF13 for 24 h (αGalCer: 1 µg/ml). IL-2 concentration in cell culture supernatants 
was measured via ELISA. Mean ± s.e.m. of pooled data from 3 independent 
experiments are shown. Statistics: unpaired two-tailed student t test. *** P≤ 
0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05.  
 
The observed iNKT hybridoma cell line response was dependent on the 
presence of glycolipid-pulsed APCs as titrating down APC numbers 
incrementally abolished iNKT hybridoma cell responses (Figure 2.2.4). 
 
Figure 2.2.4 Titration of glycolipid-pulsed CD11c+ splenic DCs in coculture 
with iNKT cell hybridoma. 
Coculture assay as described in Figure 16 A using decreasing amounts of sorted 
splenic DCs derived from C57BL/6 wild type mice. IL-2 concentration in cell culture 
supernatants was measured via ELISA. Mean ± s.e.m. of one representative of 2 
independent experiments are shown. 
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2.2.3 Increased Capacity of ATG5-Deficient APCs to Stimulate NKT 
Cells is Independent of Lipid Uptake Receptor Pathway 
To analyze if enhanced iNKT cell activation in absence of DC-inherent ATG5 
is dependent on distinct lipid uptake pathways we carried out coculture 
experiments using GalαGalCer (low density lipoprotein receptor [LDLR]-
dependent uptake) and GSL-1 (scavenger receptor A[SRA]-dependent uptake) 
in adition to αGalCer (LDLR/SRA-dependent uptake). We found that, 
regardless of which receptor uptake pathway was targeted, DC-specific 
deficiency in ATG5 yielded amplified iNKT hybridoma cell responses (Figure 
2.2.5 A-C) 
 
Figure 2.2.5 Receptor-mediated uptake of glycolipid antigens is unchanged 
in DC-Atg5−/−-derived splenic DCs. 
Receptor-mediated uptake of glycolipid antigens and costimulatory properties 
remain unchanged in DC-Atg5−/−-derived DCs. CD1d-presentation of indicated iNKT 
cell agonists ((A) αGalCer (B) GalαGalCer (C) GSL-1) by primary splenic DCs was 
assessed using activation of the iNKT hybridoma A.407 as in Figure 16 A. Mean ± 
s.e.m. of triplicate cultures are shown. 
 
2.2.4 Analysis of CD1d-Restricted Presentation of αGalCer in Absence 
of ATG5 in GM-CSF BMDCs 
We additionally generated BMDCs from Atg5-deficient mice and observed 
that coculture with glycolipid-pulsed Atg5-deficient BMDCs leads to IL-2 
production by iNKT cells to the same level as BMDCs generated from DC-
Atg5+/+ mice (Figure 2.2.6).  
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Figure 2.2.6 Coculture of glycolipid-pulsed ATG5-deficient mixed BMDCs 
with iNKT cell hybridoma cells. 
CD1d presentation of the indicated iNKT cell agonists by in vitro-GM-CSF-derived 
BMDCs was assessed using activation of the iNKT hybridoma A.407 as in Figure 
2.2.3 A. Data are representative of triplicate cultures from 1 of 2 independent 
experiments. 
 
Since in vitro-derived BMDC cultures contain heterogeneous populations 
including cells most closely resembling macrophages, DCs and neutrophils 
(Helft et al., 2015; Inaba et al., 1992), we additionally FACS-purified in vitro 
generated BMDCs for CD11c+/MHC class II+ cells, which were subsequently 
loaded with increasing concentrations of αGalCer and coincubated with iNKT 
cells. Increased IL-2 production by iNKT cells was observed only in DC-
Atg5−/−-derived CD11c+/MHC class II+ BMDC cultures loaded with high 
αGalCer concentrations (10 µg/ml) (Figure 2.2.7).  
 
Figure 2.2.7 Coculture of glycolipid-pulsed ATG5-deficient FAC-sorted 
CD11+/MHC class II+ BMDCs with iNKT cell hybridoma cells 
CD1d presentation of αGalCer by enriched in vitro GM-CSF-derived BMDCs to the 
iNKT hybridoma A.407. Both, DC-Atg5+/+- and DC-Atg5−/−-derived BMDCs were 
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FACS-purified for CD11c+/MHC class II+ cells. DC-Atg5−/−-derived BMDCs were 
further enriched for GFP-Cre+ cells. Mean ± s.e.m. of pooled data from 2 independent 
experiments are shown. Statistics: Unpaired two-tailed student t test. *** P≤ 
0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05. 
 
2.2.5 Analysis of Costimulatory Properties for NKT:DC Crosstalk in 
DC-Atg5−/−- and DC-Atg5+/+-Derived DCs 
Next, we determined whether Atg5-deficient DCs differed from their Atg5-
competent counterparts in providing costimulatory signals required for iNKT 
cell activation, i.e. CD40 expression and production of IL-12. αGalCer-
mediated activation of and subsequent cytokine secretion by iNKT cells 
requires DC-derived IL-12 and formation of an immunological synapse 
through CD40/CD40L (Kitamura et al., 1999). DC-Atg5−/−-derived DCs 
exhibited similar CD40 levels as DC-Atg5+/+-DCs (Figure 2.2.8 A, Figure 
2.1.1 E). Moreover, Atg5-deficiency did not affect the frequency of IL-12-
producing DCs or the total amount of IL-12 secreted by DCs in response to 
CD40 ligation (Figure 2.2.8 B, C). 
Taken together, these data indicate that autophagy proteins in APCs 
may regulate iNKT cell responses independent of glycolipid uptake pathways 
and most costimulatory properties. 
 
Figure 2.2.8 Analysis of costimulatory properties of DC-Atg5−/−- and DC-
Atg5+/+-derived DCs. 
(A) Splenic DCs derived from either DC-Atg5−/− or DC-Atg5+/+ animals were stained 
for CD40 surface expression. (B) Frequency of IL-12-producing splenic DCs upon 
CD40 ligation. Purified splenic DCs were either incubated with anti-CD40 overnight 
or left untreated. IL-12 production was measured via intracellular cytokine staining 
and by (C) ELISA. Mean ± s.e.m. of pooled data from 3 independent experiments are 
shown. Each experiment contained at least 3 animals per group. Statistics: Unpaired 
two-tailed student t test. *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05. MFI, mean 
fluorescence intensity. 
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2.2.6 Analysis of CD1d-surface Expression on DC-Atg5−/−- and DC-
Atg5+/+-Derived APCs and on a Macrophage-Like Cell Line 
In order to assess by which means other than costimulatory properties ATG5-
deficient splenic DCs elicited superior iNKT cell responses in vitro, we 
analyzed CD1d surface expression in purified splenic CD11c+/MHC class II+ 
DCs and CD19+/MHC class II+ B cells from DC-Atg5−/− and DC-Atg5+/+ mice. 
Surface expression of CD1d was significantly elevated in Atg5-deficient 
splenic DCs (Figure 2.2.9 A, B). Splenic B cells derived from DC-Atg5−/− mice 
have normal levels of ATG5, indicated by the absence of GFP-Cre expression 
in this cellular subset (Figure 2.1.1 A) and did not differ in their CD1d 
surface expression from DC-Atg5+/+-derived splenic B cells (Figure 2.2.9 B). 
Furthermore, also immortalized ATG5-deficient macrophage-like cells 
depicted increased surface levels of CD1d as compared to ATG5-competent 
control cells (Figure 2.2.9 B). To determine whether loss of Atg5 regulates 
CD1d expression in vivo, DC-Atg5−/− and DC-Atg5+/+ mice were injected with 
αGalCer and CD1d presentation was quantified using the monoclonal 
antibody L363 that specifically detects CD1d:αGalCer-complexes, but does not 
bind to CD1d molecules loaded with other antigens (K. O. A. Yu et al., 2007). 
Compared to autophagy-competent DCs, Atg5-deficient DCs showed increased 
expression levels of CD1d-glycolipid complexes (Figure 2.2.9 C). Levels of 
stimulatory CD1d-antigen complexes were similar for B cells in DC-Atg5−/− 
mice (Figure 2.2.9 C). In contrast to CD1d, the expression levels of CD11c 
and MHC class II remained unchanged in DC-Atg5−/−-derived DCs (Figure 
2.2.9 D).  
 
 
 
 
 
 
 
 
 
 
RESULTS 
	 57	
 
Figure 2.2.9 Analysis of CD1d-surface expression on DC-Atg5−/−- and DC-
Atg5+/+-derived APCs and on a macrophage-like cell line. 
(A) Flow cytometric analysis of CD1d surface levels on splenic DCs. Representative 
contour plots of splenic DCs or B cells and histograms showing CD1d surface 
expression. (B) Quantification of CD1d surface expression on splenic DCs, 
immortalized macrophage-like cell line and B cells. Mean ± s.e.m. of pooled data 
from >3 independent experiments are shown. Each experiment contained at least 2 
animals per group. (C) CD1d:αGalCer-complex staining (L363 clone) in splenic DCs 
or B cells 4 h after i.p. application of either αGalCer or PBS. Mean ± s.e.m. of pooled 
data from 2 independent experiments are shown. (D) DC surface expression of 
CD11c or MHC class II (MHCII). Mean ± s.e.m. of pooled data from >3 independent 
experiments are shown. Each experiment contained at least 2 animals per group. 
Statistics: Unpaired two-tailed t test. *** P≤ 0.001,** P≤ 0.01,* P≤ 0.05, ns P> 0.05. 
MFI, mean fluorescence intensity.  
 
2.2.7 Analysis of CD1d Turnover 
CD1d expression levels at the cell surface are largely determined by the rates 
of CD1d internalization and recycling through endosomal and lysosomal 
compartments (Jayawardena-Wolf et al., 2001; Sugita et al., 2004). Therefore, 
we analyzed the rates of CD1d internalization and CD1d recycling to the cell 
surface in Atg5-deficient and Atg5-competent splenic CD11c+ DCs. To 
evaluate the kinetics of CD1d internalization, the remainder of CD1d 
molecules previously labeled with biotinylated anti-CD1d was detected after 
given time points. To assess CD1d recycling rates, we quantified newly 
resurfaced CD1d molecules after the cell surface CD1d had been previously 
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blocked with unconjugated anti-CD1d antibodies (Figure 2.2.10).  
 
 
 
Figure 2.2.10 Scheme illustrating the flow cytometry-based assays used to 
quantify internalization and recycling of CD1d in Atg5-deficient and Atg5-
competent cells.   
CD1d surface levels are determined by the rates of CD1d internalization and 
recycling through endosomal and lysosomal compartments. EE, early endosomes; 
LE, late endosomes; Ly, lysosomes. 
 
We found that CD1d internalization from the cell surface is significantly 
hampered in absence of ATG5 in CD11+/MHC class II+ splenic DCs (Figure 
2.2.11 A, left panel), whereas internalization of CD1d in ATG5-competent 
CD19+/MHC class II+ splenic B cells derived from either DC-Atg5−/− or DC-
Atg5+/+ mice remained unaffected (Figure 2.2.11 A, right panel). 
Additionally, recycling kinetics of CD1d in absence of ATG5 were similar 
between ATG5-deficient and -competent splenic DCs (Figure 2.2.11 B, left 
panel) as well in ATG5-competent splenic B cells derived from both genotypes 
(Figure 2.2.11 B, right panel).  
From these observations we conclude that absence of Atg5 in splenic DCs 
impedes CD1d internalization, resulting in increased CD1d surface expression 
levels and therefore enhanced capacity of Atg5-deficient DCs to activate iNKT 
cells. 
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Figure 2.2.11 Quantification of CD1d internalization and recycling in 
splenic DCs and B cells.  
(A) Internalization of surface CD1d on splenic DCs or splenic B cells was analyzed 
using a biotin-based flow cytometric endocytosis assay. Mean ± s.e.m. of pooled data 
from at least 3 independent experiments are shown. Each experiment contained at 
least 2 animals per group. (B) CD1d recycling in splenic DCs or splenic B cells was 
analyzed using a flow cytometry based recycling assay. Mean ± s.e.m. of pooled data 
from at least 3 independent experiments are shown. Each experiment contained at 
least 2 animals per group. Statistics: Two-tailed unpaired student t test. *** P≤ 
0.001,** P≤ 0.01,* P≤ 0.05, ns P> 0.05. 
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2.2.8 Recruitment of CD1d and its Adaptor Protein AP2 to Endosomal 
Compartments is Reduced in Atg5-Deficient CD11c+ DCs 
To determine whether loss of autophagy proteins impairs trafficking of AP2 
and CD1d to endosomal compartments in primary splenic DCs, we 
investigated colocalization of both molecules with EEA1 (early endosomal 
antigen 1) by confocal microscopy (Figure 2.2.12 A). Colocalization of AP2 
and CD1d with EEA1 was significantly reduced in Atg5-deficient DCs as 
compared to DC-Atg5+/+-derived DCs (Figure 2.2.12 B). These data suggest 
that autophagy proteins assist in the recruitment of CD1d molecules into 
endosomal compartments and provide a mechanistic explanation as to how 
loss of autophagy proteins stabilizes the cell surface expression of CD1d-
glycolipid complexes on DCs. 
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Figure 2.2.12 Reduced endosomal recruitment of CD1d and its adaptor 
protein AP2 in Atg5-deficient primary DCs. (C).  
Colocalization study of AP2 and EEA1, as well as CD1d and EEA1 via confocal 
microscopy. Original magnification with 63×, 1.4 NA oil immersion lens. (A) 
Representative photographs from 2 independent experiments per colocalization 
study are shown. Scale bar: 2.5 µm. (B) Scatter dot plot representation and 
quantification of colocalization between AP2 and EEA1 and between CD1d and 
EEA1 via the Pearson coefficient. Each symbol represents one cell. Pooled data of 2 
independent experiments per colocalization study are shown. Statistics: Unpaired 
two-tailed student t test. *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05.  
 
2.2.9 Analysis of Organspecific NKT Cell and Splenic B Cell 
Frequencies at Steady State in DC-Atg5−/− and DC-Atg5+/+ Mice  
We next addressed if absence of Atg5 alters iNKT cell activation and DC 
maturation following αGalCer application in vivo. Organ-specific numbers of 
iNKT cells were quantified by staining with αGalCer-loaded CD1d tetramer 
(Benlagha et al., 2000; Matsuda et al., 2000) (Figure 2.2.13).  
 
 
Figure 2.2.13 Visualization of iNKT cells via staining with glycolipid-loaded 
or empty CD1d-tetramer in C57BL/6 wild type mice-derived splenocytes. 
 
Frequencies of splenic, thymic, and liver iNKT cells (Figure 2.2.14 A-C), 
splenic B cells (Figure 2.2.14 D) and splenic DCs (Figure 2.1.1 D) were 
similar in DC-Atg5−/− and DC-Atg5+/+ mice at steady state.  
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Figure 2.2.14 Organspecific frequencies of iNKT cells and splenic B cells at 
steady state in DC-Atg5−/− and DC-Atg5+/+ mice. 
Frequencies of iNKT cells ((A) thymus, (B) spleen and (C) liver) and (D) splenic B 
cells from naïve DC-Atg5−/− and DC-Atg5+/+ mice were quantified. Representative bar 
graphs (mean ± s.e.m.) from at least 2 independent experiments are shown. 
Statistics: Unpaired two-tailed student t test. *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns P> 
0.05.  
 
2.2.10 Serum Cytokine Quantification Upon αGalCer In Vivo 
Challenge in DC-Atg5−/− and DC-Atg5+/+ Mice 
Antigen presentation to iNKT cells by DCs leads to activation of and cytokine 
secretion by iNKT cells which in turn aids further activation and maturation 
of DCs. In order to address this reciprocal crosstalk between iNKT cells and 
DCs, we first determined IFNγ and IL-4 serum levels after glycolipid 
challenge in vivo. We found that following αGalCer injection, DC-Atg5−/− mice 
showed substantially higher IL-4 levels after 4 h and IFNγ levels after 12 h, 
as compared to DC-Atg5+/+ mice (Figure 2.2.15 A, B). 
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Figure 2.2.15 Serum cytokine kinetics upon αGalCer injection into DC-
Atg5−/− and DC-Atg5+/+ mice. 
Serum concentration kinetics of (A) IL-4 and (B) IFNγ upon glycolipid challenge in 
vivo measured via ELISA. Pooled data (mean ± s.e.m.) from 2 independent 
experiments are shown. Statistics: Unpaired two-tailed student t test. *** P≤ 
0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05.  
 
 
2.2.11 DC Phenotypisation Upon αGalCer In Vivo Challenge in DC-
Atg5−/− and DC-Atg5+/+ Mice 
The increased and prolonged iNKT cell activation observed in DC-Atg5−/− 
mice, as reflected by enhanced serum cytokine levels upon glycolipid injection 
(Figure 2.2.15 A, B), was associated with enhanced phenotypic DC 
maturation as indicated by higher expression levels of CD86 and CD40 12 h 
after αGalCer challenge. Costimulatory molecule expression by B cells 
remained low and was comparable in αGalCer-treated DC-Atg5−/− and DC-
Atg5+/+ animals (Figure 2.2.16 A, B).  
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Figure 2.2.16 Surface expression kinetics of CD86 and CD40 on splenic DCs 
and B cells upon αGalCer injection into DC-Atg5−/− and DC-Atg5+/+ mice. 
Surface expression kinetics of CD86 and CD40 on (A) splenic DCs and (B) splenic B 
cells. Each symbol represents one animal. Pooled data of at least 2 independent 
experiments are shown. Statistics: Unpaired two-tailed student t test. Statistics: 
Unpaired two-tailed student t test. *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns P> 0.05 
 
2.2.12 Sphingomonas paucimobilis In Vivo challenge in DC-Atg5−/− and 
DC-Atg5+/+ Mice 
Members of the genus Sphingomonas have been the first microorganisms 
identified to express natural ligands for iNKT cells in their LPS-free bacterial 
envelope and it has been reported that iNKT cells are essential in controlling 
both septic shock reaction and bacterial clearance in Sphingomonas infected 
mice (Kinjo et al., 2005; Mattner et al., 2005; Sriram et al., 2005). The gram-
negative, lipopolysaccharide-free bacterium Sphingomonas paucimobilis (S. 
paucimobilis) is associated with opportunistic and nosocomial infections in 
immunocompromised patients (Ryan and Adley, 2010) and contains 
glycosphingolipids that stimulate iNKT cells through their TCR in a CD1d-
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specific manner (Holzapfel et al., 2014; Kinjo et al., 2005; Mattner et al., 2005; 
Sriram et al., 2005). We therefore investigated whether iNKT cells activated 
by Atg5-deficient DCs conferred superior protection against infection with the 
pathologically relevant microorganism S. paucimobilis. The stimulatory 
potential of S. paucimobilis-derived glycosphingolipids is lower as compared 
to αGalCer, however iNKT cell recognition of these natural microbial-derived 
glycolipids induces potent proinflammatory cytokine production in vitro and 
in vivo (Holzapfel et al., 2014; Kinjo et al., 2005; Mattner et al., 2005). Upon 
infection with S. paucimobilis, DC-Atg5−/− mice exhibited significantly lower 
pathogen loads in spleens and lungs as compared to their DC-Atg5+/+ 
littermate controls (Figure 2.2.17 A, B). Reduced pathogen loads were 
associated with increased serum levels of proinflammatory cytokines such as 
IP-10 and TNF-α (Figure 2.2.17 C, D). Production of IFNγ tended to be 
higher in DC-Atg5−/− mice, whereas IL-17 production was unchanged (Figure 
2.2.17 E, F).  
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Figure 2.2.17 In vivo challenge of DC-Atg5−/− and DC-Atg5+/+ mice with 
Sphingomonas paucimobilis. 
(A) Quantification of bacterial titers (CFU/g tissue) in spleen and lung after in vivo 
infection of mice with S. paucimobilis. Each symbol represents one animal. One 
representative of 2 experiments is shown. Quantification of serum cytokines upon in 
vivo infection with S. paucimobilis. One representative of 2 experiments is shown. 
Statistics: two-tailed Mann-Whitney U Test (D). *** P≤ 0.001,** P≤ 0.01,* ≤ 0.05, ns 
P> 0.05.  
 
In conclusion, autophagy proteins in DCs regulate surface expression of 
CD1d-glycolipid complexes and thereby modify iNKT cell activation and the 
resultant DC maturation in response to exogenous glycolipid antigen αGalCer 
and natural microbial glycolipids in vivo. 	
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3. Discussion 
 
3.1 Prelude 
In this study, I investigated non-canonical use of the essential autophagy protein 
ATG5 in the context of two different antigen presenting pathways. Lack of ATG5 
in CD11c+ APCs conferred protection from development of adoptively transferred 
EAE and restrained CD4+ T cell reactivation within the CNS. On the contrary, 
CD11c+-conditional deletion in ATG5 resulted in prolonged CD1d-restricted 
exogenous glycolipid presentation, enhanced iNKT cell activation and improved 
clearance from Sphingomonas spp. infection. These data indicate that ATG5 
supports loading of endocytosed antigen onto MHC class II molecules for 
augmented CD4+ T cell recognition while restraining iNKT cell activation 
through CD1d internalization.  
 
3.2 ATG5-Dependent Autophagy During Autoimmune CNS Inflammation 
MS is a chronic neuroinflammatory condition during which autoaggressive 
leukocytes invade across a compromised blood brain barrier (BBB) into the CNS. 
On site, the infiltrated immune cells, in concert with CNS-resident cells mediate 
progressive axonal demyelination and engender spatio-temporally disseminated 
lesions within the CNS which entails diffuse cytodegeneration in grey and white 
matter areas of the CNS (Mahad et al., 2015). Although the complex 
pathoaetiology of MS prompts relevant involvement of other cellular and 
humoral immune components such as cytotoxic CD8+ T cells, B cells and 
autoantibodies ('t Hart et al., 2015; 'tHart et al., 2016; Hohlfeld et al., 2016; 
Martin et al., 2016), CD4+ T cells are considered to be the pivot of the underlying 
disease mechanism (Hohlfeld et al., 2015). Genome-wide association studies 
revealed that HLA class II haplotypes, in particular HLA-DRB1*1501/HLA-
DRB5*0101, are the strongest genetic risk factors for MS development 
(International Multiple Sclerosis Genetics Consortium (IMSGC) et al., 2013; 
International Multiple Sclerosis Genetics Consortium et al., 2011) and albeit 
frequencies of myelin protein specific CD4+ T cells in the blood have been 
reported to be similar in MS patients compared to healthy individuals, ex vivo 
treatment of blood and cerebrospinal fluid (CSF)-derived T cells with 
recombinant IL-2 lead to significant proliferation of encephalitogenic CD4+ T 
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cells in MS patient-derived specimens as compared to those derived from healthy 
individuals (Zhang et al., 1994). Promiscuous restriction, means the ability of 
some TCRs to use different HLA restriction elements. One study found that two 
out of five in vivo-expanded MS patient-derived and CSF-infiltrating CD4+ T cell 
clones were able to use different HLA class II molecules for antigen recognition. 
One of the two CD4+ T cell clones recognized identical peptides in the context of 
all MS-associated HLA class II molecules coexpressed in the HLA-DR2 haplotype 
(DRB1*1501, DRB5*0101, and DQB1*0602) arguing for a pathomechanistic role 
of this overlapping antigen presentation to CD4+ T cells during MS (Sospedra et 
al., 2006).  
EAE is a commonly used animal model of MS in which disease is induced by 
immunization with myelin-derived antigenic peptides together with adjuvant or 
by adoptively transferring pre-activated myelin-specific CD4+ T cells in naïve 
recipients (Ben-Nun, Wekerle and Cohen, 1981a; 1981b; Stromnes and 
Goverman, 2006). This model is predominantly CD4+ T cell-driven (Ben-Nun, 
Wekerle and Cohen, 1981b; Zamvil et al., 1986) and a pathomechanistic 
prerequisite for CNS damage is the local reactivation of CD4+ T cells specific for 
myelin-derived antigens (Greter et al., 2005). Reactivated CD4+ T cells together 
with activated myeloid cells initiate a cascade of proinflammatory events, which 
is believed to perpetuate CNS tissue damage leading to the development of 
clinical EAE symptoms (Becher et al., 2000; Huitinga et al., 1990; Schreiner et 
al., 2009).   
How and by which antigen-presenting cell subset pathogenic CD4+ T cells are 
locally reactivated and cause tissue damage during the course of MS and EAE is, 
however, incompletely understood. This is in part due to the fact that the 
detailed route of how myelin self-antigens are processed and presented towards 
CD4+ T cells has not been fully elucidated.  
The autophagic machinery delivers cytoplasmic constituents and substrates to 
endosomal/lysosomal compartments including MIICs for subsequent MHC class 
II presentation (Schmid et al., 2007). Additionally, autophagy proteins regulate 
degradation of extracellular material via the non-canonical use of ATGs during 
LAP (Florey et al., 2011; Henault et al., 2012; J.-Y. Kim et al., 2013; H. K. Lee et 
al., 2010; Martinez et al., 2011; 2015; 2016; Sanjuan et al., 2007).  
 
DISCUSSION 
 
	 69	
In order to investigate the role of ATG5 during EAE, we made use of a 
conditional knockout mouse in which CD11c+ cells do not express ATG5 and are 
therefore incapable of carrying out macroautophagy or LAP. Cre/loxP-mediated 
deletion of Atg5 in these mice was confined to the CD11c+ compartment, did not 
perturb steady state frequencies of splenic CD11+/MHC class II+ DCs and did not 
alter surface expression of distinctive DC markers. These results are in line with 
a previous report using the identical CD11c-Cre and Atg5flox/flox-strains and 
showing that Atg5-deficient DCs have intact migratory capacities, normal 
phagocytic activity, similar expression levels of MHC class II, CD40, CD86 in 
both steady state and upon immune activation along with similar secretion levels 
of IL-12p40, IL-6, and TNF-α (H. K. Lee et al., 2010). Furthermore Lee and 
colleagues reported that in murine DCs, TLR-dependent phagocytosed HSV-2 
can be found in LC3+ single-membraned vesicles reminiscent of LAPosomes. In 
absence of ATG5, CD4+ T cell responses against phagocytosed protein-derived 
peptides were markedly reduced, arguing for inefficient MHC class II-dependent 
processing and presentation (H. K. Lee et al., 2010). Interestingly, 
pharmacological induction of canonical macroautophagy via TORC1 inhibitor 
rapamycin did not lead to enhanced MHC class II presentation of phagocytosed 
material arguing for the non-canonical LAP pathway linking phagocytosis and 
MHC class II presentation (H. K. Lee et al., 2010). 
We therefore hypothesized that lack of ATG5 in professional antigen presenting 
cells like DCs would alter the onset and/or course of disease during EAE, where 
the presentation of myelin-derived antigens activate CD4+ T cells which 
engender disease. Potentially both, the macroautophagy pathway and LAP are 
ATG5-dependent degradation pathways, which facilitate MHC class II 
presentation of self-antigens. Nevertheless, myelin-derived candidate antigens 
are not expressed in professional APCs such as CD11c+ DCs thus an intracellular 
loading of these peptides onto MHC class II molecules in the context of CNS 
autoimmunity appears counterintuitive. LAP couples phagocytosis of 
extracellular solid cargo to key members of the autophagy machinery (including 
ATG5) (Martinez et al., 2015; Münz, 2015). A prerequisite for triggering LAP 
activity is the engagement of germline encoded pattern recognition receptors or 
Ptd-L-Ser receptors via phagocytosed material. The role of TLR signaling in the 
context of EAE has partly been investigated. TLR9 and, to some extend, TLR2 
signaling mediates the pathogenicity of EAE, both receptors that have been 
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implicated in triggering LAP (Sanjuan et al., 2007), whereas TLR1 and 6-
deficiency in mice did not have an impact on the development of active EAE 
(Miranda-Hernandez et al., 2011; M. Prinz et al., 2006). Importantly, also 
adoptive transfer EAE-induction was dependent on TLR2 signaling, discarding 
the assumption that microbial-derived constituents in the adjuvant preparation 
during active EAE serve as ligands (Miranda-Hernandez et al., 2011). 
Additionally, both studies showed that deficiency of the downstream TLR 
signaling molecule myeloid differentiation primary response gene 88 (MyD88) 
abrogates disease (Miranda-Hernandez et al., 2011; M. Prinz et al., 2006).  
There are various protocols for induction of EAE available, differing in 
parameters such as mouse genetic background, antigenic myelin peptide and 
mode of disease induction. The two most commonly used induced EAE models are 
“active EAE”, where animals are subcutaneously immunzed with an emulsion of 
myelin protein/peptide (commonly MOG35-55 or proteolipid protein [PLP]139-155) 
and complete Freund’s adjuvant (CFA) and the “adoptive transfer EAE” model, 
where activated encephalitogenic CD4+ T cells are isolated from spleen and 
draining lymph nodes of actively immunized animals and, after in vitro 
restimulation for 2 days, are injected into naïve recipient animals. While active 
EAE models the induction and effector stages of the disease, adoptive transfer 
EAE models only the effector phase (Miller and Karpus, 2007). During EAE, 
CNS-infiltrating CD4+ T cells require local reactivation by myelin-antigen 
presenting cells to efficiently induce sustained inflammatory demyelination 
(Greter et al., 2005; Kawakami et al., 2004; Kivisäkk et al., 2009). CD11c+ cells 
within the CNS alone, i.e. in the absence of secondary lymphoid tissues, are 
sufficient to present antigen in vivo to primed myelin-reactive T cells in order to 
mediate CNS inflammation and clinical disease development (Greter et al., 2005; 
Paterka et al., 2016). We found that mice with a CD11c-conditional deletion of 
Atg5 are completely protected from clinically developing EAE upon adoptive 
transfer of encephalitogenic T cells. Studies that employed inducible ablation of 
cDCs through CD11c promoter-driven human diphtheria toxin (DT) receptor 
(DTR) expression demonstrated that DT-treated mice remain susceptible to 
disease development after active EAE induction with myelin antigen emulsified 
in CFA. Isaksson et al. (Isaksson et al., 2012) reported that DT-treated mice still 
develop EAE after active immunization indicating that a population of APCs 
other than CD11c+ DCs executed initial priming of encephalitogenic T cells. 
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However, DT treatment did not ablate CD11c+ APCs in the CNS during peak of 
disease and CD11c+ APCs present in the CNS still could present myelin to 
invading encephalitogenic T cells (Isaksson et al., 2012). Yogev et al. (Yogev et 
al., 2012) also used CD11c-DTR mice to deplete CD11c+ DCs including dermal 
CD103+/CD207+ DCs and found that mice lacking these DC populations are even 
hypersusceptible to EAE induction, supporting the concept that DCs maintain 
peripheral tolerance. However, they demonstrated that after T cell priming and 
during T cell expansion within the CNS (effector phase), DC-depleted mice 
showed reduced clinical scores as compared with control mice. In line with these 
findings, Paterka and colleagues recently reported that adoptive transfer of 
primed, encephalitogenic CD4+ T cells into CD11c+-depleted recipients lead to 
reduced disease incidence and scores (Paterka et al., 2016). Thus, while the 
aforementioned studies reflect the complex roles of professional APCs during T 
cell priming and indicate that, after active EAE induction, priming synapses can 
be formed between non-DC-APC populations, they do not contradict but support 
the concept that CD11c+ DCs are the most efficient APCs in driving the re-
activation of transferred myelin-specific CD4+ T cells within the CNS during the 
effector phase of EAE (Becher and Greter, 2012). In the case of DC-depleted mice 
that remain to be susceptible for developing actively induced EAE it has yet to be 
defined which APC subset primes CD4+ T cells. Two candidate APCs would be 
macrophages and B cells and both populations have been found to take up 
fluorescent microbeads that had been coadministered with CFA. After 
phagocytosis B cells and macrophages both migrated to the draining lymphnodes 
where they could potentially prime T cells. However, depletion of CD20+ B cells 
did lead to enhanced disease (Yogev et al., 2012). Previous attempts to efficiently 
deplete macrophages via the expression of thymidine kinase of herpes simplex 
virus (HSVTK) driven by the CD11b promotor have proven unfeasible, since this 
procedure entails fatal aplastic anemia (Heppner et al., 2005). It is therefore 
conceiveable that certain macrophage populations, in absence of DCs, take over 
in priming encephalitogenic T cell in secondary lymphoid organs during the onset 
of active EAE. Additionally, also neutrophils may serve under certain 
circumstances as professional APCs and might be capable of priming T cells, 
however experimental evidence for this scenario is still lacking (Abi Abdallah et 
al., 2011; Kalyan and Kabelitz, 2014; Maletto et al., 2006). 
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At steady state, CD11c+ /MHC class II+ DCs within the CNS are enriched in the 
choroid plexus (McMenamin, 1999; Prodinger et al., 2011) which, together with 
the meningeal vasculature, is an active site for immune trafficking into and out 
of the CNS (Mohammad et al., 2014; Ransohoff et al., 2003; Schläger et al., 2016) 
and a first port of entry for pathogenic T cells during EAE (Reboldi et al., 2009). 
Choroid plexus DCs resemble splenic CD11c+/MHC class II+ DCs in morphology, 
gene expression profile, antigen-presenting function and their shared intrinsic 
requirement for Fms-related tyrosine kinase 3 (Flt3) ligand (Anandasabapathy et 
al., 2011). In line with the aforementioned studies, we identified a small 
population of CD11c+/MHC class II+ DCs that are specifically targeted by Cre-
mediated recombination within the non-diseased CNS. Targeted deletion of the 
essential autophagy protein ATG5 in this population abrogated CD4+ T cell 
reactivation as well as CNS accumulation and completely prevented clinical 
disease development of adoptive transfer EAE. Interestingly, we found higher 
frequencies of CD25+/FOXP3+ TREGS within the CNS CD4+ T cell compartment 
in DC-Atg5−/− animals at peak of disease. A previous report showed that 
supplementation of TREGs via adoptive transfer prior to inducing EAE, both 
actively or by adoptive transfer significantly reduced disease severity by biasing  
the immune response into the direction of TH2 (Kohm et al., 2002). Splenic TREG 
counts are unchanged in naïve DC-Atg5−/− animals (data Christina Sina) and we 
obtained no evidence that loss of ATG5 in DCs directly lead to an increase of 
TREGs in the CNS in DC-Atg5−/− animals. It is rather conceivable that the 
incremental accumulation of encephalitogenic CD4+ cells in the CNS of DC-
Atg5+/+ animals strongly diluted the TREG population in these animals. We 
additionally found several myeloid subsets to be enriched in the CNS of diseased 
Atg5+/+ animals at peak of disease whereas these subsets where much less 
abundant in DC-Atg5−/− animals. Also, while in steady state microglia frequencies 
and surface expression of CD40, CD86 and MHC class II were similar, upon 
adoptive transfer EAE, microglia in Atg5+/+animals strongly upregulated MHC 
class II. CD4+ T cells specific to CNS antigens constitute the only immune cell 
subset capable of conferring EAE when transferred into immunocompetent 
syngeneic recipient animals (Ben-Nun, Wekerle and Cohen, 1981a; Pettinelli and 
McFarlin, 1981). A yet to be defined myeloid subset (most likely resident) is 
probable to acquire disease relevant antigen on site and subsequently presents it 
to patroling encephalitogenic T cells, which may set off a self-perpetuating 
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sequence of proinflammatory events. Therefore, local reactivation of CD4+ T cells 
during EAE is considered to occur upstream of stepwise further accumulation of 
peripherall myeloid cells. Consequently, the reduced ingress of myeloid 
populations into the CNS of DC-Atg5−/− animals and the lack of microglial 
activation are likely to be in the wake of an inefficient local restimulation of 
CD4+ cells. 
Conditional targeting of ATG7 in CD11c+ DCs was reported to attenuate the 
disease course and lowered EAE incidence initiated by active immunization with 
myelin antigen/CFA (Bhattacharya et al., 2014). Given the negligible function of 
cDCs during the priming phase of EAE (Isaksson et al., 2012; Yogev et al., 2012) 
we investigated whether the autophagic machinery in DCs is important for local 
T cell reactivation. The data presented here thus supports the concept of CNS 
DCs as indispensible in initiating the effector phase of EAE and demonstrate the 
essential requirement of ATG5 in DCs for myelin-reactive T cells to face their 
antigen in vivo before mediating inflammatory demyelination. 
Absence of LAP in myeloid cells by means of lysozyme M-Cre-mediated gene 
deletion, which targets macrophages, monocytes, some neutrophils and CD11+ 
DCs to varying degrees, was recently shown to drive development of a systemic 
autoinflammatory syndrome in aged mice (52 weeks) with increased expression 
of IFN signature genes, occurrence of anti-double-stranded DNA and -nuclear 
antibodies, and signs of kidney damage, commonly associated with systemic 
lupus erythematosus (SLE) (Martinez et al., 2016). The aforementioned study 
showed that macrophages deficient in ATG7 or Rubicon, both reported to be 
required for LAP (Martinez et al., 2015), did engulf, but not effectively clear, 
dying cells and produced proinflammatory cytokines, including IL-1β and IL-6, 
upon challenge with apoptotic cell material (Martinez et al., 2016). An increased 
propensity of ATG7−/− macrophages to produce proinflammatory cytokines after 
engulfment of apoptotic cells has also been described in vitro (Martinez et al., 
2011) indicating that defective LAP in macrophages results in a failure to process 
engulfed dying cells, leading to elevated inflammatory cytokine production and 
the development of a SLE-like syndrome. It should be noted that macrophages 
and DCs significantly differ in their employment of lysosomal degradation. While 
macrophages harbor large amounts of lysosomal proteases and swiftly degrade 
phagocytosed material, DCs have much lower levels of these enzymes, degrade 
engulfed cargo rather slowly and seem to favor antigen rentention which 
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promotes efficient presentation (Delamarre et al., 2005). The crosstalk between 
non-canonical autophagy and MHC class II-dependent antigen presentation 
therefore is likely to be different inbetween these two myeloid lineages. This 
differential usage of phagocytosis-associated components is also illustrated in the 
case of the NADPH oxidase NOX2, another essential component of the non-
canonical autophagy pathway LAP. Its predominant and initially alloted 
function, generation of reactive oxygen species (ROS), has been linked to killing 
of intraphagosomal pathogens by providing the adequate environment for 
protease function. In professional APCs such as DCs, whose principal function is 
to take up, process and present antigens in order to initiate and shape adaptive 
immune responses rather than pathogen killing or clearance of cell debris as in 
the case of macrophages, NOX2 expression was shown to regulate antigen 
presentation due to its ability to control the level of antigen degradation via 
altering phagosomal pH levels (Savina et al., 2006). Indeed, DCs lacking NOX2 
show enhanced phagosomal acidification and increased antigen degradation, 
resulting in impaired cross presentation (Savina et al., 2006). In addition to cell 
type dependent tuning of phagosomal acidification, NOX2 has recently also been 
implicated in regulating serine and cysteine proteases (cathepsins B, L, and S) 
within phagosomes (Rybicka et al., 2012) and it has been suggested that 
increased hydrolysis of critical regions within the encephalitogenic MOG35–55 
antigen by cysteine cathepsins in the early phagosome contribute to the reduced 
incidence and delayed onset of EAE reported in NOX2-deficient mice (Allan et al., 
2014). It is conceivable that NOX2 as essential component of the non-canonical 
autophagy pathway LAP not only affects levels of phagosomal proteolysis as 
previously shown, but facilitates the execution of an alternative pathway for 
antigen loading onto MHC class II molecules, thereby contributing to CD4+ T 
cell-mediated augmentation of autoimmune CNS inflammation. 
In our study, DC-Atg5−/− mice were protected from the development of a CD4+ T 
cell-mediated autoimmune disease and ATG5 was required for DCs to efficiently 
present antigen derived from Ptd-L-Ser-exposing oligodendroglial cells to myelin-
specific CD4+ T cells. These data are in line with in vitro studies that identified 
LAP in professional APCs to support downstream CD4+ T cell responses by 
promoting sustained MHC class II antigen presentation (Ma et al., 2012; Romao 
et al., 2013). LAP was shown to be essential for retinoid recycling by phagocytic 
retinal pigment epithelial cells, which contributes to maintaining vision in mice 
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(J.-Y. Kim et al., 2013), to occur on macropinosomes (Florey et al., 2011), and at 
the ruffled border in osteoclasts (DeSelm et al., 2011) suggesting that this 
pathway contributes significantly to physiology in multiple contexts 
(Bandyopadhyay and Overholtzer, 2016). During CD4+ T cell-driven CNS 
inflammation, non-canonical autophagy in DCs may use ATG5 for enhanced 
presentation of endocytosed cargo derived from damaged oligodendrocytes on 
MHC class II molecules, thus linking oligodendrocyte injury with myelin antigen 
processing and T cell-pathogenicity. The cellular architecture of MS lesions is 
dynamic in its neuropathological features including leukocyte composition 
(Lassmann and van Horssen, 2011). Commonly, T cell infiltration occurs in two 
distinct waves (A. P. D. Henderson et al., 2009; Marik et al., 2007). Initially MS 
lesions are characterized by oligodendrocyte damage and commencing 
demyelination accompanied by microglia that show an activated phenotype. 
However, in these initial lesions lymphocytes are scarce. Thereupon progressive 
demyelination occurs, and myelin constituents are phagocytosed by microglia and 
other myeloid cells which ensues a dramatic T cell influx (Barnett and Prineas, 
2004). Widespread oligodendrocyte injury and concomitant focal demyelination 
with deterioration of axonal conduction in the CNS constitutes a unique 
pathological hallmark of MS lesions and protection of oligodendrocytes against 
injury leads to protection against the development of EAE (Butzkueven et al., 
2002; Frohman et al., 2006; A. P. D. Henderson et al., 2009; Hisahara et al., 2000; 
Lucchinetti et al., 1999; Mi et al., 2007). Importantly, primary myelin loss, can 
precede the formation of inflammatory infiltrates (Barnett and Prineas, 2004; 
Prineas and Parratt, 2012; Traka et al., 2016) and, detected by virtue of discreet 
changes in white matter areas, can be visualized several months prior to blazing 
lesions in MS patients (Fazekas et al., 2002). Furthermore, genome-wide 
epigenetic differences in the DNA methylation status have been reported 
between normal appearing white matter derived from MS patients and non-
diseased control brains (Huynh et al., 2014). The observed hypermethylation and 
subsequent diminished expression of loci in MS affected brains included genes 
that control oligodendrocyte survival (BCL2L2 and NDRG1), compatible with the 
concept that oligodendrocyte injury might trigger or augment myelin protein 
processing if professional APCs are present and suggesting that augmented 
susceptibility to injury precedes inflammatory infiltration.  
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Importantly, a recent study showed that oligodendrocyte death is sufficient to 
induce encephalitogenic T cell responses and subsequent neuroinflammation in 
vivo (Traka et al., 2016). In line with this, an increasing number of recent reports 
support the role of primary myelin-forming oligodendrocyte injury and cell death 
pathoetiologically upstream of inflammatory ingress by encephalitogenic 
lymphocytes to the CNS (Frohman et al., 2006; Furlan et al., 1999; Hisahara et 
al., 2000; 2001; Lucchinetti et al., 1999; Pender et al., 1991). In vivo multi-
spectral two-photon analyses during EAE and high resolution confocal imaging of 
actively demyelinating MS foci revealed a centripetal trajectory of 
oligodendrocyte damage, originating at protruding structures called 
myelinosomes. The vast majority of the investigated myelinosomes were located 
in the direct vicinity of non-microglial phagocytes (Romanelli et al., 2016). It is 
therefore conceivable that primary death of oligodendrocytes of yet unknown 
cause leads to subsequent uptake of myelin-derived antigenic debris by CNS-
resident APCs and the following mounting of a myelin specific adaptive response 
(Stys et al., 2012). 
There are several limitations to this study. ATG5 is not restricted to LAP but is 
also essential for canonical macroautophagy. Due to the fact that proteins that 
give rise to disease relevant antigenic peptides during EAE are not known to be 
intrinsically expressed in CNS resident professional APCs and there is no 
evidence that oligodendrocytes serve as antigen presenting cells in this context, it 
appears unlikely that our documented results can be attributed to canonical 
macroautophagy. Nevertheless, this remains to be experimentally addressed. 
Possible experiments include the conditional targeting of genes that encode for 
proteins essential for LAP but not canonical macroautophagy, e.g. cybb (encoding 
NOX2). Complementary, experiments using conditional knockouts of 
macroautophagy essential proteins that are dispensible for LAP (e.g. FIP200) 
would help to resolve this issue. Furthermore, it remains to be shown that ATG5-
deficient CNS APCs fail to reactivate encephalitogenic T cells in vivo/ex vivo. 
This will be more difficult to address, since the small numbers of target cells that 
can be obtained from the CNS of non-diseased DC-Atg5−/− animals partly 
preclude the performance of large well-controlled ex vivo cocultures.  
We conclude from our data that ATG-dependent processing of phagocytosed 
injured oligodendrocytes for antigen presentation is required for encephalitogenic 
T cells to recognize the CNS as their target organ and to induce inflammatory 
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demyelination. ATG-regulated phagocytosis in CNS DCs might also be relevant 
for the perpetuation of neuroinflammation in patients with MS and, therefore, an 
attractive therapeutic target to limit inflammatory CNS damage. 
 
3.3 ATG5-Mediated Stabilization of Surface CD1d Expression in DCs  
Both, canonical macroautophagy and LAP support loading of vesicular antigens 
onto MHC class II molecules, leading to increased and more efficient CD4+ T cell 
responses. CD1d, another antigen presenting molecule, exhibits glycolipid 
antigens to innate-like iNKT cells. iNKT cell-targeted responses and iNKT cell 
agonists are used and currently being evaluated as adjuvants to enhance the 
efficacy of anti-tumor immunotherapy. Presentation of exogenous glycolipid 
antigens for iNKT cell activation in vivo is predominantly mediated by DCs 
(Arora et al., 2014) and previous studies have shown that a proportion of CD1d 
molecules in APCs spatially associates with MHC class II molecules which are 
sorted into late endosomal MIICs before trafficking to the cell surface 
(Jayawardena-Wolf et al., 2001; Kang and Cresswell, 2002a).  
We found that already in steady state, CD1d partly colocalized with LC3 in APCs 
and this colocalization was further increased using several different TLR 
agonists. The respective contribution of different TLRs in the activation of CD1d-
restricted iNKT cells by DCs remains still unclear. It has been reported that DCs 
stimulated with the TLR9 agonist CpG ODN activate CD1d-restricted iNKT cells 
to produce IFNγ hereby conferring protection in mice against B16F10-induced 
melanoma metastases (Paget et al., 2007). Intratracheal administration of the 
prototypic glycolipid antigen αGalCer in combination with the TLR3 agonist 
poly(I:C) has been reported to upregulate IL-17A production by CD1d-restricted 
iNKT subsets rendering mice more susceptible to airway hyperreactivity (AHR) 
(Vultaggio et al., 2012). We therefore focused on these two TLR agonists for the 
colocalization analyses in primary splenic DCs and found that treatment with 
both increased colocalization of CD1d and LC3.  
Depending on the biochemical structure of the antigenic glycolipid, the elicited 
iNKT cell responses will be skewed more towards a TH1, TH2 or mixed phenotype. 
Unlike TH2-biasing agonists, which have been shown to directly load into CD1d 
molecules on the cell surface, thereby circumventing uptake and subsequent 
processing, TH1-biasing agonists (including αGalCer) require loading onto CD1d 
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molecules in endocytic compartments to be subsequently trafficked to the plasma 
membrane (Arora et al., 2011; Im et al., 2009). Given the supportive role 
autophagy pathways occupy during MHC class II-dependent antigen processing 
and presentation, we initially hypothesized a similar contribution during CD1d 
dependent presentation of glycolipids to iNKT cells. Surprisingly, in contrast to 
the auxiliary activity on MHC class II presentation, we found that the essential 
autophagy protein ATG5 negatively regulates the presentation of exogenous lipid 
antigens by CD1d.  
One candidate mechanism that we initially investigated was the use of 
differential uptake pathways for glycolipids with various biochemical properties. 
Metabolic requirements pressure cells into continuously taking up lipids which 
traffic through the circulation complexed with apolipoproteins. Amongst others, 
low density lipoprotein receptor (LDLR), scavenger receptor A (SR-A) and -BI, 
lectin-type oxidized lDl receptor 1 (LOX1; also known as OlR1) and CD36 have 
been implicated in uptake of antigenic glycolipids (Freigang et al., 2012; Greaves 
and Gordon, 2005). However, our detailed knowledge in transport and uptake 
pathways that target glycolipid antigens for CD1d presentation in APCs remains 
largely obscure. The biochemical composition of glycolipid antigen head groups 
has proven to be a key determinant for their respective receptor uptake pathway. 
While the prototypic iNKT cell agonist αGalCer facilitates uptake via both, LDLR 
and SRA, Digalactosylceramides (e.g. GalαGalCer), bearing a second galactose 
moiety in their head group, are strongly biased towards uptake via the LDLR 
pathway. Whereas glucuronylceramides (e.g. the Sphingomonas-derived GSL-1) 
carrying a carboxyl moiety on their head group, favor uptake by the SRA 
pathway (Freigang et al., 2012). Recently, it was reported that macrophages 
deficient in the essential macroautophagy gene Atg7, depict increased expression 
of two class A scavenger (SRA) receptors (Bonilla et al., 2013). However, we did 
not find any evidence for a role of ATG5 in either LDLR- or SRA-mediated 
glycolipid uptake. 
Our results obtained by using primary CD11c+ DCs were unexpected and 
appeared to be in contrast with a recent study in which Atg7-deficient GM-CSF-
differentiated bone marrow-derived DCs (BMDCs) did not differ from Atg7-
competent BMDCs in eliciting cytokine production by iNKT cells (Salio, Puleston, 
et al., 2014). To address this discrepancy we generated BMDCs from Atg5-
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deficient mice and, in line with Salio et al., observed that coculture with 
glycolipid-pulsed Atg5-deficient BMDCs leads to IL-2 production by iNKT cells to 
the same level as BMDCs generated from DC-Atg5+/+ mice. A recent study 
characterized the composition of in vitro-derived BMDC cultures and found them 
to contain heterogeneous populations including cells most closely resembling 
macrophages, DCs and neutrophils (Helft et al., 2015; Inaba et al., 1992). Helft 
and colleagues did specifically report heterogenicity within the CD11c+/MHC 
class II+ population of BMDCs (Helft et al., 2015). CD11c+/MHC class II+ BMDCs 
contained subsets that significantly differed in their expression of surface 
molecules such as CD115 and CD135 but also in their capability to release 
inflammatory mediators in response to microbial challenge (Helft et al., 2015). 
These subsets include also common monocyte precursor-derived macrophages 
which are inferior to common DC precursor antigen presenting cells in their T 
cell priming and stimulatory capacity (Guilliams and Malissen, 2015; Helft et al., 
2015). Furthermore, processes related to antigen presentation have been 
described to significantly differ in their requirement of the autophagic machinery 
dependening on the APC subset (Mintern et al., 2015). It is therefore conceivable, 
that the CD11c+/MHC class II+ population of BMDCs comprise a melange of 
APCs that may differentially make use (or not) of the autophagy machinery. 
Additionally, these subsets might fundamentally differ in their capacity to 
present CD1d ligands to begin with. We therefore continued to study DC-
mediated iNKT cell activation using FAC-sorted CD11c+ splenic DCs. 
Loss of Atg5 in CD11c+ DCs significantly impaired CD1d internalization, 
therefore leading to increased expression of stimulatory CD1d-glycolipid 
complexes, prolonged iNKT cell responses and helped in clearing Sphingomonas 
paucimobilis infection in vivo. 
The turnover of CD1d molecules is largely determined by their internalization 
and recycling. Data in reference not only to CD1d but also other CD1 isotypes 
suggest that de novo synthesized CD1d molecules are guided via signal 
sequences into the ER (Sugita et al., 1997), where self-lipids are likely to be 
loaded upon CD1d (De Silva et al., 2002; Park et al., 2004) which may function 
either as self-antigen or stabilizing chaperones ensuring structural integrity 
during trafficking through the secretory pathway towards the cell surface 
(Batuwangala et al., 2004; Bauer et al., 1997; Brutkiewicz et al., 1995; Garcia-
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Alles et al., 2006; Sugita et al., 1997). In an independent CD1d-trafficking 
pathway however, CD1d associates with the invariant chain (Ii), which governs 
CD1d/Ii-complexes prior from reaching the plasma membrane from the trans-
Golgi network into lysosomal compartments (Jayawardena-Wolf et al., 2001; 
Kang and Cresswell, 2002a). Conversely, professional APCs, deficient in Ii 
expression, show significantly increased levels of CD1d on the surface 
(Jayawardena-Wolf et al., 2001) over Ii-competent APCs while control proteins 
such as the transferrin receptor were unaffected. Interestingly, Chervonsky and 
colleagues suggested before that Ii which is not associated with MHC class II 
molecules might be directed to endosomal/lysosomal compartments via the 
autophagic pathway (Chervonsky and Sant, 1995). 
Internalization of CD1d, which contains a tyrosine-based endosomal-targeting 
motif in its cytoplasmic tail, follows a clathrin-dependent pathway that allows 
binding of CD1d to adaptor protein complexes (AP) and is essential for their 
ability to sample antigens in the endocytic system (Chiu et al., 2002; Sugita et al., 
1999). CD1d molecules can bind both AP2, which mediates CD1d internalization 
from the plasma membrane, and AP3, which targets internalized CD1d 
molecules from the early recycling pathway to late endosomes and lysosomes 
(Elewaut et al., 2003; Lawton et al., 2005; Sugita et al., 2002). During 
macroautophagy, LC3-conjugation to the autophagosomal membrane promotes 
the recruitment of specific substrates into autophagosomes via LC3-binding 
anchor proteins which function as selective autophagy receptors. A structural 
prerequisite for these anchor proteins to interact with LC3 is the presence of so-
called LC3-interacting regions (LIRs) (Noda et al., 2010). A representative of 
these motifs could first be identified in p62/sequestosome (SQSTM)1 (Pankiv et 
al., 2007). Later, the functional sequence crucial for the protein-protein 
interaction with 2 hydrophobic pockets in LC3 was narrowed down to a 
tetrapeptide with the consensus sequence of W/Y/F-X-X-I/L (Ichimura et al., 
2008; Noda et al., 2008). Using LC3 affinity purification and mass spectrometry 
analysis, immunoprecipitation, as well as live imaging analysis, Tian et al. (Y. 
Tian et al., 2013) recently identified AP2 as binding protein of LC3. Mutation of 
the identified LIR sequence “WKQL” to alanine repeats abrogated LC3 
coimmunoprecipitation with AP2 (Y. Tian et al., 2013). AP2 is a heterotetrameric 
protein complex consisting of the subunits α, β, µ, and σ (AP2A1, AP2B1, AP2M1, 
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AP2S1) (Keen, 1987). While the α subunit was shown to facilitate binding to 
target membranes (Hirst and M. S. Robinson, 1998; Kirchhausen, 1999) and the 
β subunit recruits clathrin via a clathrin box (Brodsky et al., 2001), the µ subunit 
mediates cargo recognition with its phosphoinositide-binding site (Bonifacino and 
Traub, 2003; Nakatsu and Ohno, 2003). Apart from sterically stabilizing the AP2 
complex, the precise function of the small subunit σ has not been elucidated 
(Collins et al., 2002).  
Investigating the effects of ATG5-mediated internalization of CD1d in vivo, we 
first did not observe evidence for increased iNKT cell activation upon glycolipid 
application. Unlike conventional T cells, iNKT cells rapidly release copious 
amounts of cytokines upon engagement of their invariant TCR and amongst 
others, IFNγ and IL-4 are prototypical cytokines secreted by iNKT cells upon 
activation (Bendelac et al., 2007). One of the characteristics of this innate T cell 
subset however is the immediate downregulation of numerous surface receptors 
including their TCR (Wilson et al., 2003) which initially led to the 
misinterpretation that iNKT cells would undergo dramatic cell death upon ligand 
recognition (Eberl and MacDonald, 1998; Leite-de-Moraes et al., 2000). Since the 
gold standard for detection of iNKT cells is staining with lipid-loaded CD1d-
multimers (Benlagha et al., 2000; Matsuda et al., 2000) and therefore requires 
surface expression of their TCR, glycolipid-binding-induced TCR downregulation 
precluded a robust evaluation of iNKT cell frequencies and phenotypes by lipid-
loaded CD1d-multimers after αGalCer challenge in vivo at early time points.  
The physiological consequence of facilitated internalization of CD1d by 
autophagy might be an increased colocalization of CD1d with antigens that 
require intracellular loading, for example lipid antigens released by bacteria 
during lysosomal degradation. Autophagy is currently being explored for its 
efficacy to enhance MHC class II presentation of potential vaccine antigens in 
order to establish long-lasting T cell memory and to support antigen-specific 
CD8+ T cell function (Berner et al., 2007; Jagannath et al., 2009; Marzo et al., 
2000; Ravindran et al., 2014) Our data suggest that ATG5 is an essential 
component of a non-canonical autophagy pathway which exerts a tuning function 
in lipid antigen presentation. Depending on the targets of intervention and 
depending on which other components besides ATG5 are shared between 
canonical and this non-canonical pathway, targeting macroautophagy for 
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improved CD4+ T cell immunity might limit the efficacy of vaccination strategies 
that include NKT cell ligands as adjuvants.  
Similar to the MHC class I-like molecule CD1d, a recent study found that surface 
levels of classical MHC class I molecules are elevated due to decreased 
endocytosis and degradation in ATG5-deficient DCs (Loi et al., 2016). However, 
AP2 components were not significantly reduced in immunoprecipitates of 
classical MHC class I molecules derived from Atg5-deficient cells compared to 
controls. Instead, Atg5-deficiency compromised MHC class I-association with 
AAK1 which is known to support AP2-independent, but clathrin-dependent 
endocytosis pathways (Gupta-Rossi et al., 2011; D. M. Henderson and Conner, 
2007; Loi et al., 2016). Furthermore, LIR motifs have also been described in 
clathrin itself (Rogov et al., 2014). Thus, autophagy proteins appear to affect 
different clathrin-dependent pathways for the internalization and degradation of 
classical and non-classical MHC class I molecules, respectively. 
Loss of autophagy proteins has recently been reported to exert a T cell-intrinsic 
role in regulating iNKT cell development (Pei et al., 2015; Salio, Puleston, et al., 
2014). Mice with T lymphocyte-specific deletion of Atg5 or Atg7 show reduced 
progression of thymic iNKT cells through the cell cycle and lower frequencies of 
both thymic and peripheral iNKT cell populations due to increased apoptosis and 
impaired survival (Pei et al., 2015; Salio, Puleston, et al., 2014). Frequencies of 
thymic and peripheral iNKT cells were unchanged in DC-Atg5−/− mice supporting 
the notion that the reported deficit in iNKT cell differentiation is cell-
autonomous. Our data show that while autophagy proteins regulate iNKT cell 
development via T cell-intrinsic effects, they attenuate peripheral iNKT 
activation through their function in DC-mediated antigen processing and 
presentation.  
Collectively, these data indicate that absence of the autophagy machinery protein 
ATG5 leads to increased CD1d-mediated lipid presentation due to stabilization of 
CD1d on the cell surface by interfering with AP2-mediated internalization.   
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3.4 Concluding Remarks 
Our findings identified ATG5 in CD11c+ DCs as a key regulator for both 
conventional and unconventional T cells and broaden the concept of ATG-
mediated antigen presentation beyond canonical macroautophagy. ATG5-
regulated phagocytosis supports CD4+ T cell immunity through mediating the 
loading and processing of extracellular antigen onto MHC class II molecules 
while ATG5-controlled internalization of CD1d restrains iNKT cell responses. 
The use and function of ATG5 is, therefore, context-dependent and a clear and 
comprehensive concept of how the autophagy machinery couples to antigen-
presentation and lymphocyte activation appears to be required to predict the 
outcome of therapeutic interventions in this pathway to boost adaptive 
immunity. 
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4. Materials and Methods 
  
4.1 Materials 
 
4.1.1 Machines 
Machine Company 
autoMACS Pro Separator Miltenyi Biotech  
(Bergisch Gladbach, Germany) 
BD FACSCanto-II BD Biosciences  
(San Jose, USA) 
BD LSR Fortessa BD Biosciences  
(San Jose, USA) 
C1000 Thermal Cycler Bio-Rad 
(Hercules, USA) 
CLSM Leica SP5 Mid UV-VIS  Leica Microsystems  
(Heerbrugg, Switzerland) 
Eppendorf Thermomixer 21516-170 Eppendorf 
(Hamburg, Germany) 
Fusion FX Detector Vilber-Lourmat 
(Eberhardzell, Germany) 
Leica DM IL LED Microscope Leica Microsystems  
(Heerbrugg, Switzerland) 
Microplate Reader Infinite M1000 Pro Tecan  
(Männedorf, Switzerland) 
Multipurpose Centrifuge 5810 R  Eppendorf 
(Hamburg, Germany) 
SDS-PAGE Chamber Set Up Bio-Rad 
(Hercules, USA) 
Sorvall Legend RT Plus Centrifuge Thermo Scientific  
(Rockford, USA) 
Sorvall RC 6 Plus Superspeed Centrifuge 
 
Thermo Scientific  
(Rockford, USA) 
Tissue Lyzer  Qiagen Instruments 
(Hombrechtikon, Switzerland) 
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Waldmann UV 181 BL Irradiation Unit Waldmann Group 
(Villingen-Schwenningen, Germany) 
 
4.1.2 Antibodies, Flow Cytometry and Cellular Assays 
Antigen Fluorochrome Clone Dilution/
Concent
ration 
Company 
CD103 APC 2E7 1:50 Biolegend  
(San Diego, 
USA) 
CD11b APC-Cy7 M1/70 1:200 Biolegend  
(San Diego, 
USA) 
CD11c APC N418 1:200 Biolegend  
(San Diego, 
USA) 
CD11c PE-Cy7 N418 1:400 Biolegend   
(San Diego, 
USA) 
CD16/32 unconjugated  
 
2.4G2  22.4 
µg/ml 
Bio X Cell  
(West Lebanon, 
USA) 
CD19 Alexa Fluor 700 eBio1D3 1:200 eBioscience  
(San Diego, 
USA) 
CD19 Pacific Blue 6D5 1:400 Biolegend  
(San Diego, 
USA) 
CD1d PE 1B1 1:50 
 
eBioscience  
(San Diego, 
USA) 
CD1d unconjugated 1B1 1:50 Biolegend  
(San Diego, 
USA) 
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CD1d biotinylated 1B1 1:50 Biolegend  
(San Diego, 
USA) 
CD25 Brilliant Violet 
605 
PC61 1:200 Biolegend  
(San Diego, 
USA) 
CD4  Alexa Fluor 700 GK1.5 1:200 eBioscience  
(San Diego, 
USA) 
CD4 Pacific Blue GK1.5 1:400 Biolegend  
(San Diego, 
USA) 
CD40 unconjugated  
 
FGK4.5/ 
FGK45) 
1:200 Bio X Cell  
(West Lebanon, 
USA) 
CD40 PE 3/23 1:50 Biolegend  
(San Diego, 
USA) 
CD40 PE-Cy 3/23 1:50 Biolegend  
(San Diego, 
USA) 
CD44 PerCP-Cy5.5 IM7 1:100 eBioscience  
(San Diego, 
USA) 
CD45 APC-Cy7 30-F11 1:400 BD Biosciences  
(San Jose, 
USA) 
CD45.2 Pacific Blue 104 1:400 Biolegend  
(San Diego, 
USA) 
CD62L PE-CF594 MEL-14 1:100 BD Biosciences  
(San Jose, 
USA) 
CD86  Brilliant Violet GL-1 1:200 Biolegend  
(San Diego, 
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650 USA) 
CD8α PE-CF594 53-6.7 1:400 BD Biosciences  
(San Jose, 
USA) 
CD8α Brilliant Violet 
510 
53-6.7 1:200 Biolegend  
(San Diego, 
USA) 
CD8α FITC 53-6.7 1:400 eBioscience  
(San Diego, 
USA) 
CD8α Brilliant Violet 
785  
53-6.7 1:100 Biolegend  
(San Diego, 
USA) 
CD8α PerCP-Cy5.5- 53-6.7 1:100 eBioscience  
(San Diego, 
USA) 
FOXP3 PerCP-Cy5.5 FJK-16s 1:100 eBioscience  
(San Diego, 
USA) 
GM-CSF PE MP1-
22E9 
1:250 BD Biosciences  
(San Jose, 
USA) 
I-Ab Pacific Blue M5/114.1
5.2 
1:200 Biolegend  
(San Diego, 
USA) 
I-Ab  
 
APC M5/114.1
5.2 
1:800 Biolegend  
(San Diego, 
USA) 
IFNγ FITC XMG1.2 1:400 Biolegend  
(San Diego, 
USA) 
IL-12/IL-23 p40 PE C17.8 1:100 
 
eBioscience  
(San Diego, 
USA) 
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IL-17A PE-Cy7 TC11/18
H10 
1:200 Biolegend  
(San Diego, 
USA) 
Ly-6C PerCP-Cy5.5 HK1.4 1:200 Biolegend  
(San Diego, 
USA) 
Ly-6G Alexa Fluor 700 1A8 1:200 Biolegend  
(San Diego, 
USA) 
TCRβ APC H57-597 1:50 eBioscience  
(San Diego, 
USA) 
Vβ11 TCR PE RR3-15 1:300 BD Biosciences 
(San Jose, 
USA) 
αGalCer:CD1d-
complex 
PE L363 1:50 eBioscience  
(San Diego, 
USA) 
 
4.1.3 Miscellaneous 
Isotype 
/Streptavidin/etc. 
Fluorochrome Clone Dilution Company 
Annexin V FITC --- 1:20 BD Biosciences 
(San Jose, USA) 
anti-MOG unconjugated 8-18C5 1:200 In-house 
production  
(Isaak Quast) 
IgG2bκ  PE eB149/
10H5 
1:50 eBioscience  
(San Diego, USA) 
Streptavidin PE --- 1:400 Biolegend  
(San Diego, USA) 
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4.1.4 Primary and Secondary Antibodies for Immunocytochemistry 
Conjugate Reactivity Isotype Dilution Company 
Alexa Fluor488 donkey anti-goat  IgG (H+L) 1:500 Life 
Technologies  
(Zug, 
Switzerland) 
Alexa Fluor488 goat anti-rabbit IgG (H+L) 
 
1:500 Life 
Technologies  
(Zug, 
Switzerland) 
Alexa Fluor555 rabbit anti-
mouse 
IgG (H+L) 1:500 Life 
Technologies  
(Zug, 
Switzerland) 
Alexa Fluor555 goat anti-rat IgG (H+L) 
 
1:500 Life 
Technologies  
(Zug, 
Switzerland) 
AP2 mouse anti-
mouse 
IgG (H+L) 1:250 BD Biosciences  
(San Jose, USA) 
EEA1, 
unconjugated 
goat anti-mouse polyclonal 1:250 Antibodies-
online 
LC3, 
unconjugated 
rabbit anti-
mouse 
polyclonal 1:250 MBL  
(Woburn, USA) 
 
4.1.5 Tetramer 
Tetramer Fluorochrome Dilution Company 
Non-ligand carrier-loaded 
murine CD1d tetramer 
(negative control) 
PE 1:100 ProImmune  
(Oxford, UK) 
αGalCer-loaded murine 
CD1d tetramer 
PE 1:100 ProImmune  
(Oxford, UK) 
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4.1.6 MACS Beads 
Product Company 
Anti-murine CD11c MicroBeads  Miltenyi Biotech  
(Bergisch Gladbach, Germany) 
Anti-murine CD4 (L3T4) MicroBeads Miltenyi Biotech  
(Bergisch Gladbach, Germany) 
 
4.1.7 General Material 
Product Company 
“Rapid“-Filtermax 250 Filters  TPP Techno Plastic Products AG 
(Trasadingen, Switzerland) 
1 ml Syringe Luer-Lok™ Tip BD Medical  
(Le Pont de Claix Cedex, France) 
1.8 ml Cryo Pure Tubes  Sarstedt  
(Nümbrecht, Germany) 
17 ml Tube, Thinwall, Ultra-clear™, 16 
× 102 mm Tubes (for ultracentrifuge 
rotors) 
Beckmann Coulter   
(Brea, USA) 
25G × 25 mm Needles   BD Microlance  
(Heidelberg, Germany) 
30G × 12 mm Needles  BD Microlance  
(Heidelberg, Germany) 
8-Well Glass Chamber Slides  Lab-Tek/Nunc  
(Rochester, USA) 
Butterfly™ Winged Infusion Set, 21G × 
19 mm 
Hospira  
(Warwickshire, UK) 
C-Chip Neubauer Improved DHC-N01, 
Disposable Hemocytometer  
Digital-Bio  
(Seoul, South Korea) 
Carbon Steel Surgical Blades  Swann-Morton  
(Sheffield, UK) 
Cell Freezing Container Thermo Scientific  
(Rockford, USA) 
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Cell Scraper (13 mm) SPL Life Sciences  
(Pocheon, South Korea) 
Eppendorf Safe Lock Tubes 
 
Sarstedt  
(Nümbrecht, Germany) 
FACS Tubes, 5 ml, Polystyrene Round 
Bottom  
BD Falcon / Bioswisstech  
(Schaffhausen, Switzerland) 
FACS Tubes, 5 ml, Polystyrene Round 
Bottom (with cell strainer cap) 
BD Falcon / Bioswisstech  
(Schaffhausen, Switzerland) 
Microtainer Tubes K2E BD Biosciences  
(San Jose, USA) 
Microtainer Tubes SST BD Biosciences  
(San Jose, USA) 
Non-Tissue Culture Treated Round 
Petri Dishes, ! 90 mm 
Thermo Fisher Scientific AG  
(Reinach, Switzerland) 
PVDF Membrane GE Healthcare  
(Little Chalfont, UK) 
Reusable Hemocytometer 
 
Hecht-Assistant  
(Sondheim v.d. Rhön, Germany) 
Sealing Tape for ELISA Plates Nunc / Thermo Fisher Scientific AG 
(Reinach, Switzerland) 
Syringes (2, 5, 10, 20, 50 ml) Braun  
(Melsungen, Germany) 
Tissue Culture Treated Round Dishes, 
! 100 mm 
Sigma-Aldrich  
(St. Louis, USA) 
U-100 Insulin Syringe (29G × 12.7 mm) BD Medical  
(Le Pont de Claix Cedex, France) 
Whatman Blotting Paper 3 mm CHR VWR international  
(Radnor, USA) 
 
4.1.8 NKT Cell Agonists 
Product Company 
NKT cell agonist variants  GSL-1 and GalαGalCer were kindly 
provided by Paul B. Savage, 
BYU, Provo, UT, USA. 
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α-Galactosylceramide (αGalCer)  Adipogen AG  
(Liestal, Switzerland) 
 
4.1.9 General Reagents 
Product  Company 
4',6-Diamidino-2-Phenylindole, 
Dihydrochloride 
Life Technologies  
(Zug, Switzerland) 
ACK Lysing Buffer Life Technologies  
(Zug, Switzerland) 
Acrylamide/Bis-acrylamide,  
30% Solution 
Bio-Rad  
(Hercules, USA) 
Agarose, LE, Analytical Grade  Promega  
(Dübendorf, Switzerland) 
Ammonium Persulfate (APS) Sigma-Aldrich  
(St. Louis, USA) 
Bovine Serum Albumin  Amresco  
(Solon, USA) 
Bovine Serum Albumin Solution, 30%  Sigma-Aldrich  
(St. Louis, USA) 
Brefeldin A Sigma-Aldrich  
(St. Louis, USA) 
Carboxyfluorescein Succinimidyl Ester 
 
eBioscience  
(San Diego, USA) 
Chloroquine InvivoGen  
(San Diego, USA) 
Collagenase D  Roche  
(Rotkreuz, Switzerland) 
Complete Freund’s Adjuvant Difco / BD Biosciences  
(San Jose, USA) 
cOmplete Protease Inhibitor Cocktail 
Tablets  
Roche  
(Rotkreuz, Switzerland) 
CpG ODN 1826  InvivoGen  
(San Diego, USA) 
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Cycloheximide Sigma-Aldrich  
(St. Louis, USA) 
DMSO  Sigma-Aldrich  
(St. Louis, USA) 
DNA Loading Dye, 6× Fermentas / Thermo Fisher Scientific 
AG 
(Reinach, Switzerland) 
DNAse  QIAGEN Instruments AG 
(Hombrechtikon, Switzerland) 
dNTPs, 10 mM  QIAGEN Instruments AG 
(Hombrechtikon, Switzerland)  
Dulbecco's Modified Eagle Medium (4.5 
g/L Glucose) 
Biochrom AG 
(Berlin, Germany) 
ECL Western Blotting Substrate  Thermo Scientific 
(Rockford, USA) 
EDTA Sigma-Aldrich  
(St. Louis, USA) 
Ethanol Sigma-Aldrich  
(St. Louis, USA) 
Fetal Calf Serum   Biochrom AG 
(Berlin, Germany) 
GelRedTM Nucleic Acid Gel Stain, 
10000× 
Biotium  
(Hayward, USA) 
GeneRuler 100 bp DNA Ladder  Fermentas  / Thermo Fisher Scientific 
AG 
(Reinach, Switzerland) 
Imiquimod InvivoGen  
(San Diego, USA) 
Ionomycin  Sigma-Aldrich  
(St. Louis, USA) 
Isoflurane Piramal Healthcare  
(Mumbai, India) 
Isopropanol Sigma-Aldrich  
(St. Louis, USA) 
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L-Glutamine 200 mM 100× 
 
Gibco / Thermo Fisher Scientific AG 
(Reinach, Switzerland) 
Lipopolysaccharide (LPS) InvivoGen  
(San Diego, USA) 
MEM Non-Essential Amino Acids 
(NEAA) Solution (100×) 
Gibco/Thermo Fisher Scientific AG 
(Reinach, Switzerland) 
Methanol Sigma-Aldrich  
(St. Louis, USA) 
Muller-Hinton Agar Sigma-Aldrich  
(St. Louis, USA) 
Mycobacterium Tuberculosis H37 Ra 
(Desiccated) 
Difco / BD Biosciences  
(San Jose, USA) 
NaN3 Sigma-Aldrich  
(St. Louis, USA) 
Normal Goat Serum Sigma-Aldrich  
(St. Louis, USA) 
NP-40 Sigma-Aldrich  
(St. Louis, USA) 
OneComp eBeads eBioscience  
(San Diego, USA) 
Pam3CSK4 InvivoGen  
(San Diego, USA) 
Paraformaldehyde  Santa Cruz Biotechnology Inc.  
(Dallas, USA) 
PCR Reaction Buffer with Mg2+  
 
Roche   
(Rotkreuz, Switzerland) 
Penicillin Biochrom AG 
(Berlin, Germany) 
Percoll  GE Healthcare 
(Little Chalfont, UK) 
Pertussis Toxin from B. pertussis (in 
Glycerol) 
List Biological Laboratories, Inc 
(Campbell, USA) 
Phorbol 12-Myristate 13-Acetate (PMA) Sigma-Aldrich  
(St. Louis, USA) 
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Phosphate Buffered Saline (PBS) Cantonal Pharmacy  
(Zurich, Switzerland) 
Pipet Tips with Microcapillary for Gel-
Loading  
VWR  
(Radnor, USA) 
Poly-L-lysine Sigma-Aldrich  
(St. Louis, USA) 
Poly(I:C) InvivoGen  
(San Diego, USA) 
Precision Plus Protein Dual Color 
Standards 
Bio-Rad 
(Hercules, USA) 
ProLong Gold Antifade Reagent Life Technologies  
(Zug, Switzerland) 
Proteinase K  Roche  
(Rotkreuz, Switzerland) 
Rapamycin Sigma-Aldrich  
(St. Louis, USA) 
ReBlot Plus Strong Antibody Stripping 
Solution, 10× 
Merck / Millipore  
(Schaffhausen, Switzerland) 
Recombinant Murine GM-CSF  Life Technologies  
(Zug, Switzerland) 
Recombinant Murine IL-2 R&D Systems 
(Minneapolis, USA) 
Recombinant Murine IL-23 eBioscience  
(San Diego, USA) 
Roswell Park Memorial Institute-1640 
Medium (RPMI-1640) 
Biochrom AG 
(Berlin, Germany) 
Saponin Sigma-Aldrich  
(St. Louis, USA) 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich  
(St. Louis, USA) 
SDS,  
20% solution 
Fluka / Sigma-Aldrich  
(St. Louis, USA) 
Streptomycin Biochrom AG 
(Berlin, Germany) 
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Taq DNA Polymerase  Roche  
(Rotkreuz, Switzerland) 
TEMED Bio-Rad  
(Hercules, USA) 
Triton X-100  Sigma-Aldrich  
(St. Louis, USA) 
Trypan Blue  Gibco / Thermo Fisher Scientific AG 
(Reinach, Switzerland)  
Trypsin-EDTA 0.25%  Gibco / Thermo Fisher Scientific AG 
(Reinach, Switzerland)  
Tween 20  Sigma-Aldrich  
(St. Louis, USA) 
β-Mercaptoethanol  Gibco/Thermo Fisher Scientific AG 
(Reinach, Switzerland)  
 
4.1.10 Kits 
Product  Company 
Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit 
BD Biosciences  
(San Jose, USA) 
FOXP3 Staining Buffer Set  eBioscience  
(San Diego, USA) 
LIVE/DEAD Fixable Aqua Dead Cell 
Stain Kit  
Life Technologies  
(Zug, Switzerland) 
LIVE/DEAD Fixable Near-IR Dead 
Cell Stain Kit 
Life Technologies  
(Zug, Switzerland) 
Mouse IFNγ Instant ELISA Kit eBioscience  
(San Diego, USA) 
Mouse IL-12/-23 (p40) ELISA 
Development Kit 
Mabtech AB  
(Nacka Strand, Sweden) 
Mouse IL-2 Ready-SET-GO ELISA 
Reagent Kit 
eBioscience  
(San Diego, USA) 
Mouse IL-4 Instant ELISA Kit eBioscience  
(San Diego, USA) 
Permeabilization Solution Kit BD Biosciences  
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(San Jose, USA) 
Pierce BCA Protein Assay Kit  
 
Thermo Scientific 
(Rockford, USA) 
 
4.1.11 MOG Protein and Peptide 
Product  Company 
MOG35-55 Peptide  
(MEVGWYRSPFSRVVHLYRNGK) 
GenScript  
(Piscataway, USA) 
Recombinant MOG1-124 Protein In-house production  
(Christina Sina/Isaak Quast) 
 
4.1.12 OVA Peptide 
Product  Company 
OVA323-339 Peptide  
(ISQAVHAAHAEINEAGR) 
InvivoGen 
(San Diego, USA) 
 
4.1.13 Antibodies for T Cell Stimulation During Coculture Assays 
Antigen Clone Final 
concentration 
Company 
CD28 37.51 5 µg/ml BD Biosciences  
(San Jose, USA) 
CD3 145-2C11 5 µg/ml BD Biosciences  
(San Jose, USA) 
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4.1.14 Antibodies (1° and 2°) for Western Blot 
Antigen Dilution Company 
ATG5-ATG12 
complex 
1:400 Biomol  
(Hamburg, Germany) 
HRP-conjugated 
goat anti-mouse 
IgG 
1:10000 Bio-Rad 
(Hercules, USA) 
HRP-conjugated β-
Actin 
1:50000 Abcam 
(Cambridge, UK) 
LC3 1:1000 Biomol  
(Hamburg, Germany) 
 
4.1.15 Plastic Supplies 
Plastic supplies such as multiwell plates, disposable plastic pipettes and plastic 
reaction tubes were obtained from Becton Dickinson Labware (FALCON), VWR 
International, Costar and Nunc. 
 
4.1.16 Cell Lines and Bacteria 
Specimen Kindly provided by/Bought from 
A.407  
iNKT Cell Hybridoma Cell Line 
(murine, C57BL/6 background) 
Stefan Freigang, Institute of 
Pathology, Department of 
Experimental Pathology, University of 
Bern, Bern, Switzerland 
 
FF13 
iNKT cell Hybridoma Cell Line  
(murine, C57BL/6 background)) 
Gennaro DeLibero, Singapore 
Immunology Network, Agency for 
Science, Technology and Research 
(A*STAR), Singapore, Singapore  
and Department of Biomedicine, 
Laboratory of Experimental 
Immunology, University Hospital 
Basel, University of Basel, Basel, 
Switzerland 
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Immortilized Atg5-deficient 
macrophage cell line + respective Atg5-
competent control cell line (designated 
MΘ-Atg5−/− and MΘ-Atg5+/+) 
(murine, C57BL/6 background) 
Eicke Latz, Institute of Innate 
Immunity 
Biomedical Center, University 
Hospitals / University of Bonn, Bonn, 
Germany 
 
MO3.13 
Glial (Oligodendrocytic) hybrid cell line  
(MOG-transduced and wild type cell 
lines) 
Fabienne Brilot-Turville, Brain 
Autoimmunity Group 
Institute for Neuroscience and Muscle 
Research (INMR) 
The Kids Research Institute at the 
Children's Hospital at Westmead 
University of Sydney, Australia 
 
RAW 264.7 
Leukaemic monocyte macrophage cell 
line (murine, BALB/c background) 
 
ATCC (Wesel, Germany) 
Sphingomonas paucimobilis ATCC (Wesel, Germany) 
 
4.1.16.1 NKT Cell Hybridoma Lines 
The Vα14+/Vβ8+ iNKT cell hybridoma A.407 was generated by fusion of ex vivo 
CD1d tetramer-sorted NKT cells with the murine thymoma BW5147 (S.F. 
unpublished data). The FF13 hybridoma was generated by fusion of Vα14i NKT 
cells sorted from αGalCer-treated C57BL/6 mice with mouse BW5147 thymic 
lymphoma cells (Schümann et al., 2007). 
 
4.1.16.2 Atg5-Deficient Immortalized Macrophage-Like Cell Line 
The Atg5-deficient immortalized macrophage cell line was kindly provided by 
Eicke Latz (Institute of Innate Immunity Biomedical Center, Bonn Germany). 
Immortilized cell lines were generated from DC-Atg5−/− mice using a J2 
recombinant retrovirus carrying v-myc and v-raf(mil) oncogenes as previously 
described (Peitz et al., 2002; Roberson and Walker, 1988). For functional 
disruption of macroautophagy in DC-Atg5−/−-derived macrophages through 
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conditional mutagenesis using TAT-Cre transduction, a cell-permeable Cre 
recombinase was titrated onto the cells, which resulted in deletion of floxed 
target genes upon recombination.   
 
4.1.17 PCR Primers 
Primer name Primer Target Primer sequence (5’- 3’) 
CS003 Atg5flox/flox GAATATGAAGGCACACCCCTGAAATG 
CS004 Atg5flox/flox GTACTGCATAATGGTTTAACTCTTGC 
CS005 Atg5flox/flox ACAACGTCGAGCACAGCTGCGCAAGG 
CS006 Atg5flox/flox CAGGGAATGGTGTCTCCCAC 
CS007 CD11c-Cre-GFP GCGGTCTGGCAGTAAAAACTATC 
CS008 CD11c-Cre-GFP GTGAAACAGCATTGCTGTCACTT 
CS009 CD11c-Cre-GFP 
(positive control) 
CTAGGCCACAGAATTGAAAGATCT 
CS010 CD11c-Cre-GFP 
(positive control) 
GTAGGTGGAAATTCTAGCATCATCC 
 
4.1.18 Cell Culture Media 
All media were filter-sterilized with 0.2 µm filters prior to use and stored at 4 °C. 
Medium Ingredients 
D10 DMEM Medium (high glucose) 
10% Heat Inactivated FCS 
1% Penicillin/Streptomycin 
R10 RPMI-1640 Medium 
10% Heat Inactivated FCS 
1% Penicillin/Streptomycin 
BMDC Medium RPMI-1640 Medium 
20% Heat Inactivated FCS 
1% Penicillin/Streptomycin 
50 µM β-Mercaptoethanol 
2.5 ng/ml GM-CSF (carrier-free)  
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Restimulation Medium (adoptive 
transfer) 
RPMI-1640 Medium 
10% Heat Inactivated FCS 
1% Penicillin/Streptomycin 
IL-23 (20 ng/ml) 
MOG35-55 (20 µg/ml) 
Freezing Medium Heat Inactivated FCS 
10% DMSO 
Hybridoma Media for A.407 and 
FF13 iNKT Cell Lines 
RPMI-1640 Medium 
10% Heat inactivated FCS 
1% Penicillin/Streptomycin 
2mM L-Glutamin  
1% Non-Essential Amino Acid Solution 
 
4.1.19 General Buffers 
Buffer Ingredients 
PBS (1×) 
pH 7.4 
137 mM NaCl  
2.7 mM KCl  
10 mM Na2HPO4   
1.8 mM KH2PO4  
Adjust pH to 7.4 with HCl and add H2O to 1 L 
Tail Lysis Buffer (1×; stored 
at RT) 
100 mM Tris, pH 8.0 
100 mM NaCl 
10 mM EDTA, pH 8.0 
0.2% SDS 
0.2 mg/ml Proteinase K (added freshly for each 
digestion) 
Cell Lysing Buffer (for 
protein quantification; 
prepared freshly each time) 
PBS 
1% NP-40 
1× Protease Inhibitor Cocktail 
Tissue Digestion Buffer (for 
spleen; prepared freshly 
each time) 
 
PBS 
0.4 mg/ml Collagenase D 
20 µg/ml DNase 
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Tissue Digestion Buffer (for 
CNS; prepared freshly each 
time) 
RPMI-1640 
0.2 mg/ml Collagenase D 
20 µg/ml DNase 
FACS Buffer 
(stored at 4 °C)  
PBS 
0.5% Bovine Serum Albumin (BSA) 
0.01% NaN3 
Sorting Buffer PBS 
2% BSA 
MACS Buffer 
(stored at 4 °C) 
PBS 
2 mM EDTA 
0.5% BSA 
Annexin V Staining Buffer 
(stored at 4 °C) 
10 mM Hepes/NaOH; pH 7.4 
140 mM NaCl 
2.5 mM CaCl2 
TBE (5×; stored at RT) 44.5 mM Tris Base; pH 8.5 
44.5 mM Boric Acid 
2 mM EDTA 
Laemmli Buffer 
(stored at −20 °C) 
60 mM Tris-Cl, pH 6.8 
2% SDS 
10% Glycerol 
5% β-Mercaptoethanol 
0.01% Bromophenol Blue 
 
4.1.20 Buffers Immunocytochemistry 
Buffer Ingredients 
Blocking Buffer PBS 
10% Normal Goat Serum (NGS) 
1% BSA 
Dilution Buffer PBS 
10% NGS 
1% BSA 
0.1% Saponin 
Fixation Buffer PBS 
4% PFA 
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Permeabilization Buffer PBS 
0.1% Triton X-100 
Washing Buffer PBS 
0.01% Saponin 
 
4.1.21 Buffer for SDS-PAGE and Western Blot 
Buffer Ingredients 
PBS-T PBS 
0.1% Tween 20 
Running Buffer 10×, pH 8.3, 1L 30.3 g Tris base 
144 g Glycine 
10 g SDS 
H2O 
1.5 M Tris, pH 8.8 (150 ml) 27.23 Tris Base 
H2O 
1.5 M Tris pH 6.8 (100 ml) 18.17 g Tris Base 
H2O 
Transfer buffer 1× 25 mM Tris Base 
192 mM Glycine 
20% Methanol 
 
4.1.22 ELISA Buffer 
Buffer Ingredients 
ELISA Wash buffer PBS 
0.05% Tween 20 
 
4.1.23 Recipes for SDS-PAGE Gels (0.75 mm) 
Components  12% Resolving gel  
(2 gels) 
Stacking gel  
(2 gels) 
Acrylamide/Bis-acrylamide,  
30% Solution [ml] 
4.8 1.5 
0.5M Tris pH 6.8 [ml] --- 1.2 
2M Tris pH 8.8 [ml] 2.5 --- 
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20% SDS [µl] 60 45 
H2O 4.5 6.3 
TEMED 24 12 
APS 96 80 
 
4.1.24 Percoll Solutions  
 
4.1.24.1 Leukocyte Isolation from Mouse Liver 
Solution Ingredients 
90% Percoll Solution (50 ml) 45 ml Percoll 
5 ml PBS (10×) 
70% Percoll Solution (50 ml) 38,9 ml 90% Percoll Solution 
11.1 ml PBS (1×) 
40% Percoll Solution (45 ml) 20 ml 70% Percoll Solution 
15 ml PBS (1×) 
 
4.1.24.2 Leukocyte Isolation from Mouse CNS 
Solution Ingredients 
30% Percoll Solution (15 ml; for one 
CNS) 
10.5 ml PBS (1×) 
4.5 ml Percoll 
 
4.1.25 Optical Configurations of Flow Cytometers Used 
 
4.1.25.1 BD SLR Fortessa 
Laser [wave 
length] 
Mirror  Filter Applicable Dyes 
Violet [405 nm] 735 LP 
685 LP 
640 LP 
600 LP 
505 LP  
800/50 
710/50 
670/30 
610/20 
525/50 
450/50 
Qdot800, BV785 
Qdot705, BV711 
Qdot 655, eFluor650nc, BV650, 
Qdot605, eFluor 605nc, BV605 
AmCyan, Aqua L/D stain, Pacific 
Orange, BV510 
Pacific Blue, V450, BV421, Cell Trace 
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Violet 
Blue [488] 635 LP 
505 LP 
690/50 
525/50 
488/10 
PerCP, PerCP-Cy5.5 
FITC, Alexa 488, GFP 
SSC 
Yellow/Green 
[561] 
750 LP 
685 LP 
635 LP 
600 LP 
780/60 
710/50 
670/30 
610/20 
582/15 
PE-Cy7 
PE-Cy5.5 
PE-Cy5, 7AAD 
PE-Texas Red, mCherry 
PE, DsRED, PKH26 
Red [640] 750 LP 
685 LP 
780/60 
730/45 
670/30 
APC-Cy7, APC-H7, APC-Alexa750, 
Near IR-L/D stain 
AlexaFluor 700 
APC, Alexa 647, TO-PRO-3 
 
4.1.25.2 BD FACSCanto-II 
Laser [wave 
length] 
Mirror  Filter Applicable Dyes 
Violet [405 nm] 502 LP  510/50 
450/50 
AmCyan, Aqua L/D stain 
Pacific Blue, V450, BV421, Cell Trace 
Violet 
Blue [488] 735 LP 
655 LP 
556 LP 
502 LP 
780/60 
670 LP 
585/42 
530/30 
488/10 
PE-Cy7 
PerCP, PerCP-Cy5.5, 7AAD 
PE, DsRED, PKH26 
FITC, Alexa 488, GFP 
SSC 
Red [640] 750 LP 
685 LP 
780/60 
660/20 
APC-Cy7, APC-H7, APC-Alexa750, 
Near IR-L/D stain 
APC, Alexa 647, TO-PRO-3 
 
4.2 Methods 
 
4.2.1 Mice  
8 to 12 weeks old C57BL/6 mice (female and male) were purchased from Janvier 
Labs. C57BL/6J-Tg(Itgax-cre,-EGFP)4097Ach/J mice (designated CD11c-Cre Tg) 
MATERIALS & METHODS 	
	 106	
were purchased from Charles River. Atg5flox/flox mice (Hara et al., 2006), were a 
kind gift of Noboru Mizushima (University of Tokyo, Japan). MOG-specific TCR 
transgenic mice C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (designated 
2D2/TCRMOG) were a kind gift from Vijay K. Kuchroo (Harvard Institutes of 
Medicine, USA) / Burkhard Becher (University of Zurich, Switzerland). All 
animals were bred and housed in the University of Zurich animal facility in 
individually ventilated cages on a 12 h light/dark cycle with food and water 
available ad libitum according to institutional guidelines and Swiss animal laws. 
Atg5flox/flox mice were crossed to CD11c-Cre Tg mice to obtain CD11c Cre-Atg5−/− 
(designated DC-Atg5−/−) on a C57BL/6 background. CD11c Creneg-Atg5fl/fl 
(designated DC-Atg5+/+) were used as littermate controls. All animal protocols 
were approved by and conducted in accordance with the cantonal veterinary 
office of the canton of Zurich, Switzerland (protocols 25706-ZH209/2014 and 
ZH210/2014) and the canton of Bern, Switzerland (protocols BE46/14, BE73/14).  
 
4.2.2 Mouse Organ Processing 
Mice were euthanized by CO2 inhalation. Depending on the organ of interest, 
different leukocyte isolation protocols were applied. 
 
4.2.2.1 Leukocyte Isolation from Spleen, Thymus and Lymph Nodes 
Spleens, thymus or lymph nodes were removed, collected in 15 ml tubes 
containing cold PBS, dissected into small pieces and digested for 30 min at 37 °C 
and 5% CO2 with collagenase D (0.4 mg/ml) and DNAse (20 µg/ml) in PBS (3 
ml/organ). Digest was stopped by adding 0.5 M EDTA at a 1:50 ratio for the final 
5 min at 37 °C and 5% CO2. The digested tissue was passed through a 70 µm cell 
strainer to obtain single cell solutions. After a washing step with cold PBS, red 
blood cell lysis (2 min, RT) was performed using 1 ml ACK lysis buffer per spleen 
followed by washing with cold PBS. Cell concentration was determined using 
Neubauer counting chambers and trypan blue staining for the exclusion of dead 
cells. Samples were kept on ice until further processing. 
 
4.2.2.2 Leukocyte Isolation from Liver 
The liver was removed, collected in 50 ml tubes containing cold PBS, dissected 
into small pieces and digested for 45 min at 37°C and 5% CO2 with collagenase D 
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(0.4 mg/ml) and DNAse (20 µg/ml) in PBS (4 ml/organ). The digest was stopped 
by the addition of EDTA to a final concentration of 10 mM for the last 5 min at 
37 °C and 5% CO2. The digested tissue was passed through a 70 µm cell strainer 
to obtain a single cell solution. Tubes were spun down at 400 × g and 4 °C for 5 
min. The supernatant was discarded and the resulting cell pellet was suspended 
in 1 ml of a 40% percoll solution. Another 3 ml of 40% percoll solution was added 
followed by carefully overlaying onto a 4 ml layer of 70% percoll solution in a 15 
ml tube. The 40% percoll layer was then overlayed with 2 ml RPMI. The tubes 
were spun down at 1450 × g and 4°C for 30 min. Acceleration and deceleration 
speed was set to 4 and 1 (with 9 being maximal speed), respectively. After 
centrifugation, the top layer was removed and discarded and the visible 
leukocyte ring was carefully transferred into a new 50 ml tube containing cold 
PBS. Tubes were centrifuged at 400 × g and 4 °C for 5 min. The supernatant was 
discarded, cell pellets were resuspended in 1 ml of PBS, cells were counted 
according to 4.2.25 and afterwards kept on ice until further processing.  
 
4.2.2.3 Leukocyte Isolation from CNS  
In order to remove all non-parenchymatic leukocytes from the CNS, the mice 
were perfused using 50 ml of ice cold PBS by carefully incising the right atrium 
before a 50 ml syringe with a 21G × 19 mm butterfly needle was inserted into the 
left ventricle by means of which the circulatory system was flushed. The mouse 
was decapitated and the cerebrum, cerebellum and the brain stem were carefully 
removed from the scull and transferred into a 15 ml tube containing 5 ml of ice 
cold PBS. The spinal cord was exposed as followes: the animal’s decapitated body 
was fixated and the lower extremities were carefully cut off just above the hips 
in order to expose a caudal access to the spinal canal. A 10 ml syringe with a 25G 
× 25 mm needle was inserted in the caudal end of the spinal canal and the 
needle was fixed using a surgical clamp. The spinal canal was quickly flushed 
with cold PBS in order for the spinal cord to be released intact from the cranial 
end of the exposed spinal canal. The spinal cord was then carefully removed from 
the spine and transferred into a 15 ml tube containing 5 ml of ice cold PBS. For 
each animal, brain and spinal cord were pooled, cut into small pieces using 
surgical scissors and CNS tissues were suspended in freshly prepared CNS 
digest buffer (4 ml/CNS) and incubated for 40 min at 37 °C and 5% CO2. The 
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digest was terminated by adding 0.5 M EDTA to a final concentration of 10 mM 
during the last 5 min of the incubation. The following steps were all carried out 
on ice. Firstly, using a 2 ml syringe punch, the digested tissue was meshed 
through a 70 µm nylon mesh into a 50 ml tube already containing 5 ml of cold 
PBS. The tube was filled up with cold PBS and centrifuged at 400 × g and 4 °C 
for 5 min. The supernatant was discarded and the pellet was suspended in 30% 
percoll solution. The cell suspension was then transferred into 16 ml 
ultracentrifuge tubes, positioned in a fixed angle rotor ultracentrifuge and spun 
down at 10800 rpm for 30 min at 4 °C. Acceleration and deceleration were set to 
9 and 1 respectively. The resulting lipid layer was carefully sucked off with a 
vacuum pump and discarded, the remaining cell layer but the pelleted red blood 
cells at the bottom of the tube, was transferred into a 50 ml tube which was filled 
up with cold PBS. The tubes were centrifuged at 400 × g and 4 °C for 5 min. The 
supernatant was discarded and the remaining cell pellet was suspended in 1 ml 
of ice cold PBS. Cells were counted according to 4.2.25 and left on ice until 
further processing. 
 
4.2.3 Bleeding of Mice 
Mice were positioned under a heat lamp for 5 min in order for the tail veins to 
warm up and dilate. Animals were then carefully transferred to a restraining 
tube device and a lateral vein was incised using sterile blades. Blood samples 
were collected in K2E Microtainer tubes and blood flow was stopped by applying 
pressure on the sampling site for approximately 45 sec before the animal was 
returned to its cage. Blood samples (approximately 50 µl/animal) were quickly 
spun down at 2000 × g for 10 min at 4 °C, the resulting plasma was transferred 
into a new 1.5 ml Eppendorff tube, snap frozen using liquid nitrogen and stored 
at −80 °C until further processing of the sample. 
 
4.2.4 Generation of BMDCs  
In order to obtain bone marrow derived DCs, mice were painlessly euthanized 
with CO2. Fur, skin and muscles were carefully dissected from lower extremities 
of the animal (including tibia, femur, hips) until the bare bones were exposed. 
The femur was detached from tibia and hip without opening up any bones. 
Individual bones were then cut open distally and a syringe with a 30G × 12 mm 
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needle was introduced into the bone marrow canal to flush out the bone marrow 
with sterile cold PBS. The obtained cell solution was collected on a 70 µm cell 
strainer and passed into a 50 ml tube already containing 5 ml of cold PBS. The 
tube was filled up with cold PBS, centrifuged at 400 × g for 10 min at 4 °C. After 
the supernatant was discarded, a red blood cell lysis (2 min, RT) was performed 
using 1 ml ACK lysis buffer per bone marrow equivalent to one mouse followed 
by washing with cold PBS. Single cell solutions were kept on ice until further 
processing. 2.5 - 5 × 106 bone marrow cells were plated out in a non-tissue 
culture treated petri dish in 10 ml of BMDC culture medium (see table 4.1.18 for 
medium composition). A complete medium change was performed every second 
day: supernatants including non-adherent bone marrow cells were carefully 
collected from each dish and centrifuged at 400 × g for 5 min at 4 °C. The 
resulting pellet was resuspended in 10 ml of fresh BMDC culture medium and 
the cell suspension was pipetted back into the respective culture dish. Between 
days 9 - 11 cells were harvested from the culture dishes, counted and stored on 
ice until further analysis and processing.  
 
4.2.5 Genotyping 
Animal genotype was either confirmed by flow cytometry (2D2/TCRMOG mice) or 
PCR analysis on DNA from tail or ear biopsies (all other strains).  
 
4.2.5.1 Tissue Digestion and DNA Isolation 
Tail or ear biopsies (0.3 - 0.6 cm) were obtained from mice, transferred to 1.5 ml 
Eppendorf safe-lock tubes and either stored at −20 °C or immediately immersed 
in 100 µl of tail lysis buffer. For each lysis preparation tail lysis buffer was 
freshly supplemented with proteinase K at a dilution of 1:50. Tissue biopsies 
were digested between 4 - 12 h at 56 °C at 550 rpm in a thermoshaker. Following 
the tissue digest, 300 µl of ddH2O was added to each sample and tubes were 
centrifuged in order to pellet the tissue debris (12 000 rpm/10 min). 
Supernatants were transferred to freshly prepared 1.5 ml Eppendorf tubes 
containing 500 µl isopropanol. The tubes were vortexed followed by another 
centrifugation step (12000 rpm/10 min). Supernatants were carefully discarted 
and 200 µl of ice-cold (−20 °C) 70%-EtOH was added to the pelleted DNA 
followed by another centrifugation step (12000 rpm/10 min). Supernatants were 
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discarted and the remaining droplets were carefully removed using a vacuum 
pump. The precipitated DNA was air dried in 1.5 ml centrifuge tubes with open 
lids for a maximum amount of 15 min. DNA was resuspended in 50 µl of ddH2O 
and stored at 4 °C until further processing for genotyping.  
 
4.2.5.2 Atg5flox/flox Genotyping  
In order to genotype the Atg5flox/flox allele the FIREPol® 5× Mix 7.5 mM Ready to 
Load system was used. 
The anticipated PCR products were 650 bp for the Atg5 floxed allele and 350 bp 
for the Atg5 wt allele.  
 
4.2.5.3 Master Mix Components and PCR Program 
FIREPol® Master Mix (1×) 
Reagent Volume (µl) 
DNA 2.0 
5× FIREPol® mix 4.0 
Primer CS 003, 10 µM 0.5 
Primer CS 004, 10 µM 0.5 
Primer CS 005, 10 µM 0.5 
Primer CS 006, 10 µM 0.5 
H2O 12.00 
Total Volume 20.0 
 
PCR program  
Temperature Time 
95 °C  10 min 
95 °C 30 sec  
×35 60 °C 30 sec 
72 °C 1 min 
72 °C 10 min  
12 °C ∞ 
 
 
MATERIALS & METHODS 	
	 111	
4.2.5.4 CD11c-Cre Genotyping 
In order to genotype the Cre allele the FIREPol® 5× Mix 7.5 mM Ready to Load 
system was used. 
The anticipated PCR products were 100 bp for the Cre transgene and 324 bp for 
the internal positive control.  
 
4.2.5.5 Master Mix Components and PCR Program 
FIREPol® Master Mix (1×) 
Reagent Volume (µl) 
DNA 2.0 
5× FIREPol® mix 4.0 
Primer CS 007, 10 µM 0.5 
Primer CS 008, 10 µM 0.5 
Primer CS 009, 10 µM 0.5 
Primer CS 010, 10 µM 0.5 
H2O 12.00 
Total Volume 20.0 
 
PCR program  
Temperature Time 
94 °C  3 min 
94 °C 30 sec  
×35 63 °C 1 min 
72 °C 1 min 
72 °C 5 min  
12 °C ∞ 
 
4.2.5.6 2D2/TCRMOG Genotyping 
2D2/TCRMOG transgenic mice carry the Vα3.2 Jα18 and Vβ11DJβ1.1 region of a 
the MOG-specific murine T cell clone 2D2 (Bettelli et al., 2003).  
In virtue of their transgenic MOG-specific TCR expressed within the CD4+ T cell 
compartment, 2D2/TCRMOG transgenic mice were genotyped via flow cytometry 
using Vα3.2 and Vβ11 specific antibodies and transgenic animals were identified 
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due to the overrepresentation of these TCR α and β chains in their CD4 T cell 
repertoire (Bettelli et al., 2003). Therefore, animals were painlessly bled from the 
tail vein according to Swiss animal laws and institutional guidelines. The 
collected blood was mixed with an appropriate amount of heparin in order to 
avoid clotting. 30-50 µl of the blood:heparin mix were transferred to FACS tubes 
and supplemented with 1 ml of ACK lysing buffer. After incubation with the 
lysing buffer for 3 min at RT, FACS tubes were filled up with PBS and 
centrifuged at 400 × g for 5 min. Supernatants were discarded and the cell 
pellets were resuspended in 50 µl of antibody mix. Samples were stained on ice 
for 20 min, followed by another washing step with PBS as described above. 
Finally, cell pellet was resuspended in 50 µl of FACS buffer and samples were 
immediately aquired on a FACSCanto-II (BD) (see 4.1.25.2 for optical 
configuration) using FACSDiva software v6.1.3 (BD Biosciences) and analyzed 
with FlowJo software v9.3.1 (Tree Star Inc). 
 
4.2.6 Flow Cytometry  
For surface and intracellular expression analysis of CD40, CD1d, CD11c and I-
Ab, DC-Atg5+/+- and DC-Atg5−/−-derived splenocytes were purified for CD11c+ cells 
using magnetic microbeads according to the manufacturer’s recommendation. 
After Fc receptor block (22.4 µg/ml, 20 min, 4 °C) and a subsequent washing step, 
CD11c-enriched fractions were stained for 20 min with LIVE/DEAD fixable 
Aqua Dead Stain Kit in PBS at 4 °C in the dark. The CD11c-depleted fractions 
were used for CD1d surface staining of B cells (gated on CD19/MHC class II 
double positive cells). Samples were washed twice in cold PBS followed by 
incubation with respective fluorochrome-labeled antibodies in FACS buffer (1% 
BSA/0.1% NaN3 in PBS) for 25 min at 4 °C in the dark. For intracellular CD1d 
staining, the incubation with fluorochrome-labeled antibodies was preceded by 
permeabilization of cells in 0.5% saponin for 10 min at RT. After 2 washing steps 
with cold PBS, samples were resuspended in 50 µl FACS buffer prior to sample 
acquisition using FACSDiva software v6.1.3 (BD Biosciences) on FACSCanto-II 
(BD) and analysis with FlowJo software v9.3.1 (Tree Star Inc). For IL-12 
intracellular cytokine staining (ICS) using BD’s Fixation/Permeabilization 
Solution Kit, CD11c-enriched fractions were plated out at 5 × 105 cells/well in 48-
well tissue culture plates and incubated for 12 hours in R10 either supplemented 
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with 15 µg/ml anti-CD40 or not at 37 °C and 5% CO2. For flow cytometry 
analysis of IL-12+ cells, samples were additionally treated with Brefeldin A (10 
µg/ml) during the last 5 hours of the incubation time to block IL-12 secretion. 
Cells were washed twice with PBS and stained for live cells and the surface 
molecules CD11c and MHC class II (see above). Fixation and permeabilization 
for subsequent ICS was carried out according to the manufacturers 
recommendations (Fixation/Permeabilization Solution Kit). Samples were 
acquired with a FACSCanto-II (BD) using FACSDiva software v6.1.3 (BD 
Biosciences) and all data were analyzed using FlowJo software v9.3.1  (Tree 
Star). The same set up as the ICS experiments was carried out omitting the 
addition of Brefeldin A. In these instances, cell culture supernatants were 
collected after 12 hours for analysis of secreted IL-12 via ELISA.  
 
4.2.7 Magnetic Activated Cell Sorting (MACS) 
All magnetic activated cell sorting procedures were carried out using magnetic 
MicroBeads from Miltenyi (anti-CD11c and anti-CD4), the autoMACS Separator 
(Miltenyi) and in accordance with the provider’s protocol recommendations. 
Generally, single cell suspensions derived from organ isolates (spleen, liver, 
brain, bone marrow, blood) were incubated with 100 µl of MicroBead solution / 1 
× 108 cells in 400 µl of MACS buffer (CD11c+ purification) or 10 µl of MicroBead 
solution / 1 × 107 cells in 90 µl of MACS buffer (CD4+ purification) for 15 min at 4 
°C in 15 ml tubes. Tubes were then filled up with cold MACS buffer and 
centrifuged at 400 × g for 10 min. The supernatant was aspirated and the pellet 
was resuspended in 500 µl of cold MACS buffer / 1 × 108 cells (CD11c+ and CD4+ 
purification). Before automatic separation, cell suspensions were passed through 
a 70 µm cell strainer in order to avoid cell clumps. Cell suspensions were kept on 
ice throughout the entire preparation procedure. Cell suspensions were installed 
into the autoMACS machine in pre-cooled racks and an appropriate separation 
program was chosen (possel”d” and possel for CD11c+ and CD4+ purification, 
respectively).  
 
4.2.8 UVB Irradiation 
ODCMOG+ were UVB-irradiated at 870 mJ/cm2 using a Waldmann UV 181 BL 
irradiation unit. On day 0, cells were detached, washed in PBS and plated in 
tissue culture dishes and cultured in serum free DMEM supplemented with 1% 
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P/S overnight at 37 °C, 5% CO2 (1 × 105 cells/dish, 2 ml volume). On day 1, 
medium was removed and 2 ml of PBS were added to each dish. Cells were UVB 
irradiated and, after irradiation, PBS was substituted with fresh serum free 
medium. Cells were again incubated overnight at 37 °C, 5% CO2. Surface Ptd-L-
Ser+ of irradiated (Ptd-L-Serhi ODCMOG+) and non-irradiated MO3.13 cells (Ptd-L-
Serlo ODCMOG+) were quantified one day after irradiation by flow cytometry 
analysis using annexin V staining.  
 
4.2.9 Quantification of Ptd-L-Ser+ Cells 
Single ODCMOG+ cell suspension was washed twice with cold PBS and pellet was 
resuspended in 1× annexin V binding buffer at a concentration of 1 × 106 
cells/ml. FITC-conjugated annexin V (1:20) was added, cells were gently mixed 
and incubated for 15 min at RT in the dark. Suspensions were then washed and 
resuspended in 400 µl of annexin V staining buffer. Samples were acquired on a 
FACSCanto-II (BD) within 1 hour using FACSDiva v6.1.3 (BD Biosciences) 
software and analyzed with FlowJo software V9.3.1 (Tree Star Inc.). 
 
4.2.10 Ptd-L-Ser-Expressing Cell Phagocytosis and Coculture Assay 
ODCMOG+ were either UVB irradiated (870 mJ/cm2) or left untreated. DC-Atg5−/−- 
and DC-Atg5+/+-derived splenocytes were isolated and frequency of CD11c+/MHC 
class II+ DCs was determined via flow cytometry using a small aliquot of the 
splenocyte suspension. Bulk splenocytes from DC-Atg5−/−- and DC-Atg5+/+ mice 
where then cocultured overnight (37 °C, 5% CO2) in cell culture dishes with 
either Ptd-L-Serhi or Ptd-L-Serlo ODCMOG+ (10:1 ratio of ODCMOG+ to 
CD11c+/MHC class II+ DCs based on their frequencies within splenocyte 
suspension determined earlier) in R10 medium + 1% P/S. On the next day, 
CD11c+/MHC class II+ DCs were MACS-purified from all conditions (DC-Atg5−/− + 
Ptd-L-Serlo ODCMOG+; DC-Atg5−/− + Ptd-L-Serhi ODCMOG+; DC-Atg5+/+ + Ptd-L-Serlo 
ODCMOG+; DC-Atg5+/+ + Ptd-L-Serhi ODCMOG+) CD11c-enriched fractions were 
further cocultured at 1:5 ratio (DC:T cell) in a 96-well plate U bottom overnight 
(37 °C, 5% CO2) with 2D2/TCRMOG-derived MACS-purified CD4+ T cells in a total 
volume of 200 µl of R10 supplemented with 1% P/S and IL-2 (10 ng/ml). Wells 
containing 2D2/TCRMOG CD4+ T cells only and, MOG35-55 peptide (20 µg/mL), anti-
CD3 and anti-CD28 antibodies (5 µg/ml each) were also included. All conditions 
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were performed in triplicates. After 24 h of incubation, cell culture supernatants 
were collected for analysis of IFNγ concentrations by ELISA.  
 
4.2.11 Fluorescent Activated Cell Sorting   
In some experimental settings (DC:iNKT  cell cocultures, 2.2.2), MACS-derived 
CD11c+-enriched populations were further purified using fluorescent activated 
cell sorting with a BD FACS Aria III. Briefly, post-MACS CD11c+-enriched cell 
suspensions were stained with fluorochrome-labeled antibodies (anti-CD11c and 
anti-I-Ab) and a dead cell marker for 20 min on ice and in the dark. CD11chi/I-Ab-
hi double positive cells were determined as target population and either bulk 
sorted into 15 ml tubes or 96-well round bottom plates, both already containing 
the appropriate culture medium. 
 
4.2.12 Immunocytochemistry and Colocalization Assays  
For assessing colocalization between LC3 and CD1d in splenic DCs, C57BL/6-
derived splenocytes were MACS-sorted via magnetic CD11c microbeads 
according to the manufacturer’s recommendation using an autoMACS Pro 
Separator (Miltenyi). 8-well glass chamber slides were coated with 0.01% poly-l-
lysine in ddH2O and extensively washed with PBS before MACS-purified CD11c+ 
cells were plated at a density of 1 × 105 per chamber. CD11c+ splenocytes were 
either kept in R10 (RPMI-1640 + 10% FCS + 50 U/ml P/S) only or R10 
supplemented with 2 µg/ml of the B-class murine TLR9 agonist CpG ODN 1826 
for 5 hours at 37 °C and 5% CO2. A cytospin was performed (3 min, 300 × g), 
supernatants were carefully aspired and chambers were washed twice (200 
µl/chamber) with cold PBS. Cells were fixed for 15 min at RT in 3% PFA in PBS 
followed by 2 washing steps with PBS (200 µl/chamber). For CD1d and EEA1 
colocalization studies, cells were incubated with Fc blocking antibody, labeled for 
CD1d 30 min at 4 °C, then incubated at 37 °C for an additional hour in R10, 
before fixation. Cells were permeabilized for 5 min at RT in 200 µl of 0.1% Triton 
X-100 in PBS followed by 30 min of blocking with 100 µl of 1% BSA, 10% NGS in 
PBS at RT. Cells were permeabilized for 5 min at RT in 200 µl of 0.1% Triton X-
100 in PBS followed by 30 min of blocking with 100 µl of 1% BSA/10% NGS in 
PBS at RT. Afterwards cells were incubated with primary antibodies (rabbit 
anti-LC3, rat anti-CD1d, anti-EEA1 and anti-AP2) in 0.1% saponin/10% NGS in 
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PBS for 1 hour at RT. Chambers were carefully washed twice with 0.1% saponin 
in PBS (200 µl/chamber) followed by a 45 min incubation with secondary 
antibodies in 0.1% saponin/10% NGS in PBS (Alexa Fluor488-conjugated or 
Alexa Fluor555-conjugated anti-rabbit, anti-rat, anti-goat and anti-mouse). Cells 
were washed twice with PBS (200 µl/chamber), followed by incubation with DAPI 
for 2 min at RT. Washing steps as above were performed and slides were 
mounted with ProLong Gold antifade reagent, let sit for 24 hours at RT in the 
dark and transferred to 4 °C in the dark until further analysis. Pictures were 
acquired using a 63×, 1.4 NA oil immersion lens with an inverted confocal laser 
scanning microscope (SP5-UV). To determine colocalization, Pearson’s 
correlation coefficient values were calculated using JACoP (Just Another 
Colocalization Plugin) in ImageJ software. A Pearson score >0.5 indicates a 
statistically relevant colocalization of the signals. 
 
4.2.13 Coculture Assays with Splenic DCs and NKT Cell Hybridoma 
CD1d-mediated presentation of lipid antigens was measured using the murine 
Vα14+/Vβ8+ NKT cell hybridomas A.407 and FF13. NKT cell hybridomas were 
cultured in hybridoma culture medium (RPMI-1640 supplemented with 10% 
FCS, 50 U/ml P/S, 2 mM L-glutamine and non-essential amino acids) at 37 °C 
and 5% CO2. For coculture assays DC-Atg5+/+- and DC-Atg5−/−-derived splenocytes 
were purified for CD11c+ cells using magnetic microbeads according to the 
manufacturer’s recommendation. CD11c-enriched fractions were further purified 
through FAC-sorting using an ARIA III FCF (BD) (gated on live CD11c/I-Ab 
double positive cells). Purified splenic DCs were directly sorted in round-bottom 
96-well tissue culture plates at 3 × 104 cells/well and kept in R10 at 37 °C and 
5% CO2 for 45 min in order to settle. Afterwards, wells were either supplemented 
with increasing amounts of the glycolipid antigen αGalCer  (0.01 – 10 µg/ml) or 
left untreated for 4 hours. Each condition was applied in triplicates. Wells were 
carefully washed 3× with PBS (200 µl/well) and 5 × 104 NKT hybridoma cells 
(A.407 or FF13) in hybridoma culture medium were added to a final volume of 
200 µl/well. Control wells containing APC- and NKT hybridoma cells-only (with 
or without addition of αGalCer) were included. Wells were incubated at 37 °C 
and 5% CO2. After 24 hours, cell culture supernatants were collected for analysis 
of IL-2 concentrations via ELISA. In some experiments, titrated concentrations 
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of indicated glycolipid antigens were used instead of αGalCer (Freigang et al., 
2012). In some experiments (2.2.2) instead of purified splenic DCs, an ATG5-
defiecent (and the ATG5-competent counterpart) macrophage-like cell line was 
used (MΘ-Atg5−/− and MΘ-Atg5+/+). 
 
4.2.14 CD1d Antigen Presentation Assays  
BMDCs were generated by culturing the bone marrow of DC-Atg5+/+ or DC-Atg5−/− 
mice in presence of 2 ng/ml recombinant GM-CSF in vitro. After 7 days, 
differentiated BMDCs were harvested, purified over a 14.5% Histodenz gradient 
and pulsed with titrated amounts of lipid antigens for 4 hours at 37 °C and 5% 
CO2. Thereafter, cells were washed and 1 × 104 BMDCs were used to stimulate 5 
× 104 A.407 NKT hybridoma cells in triplicate cultures in 96-well tissue culture 
plates. IL-2 concentrations in 24 hours cell culture supernatant were determined 
by ELISA. In some experiments (2.2.4) BMDCs were further FACS-purified for 
CD11c/MHC class II double positive cells using ARIA III FCF (BD).  
 
4.2.15 NKT Cell Detection  
NKT cells were detected using αGalCer-loaded CD1d tetramers. Single-cell 
suspensions from spleens, livers, and thymi were pre-treated with Fc block and 
0.5 mg/ml avidin in FACS buffer for 10 min. After 2 washes, cells were incubated 
with CD1d/αGalCer tetramers at RT for 15 min before addition of anti–CD3ε and 
further staining for 30 min. Washed cells were depleted of erythrocytes, fixed 
and acquired on a LSR Fortessa system (BD) using FACSDiva software v6.1.3 
(BD Biosciences). Analysis was performed using the FlowJo software v9.3.1 (Tree 
Star Inc.). 
 
4.2.16 Determination of Cytokine Concentration  
The IL-2 concentrations in coculture supernatants was measured using the 
eBioscience Mouse IL-2 Ready-SET-GO Reagent Kit. IL-12 concentrations in cell 
culture supernatants were measured using the Mabtech Mouse IL-12/-23 (p40) 
ELISA Development Kit. Serum concentrations of IFNγ and IL-4 were measured 
using the eBioscience Mouse IFNγ or Mouse IL-4 Instant ELISA Kit. All 
measurements were carried out according to the respective manufacturer’s 
recommendation. 
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4.2.17 CD1d Internalization Assay  
For assessing internalization of surface CD1d in splenic DCs and B cells 
respectively, DC-Atg5+/+- and DC-Atg5−/−-derived splenocytes were purified for 
CD11c+ cells using magnetic microbeads according to the manufacturer’s 
recommendation. After Fc receptor block (22.4 µg/ml, 20 min, 4 °C) and 
subsequent washing step, the CD11c-enriched fraction was incubated for 30 min 
on ice with a biotinylated-CD1d antibody. After extensive washing with ice cold 
PBS cells were fractionated into the following groups (1 × 105/group): 90 min on 
ice, 90, 60 and 30 min at 37 °C, 5% CO2. To assess CD1d internalization in B 
cells, the negative fraction from the MACS purification was processed 
accordingly in parallel. After respective incubation time, cells were washed with 
ice cold PBS and incubated with PE-labeled streptavidin, anti-CD11c (CD11c-
enriched fraction for DC analysis) or anti-CD19 (CD11c-depleted fraction for B 
cell analysis), anti-I-Ab and LIVE/DEAD fixable Aqua Dead Stain Kit for 20 min 
on ice in the dark. Samples were fixed with 3% PFA in PBS and acquired with a 
FACSCanto-II (BD) using FACSDiva software v6.1.3 (BD Biosciences). Analysis 
was performed using the FlowJo software v9.3.1 (Tree Star Inc.). To obtain % 
internalized CD1d values, the following equation was employed:   
 
 
% internalized CD1d = 100 − [ MFIsampleMFI90min ice ×100] 
 
4.2.18 CD1d Recycling Assay  
CD11c-enriched or -depleted fractions of DC-Atg5+/+- and DC-Atg5−/−-derived 
splenocytes (see internalization assay for details) were incubated with protein 
synthesis inhibitor cycloheximide (1 µg/ml) supplemented R10 (60 min at 37 °C, 
5% CO2). After extensive washing with ice cold PBS, cells were either incubated 
with unconjugated anti-CD1d antibody for 30 min (pre-blocked) or left untreated 
(non-blocked) on ice. After washing step, cells were divided into the following 
groups (1 × 105/group): 30 min on ice (pre-blocked), 30 min on ice (non-blocked), 
30, 20, 10, 5  min at 37 °C, 5% CO2. After respective incubation times, cells were 
washed with ice cold PBS and incubated with PE-labeled anti-CD1d antibody (of 
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the same clone used for pre-blocking), anti-CD11c (CD11c-enriched fraction for 
DC analysis) or anti-CD19 (CD11c-depleted fraction for B cell analysis), anti-I-Ab 
and LIVE/DEAD fixable Aqua Dead Stain Kit for 20 min on ice in the dark. A 
non-blocked sample was stained with PE-labeled isotype control instead of the 
PE-labeled anti-CD1d antibody. Samples were fixed with 3% PFA in PBS and 
acquired with a FACSCanto-II (BD) using FACSDiva software v6.1.3 (BD 
Biosciences). Analysis was performed using the FlowJo software v9.3.1 (Tree 
Star Inc.). To obtain % recycled CD1d values, the following equation was 
employed: 
 % recycled CD1d = [ MFI sample −MFI preblockedMFI unblocked AB −MFI unblocked isotype ]×100 
 
4.2.19 Lipid In Vivo Chase  
DC-Atg5+/+ and DC-Atg5−/− mice were either injected i.p. with 200 µl PBS or 
αGalCer (1 µg). Injection time points were chosen as such that animals could be 
sacrificed at the same time point. Blood for serum cytokine analysis was 
collected via cardiac puncture. Blood was utilized for serum cytokine analysis 
(IFNγ, IL-4). Spleens were processed as described above (see mouse organ 
processing). MFI of costimulatory molecules was analyzed on either Cre+ (DC-
Atg5−/−) or Cre− (DC-Atg5+/+) CD11c/MHC class II double positive splenocytes. 
 
4.2.20 Infection with S. paucimobilis  
Mice were intravenously (i.v.) infected with 107 colony forming units (CFU) S. 
paucimobilis and organs were harvested and weighed at 24 hours post infection. 
After homogenizing the organs in sterile H2O using a tissue lyzer, tenfold serial 
dilutions were plated onto Muller-Hinton agar containing 200 µg/ml 
streptomycin and incubated for 48 hours at 30 °C. Colonies were then counted 
and bacterial titers calculated as CFU per g tissue.  
 
4.2.21 Adoptively Transferred EAE 
For induction of adoptively transferred EAE, 8 to 12 weeks old C57BL/6 or 
2D2/TCRMOG transgenic mice were used as donor mice. On day 0, donor mice 
(either C57BL/6 or 2D2/TCRMOG transgenic mice) were anaesthetized with 
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isoflurane and subsequently injected s.c. with 100 µl of a MOG35-55/CFA emulsion 
in each flank using a 24G needle attached to a 1 ml syringe. Additionally, each 
mouse was i.p. injected with 100 µl containing 200 ng Pertussis toxin in PBS 
using a 29G × 12.7 mm insulin syringe. The MOG35-55/CFA emulsion was 
prepared as followes: MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) at a 
stock concentration of 5 mg/ml was diluted in PBS to obtain a final concentration 
0.5 mg/ml. An equal volume of CFA additionally supplemented with desiccated 
inactivated Mycobacterium tuberculosis (at 3.333 mg per 1 ml of CFA) was added 
to obtain 200 µl of a 1:1 ratio of the MOG35-55/CFA emulsion per mouse (100 µl 
per flank). An excess volume of 20% was prepared in addition to account for 
partial loss of the viscous emulsion within the syringes. The MOG35-55/CFA 
emulsion was thoroughly mixed via quick repetitive transfer in between two 
syringes connected by a luer-lock interconnector device for 20 min at RT. On day 
7 after immunization with MOG35-55/CFA, donor mice were euthanized with CO2 
(in none of the experiments carried out did any of the donor mice develop clinical 
signs of EAE within these first 7 days upon immunization). Spleen and draining 
lymph nodes (dLN) were harvested and leukocytes were purified according to 
4.2.2. Bulk leukocytes were counted and re-plated at 1-2 × 107 cells/ml 
restimulation medium in 10 cm tissue-culture-treated round dishes (10 ml/dish). 
The restimulation medium contained IL-23 (10 ng/ml) and MOG35-55 (10 µg/ml). 
Cells were incubated for 48 hours at 37 °C and 5% CO2. Afterwards cells were 
collected, washed with sterile cold PBS twice and adjusted to a density of 5 × 106 
cells/100 µl PBS. 200 µl of this cell suspension was i.p. injected into each 
recipient mouse which had been sublethally irradiated with 550 rad (using a 
cesium source irradiator) one day prior to cell transfer. After the induction of 
EAE (either by active immunization with MOG35-55 peptide as applied to the 
donor mice or by adoptively transferring donor splenocytes into recipient mice), 
mice were observed daily for well-being and accessibility of food and water. 
Furthermore, clinical manifestations of EAE and weight loss were monitored and 
documented daily using a stringent scoring procedure including a grid test and 
manual examination:   
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Disease 
score 
Clinical manifestation 
0 No detectable signs of EAE 
0.5 Distal limp tail 
1 Complete limp tail 
1.5 Limp tail and hint limp weakness 
2 Unilateral partial hind limb paralysis 
2.5 Bilateral partial hind limb paralysis 
3 Complete bilateral hind limb paralysis 
3.5 Complete bilateral hind limb paralysis and partial fore limb 
paralysis 
4 Moribund (animal unable to move due to paralysis) 
5 Animal found dead 
 
In the following instances animals were immediately euthanized with CO2 upon 
evaluation: Disease score of 3 for more than 7 days, disease score of 3.5 for more 
than 3 days, reaching disease score of 4 or loss of more than 30% of the animal’s 
maximum body weight. 
 
4.2.22 Detection of Regulatory T Cells Via Intranuclear FOXP3 Staining 
The detection of FOXP3+ regulatory T cells (Tregs) in CNS-derived and splenic 
lymphocytes was carried out using eBioscience’s FOXP3 Staining Buffer Set 
according to the manufacturer’s recommendations. In brief, Samples were 
initially stained for surface molecules (including at least CD4, CD8 and CD25) 
and with a fixable live cell marker according to standard surface staining 
procedures for flow cytometry analyses (4.2.6). Next, Fixation/Permeabilization 
Working Solution was prepared freshly by diluting Fixation/Permeabilization 
Concentrate (1 part) in Fixation/Permeabilization Diluent (3 parts). After surface 
staining, the cell pellet was suspended in 500 µl of Fixation/Permeabilization 
Working Solution/sample for fixation. Samples were incubated at 4 °C for 30 min 
in the dark. Samples were washed twice with 1 ml of 1× Permeabilization Buffer 
(10× stock solution diluted in H2O) followed by centrifugation at 400 × g and 4 °C 
for 5 min. Each sample was stained with 10 µl of a 1:100 dilution of a 
fluorescently labeled anti-mouse FOXP3 antibody in 1× permeabilization buffer 
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and incubated at 4 °C for 30 min in the dark. Cells were washed once with 1× 
permeabilization buffer, followed by centrifugation step at 400 × g and 4 °C for 5 
min. Supernatant was discarded and cell pellet was resuspended in FACS buffer 
and samples were immediately recorded with a LSR Fortessa system (BD) using 
FACSDiva software v6.1.3 (BD Biosciences). Analysis was performed using the 
FlowJo software v9.3.1 (Tree Star Inc.). 
 
4.2.23 Detection of the Intracellular Cytokines IFNγ, IL-17 and GM-CSF  
During some EAE peak of disease experiments intracellular cytokines were 
determined in CNS-derived and splenic CD4+ T cells upon restimulation with 
either MOG35-55 peptide, OVA323-339 peptide (negative control) or PMA/Ionomycin 
(positive control). Leukocytes were isolated and purified from the respective 
organs according to 4.2.2. For each sample/animal the organ-specific (CNS or 
spleen) cell suspension was divided in three groups determined by the 
restimulation agent (MOG35-55 peptide, OVA323-339 peptide, or PMA/Ionomycin). 
Brefeldin A was added to inhibit cytokine secretion by induction of retrograde 
transport from the Golgi apparatus back to the ER (Sciaky et al., 1997). Each 
sample was resuspended in 500 µl of the respective restimulation medium: 
 
Restimulation 
medium 
Ingredients 
I OVA323-339 peptide + Brefeldin A in R10 + P/S 
II MOG35-55 peptide + Brefeldin A in R10 + P/S 
III PMA/Ionomycin + Brefeldin A in R10 + P/S 
  
Concentrations of restimulation agents 
 OVA323-339 
peptide 
MOG35-55 
peptide 
PMA Ionomycin Brefeldin A 
Stock 5 mg/ml 5 mg/ml 1 mg/ml 1 mM 10 mg/ml 
Dilution 1:250 1:250 1:50000 1:747 1:1000 
 
Samples were incubated in restimulation media at 37 °C and 5% CO2 for 4 hours, 
then washed twice in cold PBS followed by centrifugation at 400 × g and 4 °C for 
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5 min. Supernatants were discarded and each cell pellet was resuspended in 50 
µl of staining solution containing the antibodies against the respective surface 
antigens and a fixable live cell marker according to standard surface staining 
procedures for flow cytometry analyses (4.2.6). In order to detect intracellular 
cytokines, BD’s Cytofix/Cytoperm Fixation/Permeabilization Solution Kit was 
used according to the manufacturer’s recommendation. Briefly, cell pellets were 
resuspended in 200 µl of Cytofix/Cytoperm Buffer and incubated for 30 min at 4 °C in 
the dark. Next, 1 ml of 1× Permeabilization/Wash Buffer was added to each 
sample followed by a centrifugation step at 400 × g and 4 °C for 5 min. 
Supernatants were discarded and each cell pellet was resuspended in 50 µl 
staining solution containing the appropriate dilutions of antibodies against 
murine IFNγ, IL-17A and GM-CSF in 1× Permeabilization/Wash Buffer. 
Samples were incubated in the dark at 4 °C for 20 min. Samples were washed in 
1 ml of 1× Permeabilization/Wash Buffer, centrifuged at 400 × g and 4 °C for 5 
min and supernatants were discarded. Cell pellets were resuspended in PBS and 
immediately recorded using LSR Fortessa (BD) with FACSDiva software v6.1.3 
(BD Biosciences). Analysis was performed using the FlowJo software v9.3.1 (Tree 
Star Inc.). 
 
4.2.24 Cell Culture 
In general, all cell lines and murine primary cells were maintained and cultured 
at 37°C, 5% CO2. All materials used during cell culture were sterile. Cell culture 
work was only performed under sterile conditions using a biological safety hood.  
 
4.2.25 Cell Count 
Regularly, the number of cells in a given suspension had to be determined. 
Depending on the expected cell density within the suspension an appropriate 
pre-dilution was chosen. In order to distinguish live from dead cells, cell 
suspension was further diluted with trypan blue staining solution at a 1:1 ratio. 
10 µl of this dilution was pipetted into a hemocytometer (Neubauer-counting 
chamber). Live (trypan blueneg cells) were counted in 4 quadrants using an 
inverted laboratory light microscope and cell concentration was calculated. 
4.2.26 Freezing Cells 
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Cell line-derived cells and murine BMDCs were frozen down using freezing 
medium (10% DMSO in FCS). In doing so cells were carefully and slowly 
resuspended in freezing medium and transferred into 1.8 ml cryo tubes. Cryo 
tubes were positioned into a isopropanol containing freezing container that 
allowed for an optimal 1 °C/min cooling rate. The freezing container was stored 
at −80 °C overnight. Afterwards cryo tubes were stored in liquid nitrogen until 
further useage.  
For thawing, cryo tubes were quickly transferred from liquid nitrogen into a 37 
°C water bath just until only a small amount of cell suspension was still frozen. 
Cryo tubes were removed from water bath, sprayed with 70%-EtOH. The cell 
suspension was slowly pipetted up and down in order to thaw the remainder 
suspension. The thawed content of the cryo tubes was transferred into a 50 ml 
tube. The tube was filled up with cold sterile PBS and centrifuged at 400 × g and 
4 °C for 5 min. Supernatant was discarded and cell pellet was resuspended in 
fresh culture medium dependend on the nature of the cells. 
 
4.2.27 Cell Lysis for Protein Quantification 
The culture medium of the cell population of interest was removed and cells were 
washed twice with cold PBS. Adherent cells were removed from culture plate by 
trypsinization or mechanical detachment using a cell scraper. The obtained cell 
suspension was transferred in a 15 ml tube. The tube was filled up with cold PBS 
and centrifuged at 400 × g and 4 °C for 5 min. From this step on, samples were 
meticulously kept on ice at all times. Supernatant was discarded and the cell 
pellet was resuspended with 1 ml of cold PBS. The cell suspension was 
transferred in 1.5 ml tubes and centrifuged at 400 × g and 4 °C for 5 min. 
Supernatant was discarded and cell pellet was resuspended in an appropriate 
amount of freshly prepared cold lysis buffer (50 µl/ 1 × 106 cells). Cell suspension 
was forcefully pipetted up and down in order to mechanically benefit the lysis. 
Samples were incubated in lysis buffer for 30 min on ice and centrifuged at 
>20000 × g and 4 °C for 10 min. The supernatant was carefully transferred into a 
fresh 1.5 ml tube. At this stage, a small amount of each sample was set aside to 
use for determination of protein concentration. The remainder of each sample 
was stored at −80 °C until further use. 
4.2.28 BCA/Protein Quantification 
MATERIALS & METHODS 	
	 125	
For determination of the protein concentration in whole cell lysates the Pierce 
BCA Protein Assay Kit was used according to the manufacturer’s 
recommendation. In brief, for each measurement a fresh BSA in PBS serial 
dilution ranging from 25 - 2000 µg/ml was prepared. To obtain the BCA Working 
Reagent (200 µl required per sample/standard singlet), reagent A was mixed with 
reagent B at a 50:1 ratio. 10 µl of each standard and sample were pipetted into a 
flat bottom 96-well plate in duplicates (of note: in this particular sample-saving 
microplate set-up the working range of the assay was limited to 125 - 2000 
µg/ml). Usually, samples were pre-diluted (1:10, 1:50). Then, 200 µl of BCA 
Working Reagent was added per well. The 96-well plate was put on a rocking 
plate shaker for 30 sec in order to thoroughly mix the substances. Thereafter, the 
plate was covered with multi well sealing film and incubated at 37 °C for 30 min. 
After equilibration to RT, absorbance at 540 nm was measured.  
 
4.2.29 SDS-PAGE and Western Blot 
Protein samples (which had been prepared for subsequent SDS-PAGE as 
described in (4.2.27, 4.2.28) were diluted with 5× Laemmli Buffer and boiled for 
5 min at 95 °C. The 0.75 mm gels had either been prepared one day in advance, 
wrapped in moist paper towels and stored at 4 °C or were prepared freshly 
according to the recipes in 4.1.23. The gels were assembled in a Bio-Rad stacking 
system and protein samples including a protein ladder were carefully loaded into 
the gel pockets using Corning gel-loading pipet tips. Gel was run at 70V until 
samples had entered the resolving gel when the voltage was increased to 100V 
until the protein front had almost reached the bottom of the gel. When the SDS-
PAGE was done, the gel was gently removed from inbetween the glass plates. A 
polyvinylidenefluoride (PVDF) membrane was activated in 100% methanol for 2 
min. Appropriatly tailored Whatman filter papers, PVDF membrane and gel 
were soaked in 1× transfer buffer for equilibration for 10 min. Proteins were 
transferred via a semi-dry transfer system at 10V for 1 hour. The membrane was 
removed and blocked for 1 hour at RT in 4% skimmed milk in PBS-T buffer 
(blocking solution) followed by incubation with primary antibody diluted in 
blocking solution overnight at 4 °C on a shaker. After washing for at least 5 min 
with PBS-T, the membrane was incubated for 1 hour at RT with secondary 
antibody (HRP labeled anti-goat, -mouse, -rat or -rabbit IgG) diluted in blocking 
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solution on a shaker. Membrane was again washed three times for at least 5 min 
with PBS-T and finally once with PBS for 5 min. Pierce ECL Western Blotting 
Subrate was used to develop the membrane. Protein bands were visualized with 
a Fusion FX detector (Vilber-Lourmat). In some instances stripping of the PVDF 
membrane was required. In doing so, the membrane was washed twice in PBS-T 
and twice in H2O for at least 5 min. Afterwards the membrane was incubated 
rocking with 5 ml of 1× ReBlot System Strong Solution for 30 min at RT. The 
membrane was washed twice in H2O followed by two washes in PBS-T for 5 min 
each. Henceforth, the protocol regarding blocking, incubation with primary and 
secondary antibodies and detection corresponded to the procedures mentioned 
above. 
 
4.2.30 Statistics  
Statistical tests applied are indicated in the respective figure legends. Unpaired, 
two-tailed student t test, Mann-Whitney U test and Pearson correlation 
coefficient were performed/calculated. A P-value <0.05 was considered 
statistically significant. The asterisks depicted in the figures translate into the 
following grouping: * P<0.05, ** P<0.01,*** P<0.001. All quantitative analyses 
were performed with GraphPad Prism v5.0a for Mac OSX (GraphPad Software, 
Inc).  
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6. Abbreviations 
 
AAK1 Adaptor-associated kinase 1 
ACK Ammonium-chloride-potassium 
AMPK AMP-activated protein kinase 
AP2 Adaptor protein complex 2 
APC Antigen presenting cell 
APS Ammonium persulfate 
Atg Autophagy-related gene 
ATG Autophagy related protein 
BBB Blood brain barrier 
BCA Bicinchoninic acid  
Bcl-2 B-cell lymphoma 2 
BMDC Bone marrow-derived dendritic cells 
Bp Base pairs 
BSA Bovine serum albumin 
CAMKK2 Ca2+/calmodulin-dependent protein kinase kinase 2 
CAR Chimeric antigen receptors 
CD  Cluster of differentiation 
CFA  Complete Freund’s adjuvant 
CFSE Carboxyfluorescein succinimidyl ester 
CLIP Class II-associated invariant chain peptide 
CMA  Chaperone-mediated autophagy 
CNS Central nervous system 
COPII Coat protein complex II 
Cre  Cyclization (or causes) recombination enzyme 
CTL Cytotoxic T lymphocyte 
DAPI 4’,6-diamidino-2-phenylindole 
DAPK Death-associated protein kinase 
DC Dendritic cell 
dLN Draining lymph node 
DMSO Dimethyl sulfoxide 
DNA Desoxyribnucleic acid 
DNAse Desoxyribonuclease 
dNTP Desoxyribonucleotide 
DTR diphtheria toxin (DT) receptor 
EAE  Experimental autoimmune encephalomyelitis 
EDTA Ethylenediaminetetraacetic acid 
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EE Early endosome 
EEA1 Early endosome antigen 1 
EGFP  Enhanced green fluorescent protein 
ER  Endoplasmic reticulum 
ESCRT Endosomal sorting complexes required for transport 
EtOH Ethanol 
FACS  Fluorescent activated cell sorting 
FCS  Fetal calf serum 
FIP200 FAK family kinase-interacting protein of 200 kDa 
Fl or flox  
 
DNA sequence that is flanked by two loxP sites 
Flt3 Fms related tyrosine kinase 3 
FOXO3 Forkhead box O3 
FOXP3 Forkhead box P3 
FSC  Forward scatter 
GalαGalCer Digalactosylceramide 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GM2A GM2 ganglioside activator 
GSL-1 Glucuronylceramide 
HLA  Human leukocyte antigen 
HRP  Horseradish peroxidase 
HSC70 Heat shock cognate protein of 70 kDa 
HSVTK Thymidine kinase of herpes simplex virus 
i.p.  Intraperitoneal (injection) 
ICS  Intracellular cytokine staining 
IFN  Interferon 
IgG Immunoglobulin G 
Ii  Invariant chain 
IL  Interleukin 
iPSC Induced pluripotent stem cells 
IRF7 Interferon regulatory factor 7 
kb Kilobase  
kDa Kilodalton 
KFERQ One-letter code for amino acid sequence Lys-Phe-Glu-Arg-Gln 
KO Knockout 
LAMP-2a  Lysosomal membrane-associated protein 2a 
LAP  LC3-associated phagocytosis 
LC3  Microtubule-associated protein 1A/1B-light chain 3 
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LDLR Low density lipoprotein receptor 
LE Late endosome 
LIR  LC3-interacting region 
LKB1 Liver kinase B1 
loxP  Locus of crossover (x) in P1 
LPS  Lipopolysaccharide 
LTP Lipid transfer protein 
Ly Lysosome 
MA Macroautophagy 
MACS  Magnetic activated cell sorting 
MAIT cells Mucosal-associated invariant T cells 
MBP  Myelin basic protein 
MHC Major histocompatibility complex 
MI Microautophagy 
MIIC  MHC class II-containing compartments 
min Minutes 
moDC  Monocyte-derived DCs 
MOG  Myelin oligodendrocyte glycoprotein 
mRNA  Messenger RNA 
MS  Multiple sclerosis 
mTOR  Mammalian target of rapamycin 
MTP Microsomal triglyceride transfer protein 
MVB Multivesicular bodies 
MyD88 Myeloid differentiation primary response gene 88 
NaCl Sodium chloride 
NEAA Non-essential amino acids 
NGS Normal goat serum 
NK cells  Natural killer cells 
NKT cells  Natural killer T cells 
NOX2 NADPH oxidase 2 
NPC1/2 Niemann-Pick type C1 and C2 proteins 
p62 (SQSTM1) Ubiquitin-binding protein involved in cell signaling 
PAGE Polyacrylamide gel electrophoresis 
Pam3CSK4  Pam3Cys-Ser-(Lys)4, Synthetic triacylated lipoprotein 
PAMPs  Pathogen-associated molecular patterns 
PAS  Pre-autophagosomal structure 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
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pDC  Plasmacytoid DC 
PE Phosphatidylethanolamine 
PFA  Paraformaldehyde 
PI3K  Phosphatidylinositol 3-kinase 
PI3P  Phosphatidylinositol 3-phosphate 
PMA  Phorbol-12-myristate-13-acetate 
PNS  Peripheral nervous system 
PRAS40 Proline-rich Akt substrate of 40 kDa 
PRR  Pattern recognition receptor 
Ptd-L-Ser  Phosphatidylserine 
PTx  Pertussis toxin 
RA  Rheumatoid arthritis 
RAP Rapamycin 
Rheb Ras homolog enriched in brain 
RNA  Ribonucleic acid 
ROS Reactive oxygen species 
rpm  Rounds per minute 
RT  Room temperature 
s.c.  Subcutaneous (injection) 
SDS  Sodium dodecyl sulfate 
sec seconds 
SLE  Systemic lupus erythematosus 
SNARE SNAP [Soluble NSF Attachment Protein] Receptor 
SNP  Single nucleotide polymorphism 
SRA Scavenger receptor A 
SSC  Side scatter 
ssRNA  Single stranded RNA 
T cell  T lymphocyte, matured in the thymus 
TAK1 Transforming growth factor beta-activated kinase 1 
TAP-1 and 2  Transporter-associated with antigen processing-1 and -2 
TBE  Tris-borate-EDTA buffer 
TCR  T cell receptor 
TEM  Transmission electron microscopy 
TEMED Tetramethylethylenediamine 
TGF  Transforming growth factor 
TH cell T helper cell 
TIM4  T cell immunoglobulin mucin-4 
TLR  Toll-like receptor 
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TNF  Tumor necrosis factor 
Treg  Regulatory T cell 
TSC Tuberous sclerosis complex 
ULK1  Uncoordinated (UNC)-51-like kinase 1 
VAMP3 Vesicle-associated membrane protein 3 
VPS34  Vacuolar protein sorting protein 34; is a class III PI 3-kinase 
WIPI WD repeat domain phosphoinositide-interacting protein 
wt Wild type 
ZNS  Zentrales Nervensystem 
αGalCer α-Galactosyceramide 
β2-m β2-microglobulin 
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